Ribonucleoprotein nanocomplex vaccines and uses thereof
Nanoconjugate vaccines with a viral RNA scaffold and adapter-antigen polypeptide address the limitations of traditional vaccine administration by inducing effective mucosal immunity and broad viral protection through intranasal or intradermal routes.
Patent Information
- Application Number
- JP2024070290
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-24
- Filing Date
- 2024-04-24
- Publication Date
- 2024-11-06
AI Technical Summary
Traditional vaccines administered intramuscularly fail to effectively prime resident lung immune cells against respiratory viruses, and nasal administration without adjuvants is not safe or effective, while conventional adjuvants cause adverse immune responses.
A vaccine composition comprising nanoconjugates with a viral RNA scaffold and an adapter-antigen polypeptide, where the molar ratio of adapter-antigen polypeptide to scaffold molecule is greater than 5:1, effectively stimulating mucosal immunity through intranasal or intradermal administration.
The nanoconjugate vaccines induce robust mucosal and systemic immune responses, providing safe and effective protection against multiple viral infections with reduced side effects, including heterosubtypic protection across various viral subtypes.
Smart Images

Figure 2024156641000018 
Figure 2024156641000019 
Figure 2024156641000020
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 497,895, filed April 24, 2023, the entire contents of which are incorporated herein by reference in their entirety.
[0002] Reference to Electronic Sequence Listing The contents of the electronic sequence listing (253322000342seqlist.xml, size: 75,643 bytes, and creation date: April 19, 2024) are incorporated herein by reference in their entirety.
[0003] The present invention relates to vaccine compositions comprising a complex comprising an adaptor-antigen polypeptide and a nucleic acid scaffold (e.g., viral RNA). Further provided herein are pharmaceutical compositions comprising the vaccine, methods of using the vaccine to prevent or ameliorate viral infection, methods of making the same, and kits comprising the vaccine. The present invention relates to vaccine compositions specifically containing a complex comprising an adaptor-antigen polypeptide and a viral RNA scaffold. The present invention further relates to the use of the vaccine for the preparation of a pharmaceutical composition, methods of treating or preventing viral infection, and kits comprising the vaccine. [Background technology]
[0004] Vaccines act to stimulate a protective immune response in an individual, such as a human, against a specific pathogen, so that if the individual is later infected with that pathogen, the immune system can quickly prevent the infection from spreading through the body and causing disease. In this manner, the vaccine mimics a natural infection without causing illness. Traditionally, vaccines are administered by intramuscular injection. However, this method of administration does not successfully prime localized tissue-resident specific immune cells found within tissues or organs affected by viral infection (e.g., resident lung immune cells to prevent respiratory viral infections such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV)).
[0005] Administration of vaccines, such as recombinant protein vaccines, via nasal administration (e.g., nasal inhalation) has not yet been proven to be particularly effective and safe in humans, except when combined with an adjuvant. However, traditional adjuvants such as alum are generally inappropriate for mucosal vaccination in the human airway due to adverse side effects, including stimulating inflammatory immune responses, caused by exogenous adjuvants. There is a need for safe and effective vaccines that can be administered to relevant tissues (e.g., intranasally, orally, mucosally) to prime tissue-resident immune cells against viral targets in patients without causing side effects such as systemic inflammatory innate immune responses. Summary of the Invention [Means for solving the problem]
[0006] In one aspect, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising viral RNA; and ii) an adapter-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA.
[0007] In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is greater than about 5:1, such as any of 6:1, 7:1, 8:1, 9:1, or 10:1 or greater.
[0008] In some embodiments of any of the above vaccine compositions, the viral antigen is an antigenic polypeptide. In some embodiments, the viral antigen is an immunogenic protein.
[0009] In some embodiments of any of the above vaccine compositions, the viral antigen is fused to the C-terminus of the viral nucleoprotein. In some embodiments, the viral antigen is fused to the N-terminus of the viral nucleoprotein.
[0010] In some embodiments according to any of the above vaccine compositions, the viral RNA comprises an untranslated region of the viral genome, for example, a 5' untranslated region or a 3' untranslated region of a viral gene of the viral genome.
[0011] In some embodiments of any of the above vaccine compositions, the viral RNA is about 10 to about 500 (e.g., about 10 to about 300) nucleotides in length, for example, about 200 to about 500 (e.g., about 200 to about 300) nucleotides in length. In some embodiments, the viral RNA is at least about 200 nucleotides in length.
[0012] In some embodiments of any of the vaccine compositions above, the viral RNA is derived from SARS-CoV-2. In some embodiments, the viral RNA comprises nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome set forth in SEQ ID NO:25.
[0013] In some embodiments of any of the above vaccine compositions, the viral RNA is derived from an influenza A virus (IAV). In some embodiments, the viral RNA is derived from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. In some embodiments, the viral RNA comprises nucleotides 1-326 of the gene of the IAV genome set forth in SEQ ID NO:30.
[0014] In some embodiments of any of the above vaccine compositions, the viral nucleoprotein is derived from SARS-CoV-2. In some embodiments, the viral nucleoprotein derived from SARS-CoV-2 comprises the amino acid sequence of SEQ ID NO: 12.
[0015] In some embodiments of any of the above vaccine compositions, the viral core protein is derived from an IAV. In some embodiments, the viral core protein is derived from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. In some embodiments, the viral core protein from IAV H5N1 comprises the amino acid sequence of SEQ ID NO: 13.
[0016] In some embodiments of any of the above vaccine compositions, the viral nucleoprotein and viral antigens are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigens are derived from different viruses.
[0017] In some embodiments according to any of the above vaccine compositions, the viral antigen is a SARS-Cov-2 protein or a fragment or variant thereof, such as a SARS-CoV-2 spike protein or a fragment or variant thereof.
[0018] In some embodiments of any of the above vaccine compositions, the viral antigen comprises a receptor binding domain (RBD). In some embodiments, the SARS-CoV-2 viral antigen comprises the amino acid sequence of SEQ ID NO: 14 or 15.
[0019] In some embodiments according to any of the above vaccine compositions, the viral antigen is an influenza virus protein or a fragment or variant thereof, such as an influenza HA protein or a fragment or variant thereof. In some embodiments, the influenza virus protein or a fragment or variant thereof is derived from an influenza A virus (IAV) or an influenza B virus (IBV). In some embodiments, the influenza virus protein or a fragment or variant thereof is derived from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. In some embodiments, the IAV viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31. In some embodiments, the influenza virus protein or a fragment or variant thereof is derived from an IBV subtype of Yamagata or Victoria. In some embodiments, the IBV viral antigen comprises an amino acid sequence of SEQ ID NO: 19 or 20.
[0020] In some embodiments of any of the above vaccine compositions, the viral antigen is a respiratory syncytial virus ("RSV") protein, such as a RSV F protein or a fragment or variant thereof. In some embodiments, the RSV F protein or a fragment or variant thereof is derived from a RSV subtype selected from the group consisting of RSV A subtypes and RSV B subtypes. In some embodiments, the RSV viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22.
[0021] In some embodiments of any of the above vaccine compositions, the viral antigen is a Hepatitis C Virus ("HCV") protein or a fragment or variant thereof, such as an HCV E2 protein or a fragment or variant thereof. In some embodiments, the HCV E2 protein or a fragment or variant thereof is derived from an HCV genotype of HCV genotype 1a or HCV genotype 2a. In some embodiments, the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24.
[0022] In some embodiments of any of the above vaccine compositions, the adapter-antigen polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11 and 26-29.
[0023] In some embodiments of any of the vaccine compositions described above, the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm.
[0024] In some embodiments according to any of the above vaccine compositions, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV.
[0025] In some embodiments of any of the above vaccine compositions, the vaccine composition provides heterosubtypic protection against two or more viral subtypes that are from the same viral species (e.g., IAV, e.g., two or more of H1N1, H3N2, H5N1, and H7N9).
[0026] In another aspect, a method of preventing a viral infection in an individual (e.g., a human) is provided, comprising administering to the individual an effective amount of any of the above vaccine compositions. In some embodiments, the vaccine composition is administered by intranasal or intradermal administration. In some embodiments, the vaccine composition is administered in an initial dose, followed by one or two booster doses. In some embodiments, the initial dose and one or two booster doses are administered about 7 to about 21 days apart. In some embodiments, the initial dose and one or two booster doses are administered about 14 days apart. In some embodiments, the initial dose and the first booster dose, and the first booster dose and the second booster dose are administered about 7 to about 21 days apart, optionally about 14 days apart.
[0027] In some embodiments according to any of the above methods, the method prevents viral infection by two or more viruses from different viral genera. In some embodiments, the method prevents viral infection by SARS-CoV-2 and IAV. In some embodiments, the vaccine composition provides heterosubtypic protection against two or more viral species that are part of the same viral family, optionally the two or more viral species are part of the same viral genus. In some embodiments, i) the two or more viral species are from the same viral family, or ii) the two or more viral species are from different viral families. In some embodiments, the method prevents viral infection by three or more viral species, i) the three or more viral species are from the same viral family, ii) the three or more viral species are from different viral families, or iii) the three or more viral species include (a) two or more viral subtypes or subspecies that are from the same viral species, and (b) one or more viral species that are from a different viral family than the virus in (a).
[0028] The drawings illustrate certain features and advantages of the present disclosure. These embodiments are not intended to limit the scope of the appended claims in any manner. [Brief description of the drawings]
[0029] [Figure 1A] Nanocomposite vaccines against various viral antigens are shown. FIG. 1A shows a vaccine targeting coronavirus (i.e., SARS-CoV-2), including NC-CoV-01 and NC-CoV-02. FIG. 1B shows a vaccine targeting influenza virus, including NC-IAV-01, NC-IAV-02, NC-IAV-03, NC-IBV-01, and NC-IBV-02. FIG. 1C shows a vaccine targeting RSV, including NC-RSV-01 and NC-RSV-02. FIG. 1D shows a vaccine targeting HCV, including NC-HCV-01 and NC-HCV-02. RBD, receptor binding domain; HA, hemagglutinin; monoF, RSV F monomer; E2, envelope glycoprotein E2; NP, nucleoprotein; mini-vRNA, miniviral RNA. [Figure 1B] Nanocomposite vaccines against various viral antigens are shown. FIG. 1A shows a vaccine targeting coronavirus (i.e., SARS-CoV-2), including NC-CoV-01 and NC-CoV-02. FIG. 1B shows a vaccine targeting influenza virus, including NC-IAV-01, NC-IAV-02, NC-IAV-03, NC-IBV-01, and NC-IBV-02. FIG. 1C shows a vaccine targeting RSV, including NC-RSV-01 and NC-RSV-02. FIG. 1D shows a vaccine targeting HCV, including NC-HCV-01 and NC-HCV-02. RBD, receptor binding domain; HA, hemagglutinin; monoF, RSV F monomer; E2, envelope glycoprotein E2; NP, nucleoprotein; mini-vRNA, miniviral RNA. [Figure 1C]Nanocomposite vaccines against various viral antigens are shown. FIG. 1A shows a vaccine targeting coronavirus (i.e., SARS-CoV-2), including NC-CoV-01 and NC-CoV-02. FIG. 1B shows a vaccine targeting influenza virus, including NC-IAV-01, NC-IAV-02, NC-IAV-03, NC-IBV-01, and NC-IBV-02. FIG. 1C shows a vaccine targeting RSV, including NC-RSV-01 and NC-RSV-02. FIG. 1D shows a vaccine targeting HCV, including NC-HCV-01 and NC-HCV-02. RBD, receptor binding domain; HA, hemagglutinin; monoF, RSV F monomer; E2, envelope glycoprotein E2; NP, nucleoprotein; mini-vRNA, miniviral RNA. [Figure 1D] Nanocomposite vaccines against various viral antigens are shown. FIG. 1A shows a vaccine targeting coronavirus (i.e., SARS-CoV-2), including NC-CoV-01 and NC-CoV-02. FIG. 1B shows a vaccine targeting influenza virus, including NC-IAV-01, NC-IAV-02, NC-IAV-03, NC-IBV-01, and NC-IBV-02. FIG. 1C shows a vaccine targeting RSV, including NC-RSV-01 and NC-RSV-02. FIG. 1D shows a vaccine targeting HCV, including NC-HCV-01 and NC-HCV-02. RBD, receptor binding domain; HA, hemagglutinin; monoF, RSV F monomer; E2, envelope glycoprotein E2; NP, nucleoprotein; mini-vRNA, miniviral RNA. [Diagram 2] FIG. 1 shows a schematic diagram of the adaptor-antigen polypeptide and RNA scaffold components in an exemplary nanocomposite vaccine. [Figure 3A]Results from testing the nanocomplex formation of NC-CoV-01 vaccines are shown. Figure 3A shows the structure prediction of the adaptor-antigen component, nucleocapsid (NP)-RBD. Figure 3B provides SDS-PAGE results of the NP-RBD proteins tested. The left panel of Figure 3C shows the RNA secondary structure prediction of R266 (an exemplary RNA scaffold) and the right panel shows the 3D structure prediction of R266. Figure 3D shows that R266 was visualized using urea-PAGE. Figure 3E shows that the association of adaptor-antigen with R266 was confirmed by gel shift assay. Increasing amounts of NP-RBD and R266 were mixed and analyzed by urea-PAGE (top panel) and Western blot (bottom panel). Figure 3F shows that the association of adaptor-antigen with R266 was further confirmed by fluorescence polarization. Briefly, increasing concentrations of NP-RBD, full-length NP, and spike RBD proteins were mixed with HEX-labeled RNA oligos and fluorescence polarization measurements were taken. Kd in a particular buffer system was calculated. [Figure 3B] Results from testing the nanocomplex formation of NC-CoV-01 vaccines are shown. Figure 3A shows the structure prediction of the adaptor-antigen component, nucleocapsid (NP)-RBD. Figure 3B provides SDS-PAGE results of the NP-RBD proteins tested. The left panel of Figure 3C shows the RNA secondary structure prediction of R266 (an exemplary RNA scaffold) and the right panel shows the 3D structure prediction of R266. Figure 3D shows that R266 was visualized using urea-PAGE. Figure 3E shows that the association of adaptor-antigen with R266 was confirmed by gel shift assay. Increasing amounts of NP-RBD and R266 were mixed and analyzed by urea-PAGE (top panel) and Western blot (bottom panel). Figure 3F shows that the association of adaptor-antigen with R266 was further confirmed by fluorescence polarization. Briefly, increasing concentrations of NP-RBD, full-length NP, and spike RBD proteins were mixed with HEX-labeled RNA oligos and fluorescence polarization measurements were taken. Kd in a particular buffer system was calculated. [Figure 3C]Results from testing the nanocomplex formation of NC-CoV-01 vaccines are shown. Figure 3A shows the structure prediction of the adaptor-antigen component, nucleocapsid (NP)-RBD. Figure 3B provides SDS-PAGE results of the NP-RBD proteins tested. The left panel of Figure 3C shows the RNA secondary structure prediction of R266 (an exemplary RNA scaffold) and the right panel shows the 3D structure prediction of R266. Figure 3D shows that R266 was visualized using urea-PAGE. Figure 3E shows that the association of adaptor-antigen with R266 was confirmed by gel shift assay. Increasing amounts of NP-RBD and R266 were mixed and analyzed by urea-PAGE (top panel) and Western blot (bottom panel). Figure 3F shows that the association of adaptor-antigen with R266 was further confirmed by fluorescence polarization. Briefly, increasing concentrations of NP-RBD, full-length NP, and spike RBD proteins were mixed with HEX-labeled RNA oligos and fluorescence polarization measurements were taken. Kd in a particular buffer system was calculated. [Figure 3D] Results from testing the nanocomplex formation of NC-CoV-01 vaccines are shown. Figure 3A shows the structure prediction of the adaptor-antigen component, nucleocapsid (NP)-RBD. Figure 3B provides SDS-PAGE results of the NP-RBD proteins tested. The left panel of Figure 3C shows the RNA secondary structure prediction of R266 (an exemplary RNA scaffold) and the right panel shows the 3D structure prediction of R266. Figure 3D shows that R266 was visualized using urea-PAGE. Figure 3E shows that the association of adaptor-antigen with R266 was confirmed by gel shift assay. Increasing amounts of NP-RBD and R266 were mixed and analyzed by urea-PAGE (top panel) and Western blot (bottom panel). Figure 3F shows that the association of adaptor-antigen with R266 was further confirmed by fluorescence polarization. Briefly, increasing concentrations of NP-RBD, full-length NP, and spike RBD proteins were mixed with HEX-labeled RNA oligos and fluorescence polarization measurements were taken. Kd in a particular buffer system was calculated. [Figure 3E]Results from testing the nanocomplex formation of NC-CoV-01 vaccines are shown. Figure 3A shows the structure prediction of the adaptor-antigen component, nucleocapsid (NP)-RBD. Figure 3B provides SDS-PAGE results of the NP-RBD proteins tested. The left panel of Figure 3C shows the RNA secondary structure prediction of R266 (an exemplary RNA scaffold) and the right panel shows the 3D structure prediction of R266. Figure 3D shows that R266 was visualized using urea-PAGE. Figure 3E shows that the association of adaptor-antigen with R266 was confirmed by gel shift assay. Increasing amounts of NP-RBD and R266 were mixed and analyzed by urea-PAGE (top panel) and Western blot (bottom panel). Figure 3F shows that the association of adaptor-antigen with R266 was further confirmed by fluorescence polarization. Briefly, increasing concentrations of NP-RBD, full-length NP, and spike RBD proteins were mixed with HEX-labeled RNA oligos and fluorescence polarization measurements were taken. Kd in a particular buffer system was calculated. [Figure 3F] Results from testing the nanocomplex formation of NC-CoV-01 vaccines are shown. Figure 3A shows the structure prediction of the adaptor-antigen component, nucleocapsid (NP)-RBD. Figure 3B provides SDS-PAGE results of the NP-RBD proteins tested. The left panel of Figure 3C shows the RNA secondary structure prediction of R266 (an exemplary RNA scaffold) and the right panel shows the 3D structure prediction of R266. Figure 3D shows that R266 was visualized using urea-PAGE. Figure 3E shows that the association of adaptor-antigen with R266 was confirmed by gel shift assay. Increasing amounts of NP-RBD and R266 were mixed and analyzed by urea-PAGE (top panel) and Western blot (bottom panel). Figure 3F shows that the association of adaptor-antigen with R266 was further confirmed by fluorescence polarization. Briefly, increasing concentrations of NP-RBD, full-length NP, and spike RBD proteins were mixed with HEX-labeled RNA oligos and fluorescence polarization measurements were taken. Kd in a particular buffer system was calculated. [Figure 4A]We demonstrate that NC-CoV-01 induced mucosal immunity in vivo. Figure 4A provides a schematic showing immunization of NC-CoV-01 in animals. BALB / c mice were immunized intranasally with three doses of NP-RBD, NP-RBD+R20 (20 nt viral RNA) control, or NP-RBD+R266 (NC-CoV-01). Serum and bronchoalveolar fluid (BALF) were collected and tested by ELISA for antigen-specific antibodies. Figure 4B shows anti-spike RBD IgA responses in BALF. Figure 4C shows anti-spike RBD IgG responses in BALF. Figure 4D shows anti-spike RBD IgG responses in serum over days 14, 28, and 42 of the experiment. All ELISA results were presented as geometric mean titers with 95% confidence intervals. *: p<0.05, **: p<0.005, ***: p<0.0005, ns: not significant. [Figure 4B] We demonstrate that NC-CoV-01 induced mucosal immunity in vivo. Figure 4A provides a schematic showing immunization of NC-CoV-01 in animals. BALB / c mice were immunized intranasally with three doses of NP-RBD, NP-RBD+R20 (20 nt viral RNA) control, or NP-RBD+R266 (NC-CoV-01). Serum and bronchoalveolar fluid (BALF) were collected and tested by ELISA for antigen-specific antibodies. Figure 4B shows anti-spike RBD IgA responses in BALF. Figure 4C shows anti-spike RBD IgG responses in BALF. Figure 4D shows anti-spike RBD IgG responses in serum over days 14, 28, and 42 of the experiment. All ELISA results were presented as geometric mean titers with 95% confidence intervals. *: p<0.05, **: p<0.005, ***: p<0.0005, ns: not significant. [Figure 4C]We demonstrate that NC-CoV-01 induced mucosal immunity in vivo. Figure 4A provides a schematic showing immunization of NC-CoV-01 in animals. BALB / c mice were immunized intranasally with three doses of NP-RBD, NP-RBD+R20 (20 nt viral RNA) control, or NP-RBD+R266 (NC-CoV-01). Serum and bronchoalveolar fluid (BALF) were collected and tested by ELISA for antigen-specific antibodies. Figure 4B shows anti-spike RBD IgA responses in BALF. Figure 4C shows anti-spike RBD IgG responses in BALF. Figure 4D shows anti-spike RBD IgG responses in serum over days 14, 28, and 42 of the experiment. All ELISA results were presented as geometric mean titers with 95% confidence intervals. *: p<0.05, **: p<0.005, ***: p<0.0005, ns: not significant. [Figure 4D] We demonstrate that NC-CoV-01 induced mucosal immunity in vivo. Figure 4A provides a schematic showing immunization of NC-CoV-01 in animals. BALB / c mice were immunized intranasally with three doses of NP-RBD, NP-RBD+R20 (20 nt viral RNA) control, or NP-RBD+R266 (NC-CoV-01). Serum and bronchoalveolar fluid (BALF) were collected and tested by ELISA for antigen-specific antibodies. Figure 4B shows anti-spike RBD IgA responses in BALF. Figure 4C shows anti-spike RBD IgG responses in BALF. Figure 4D shows anti-spike RBD IgG responses in serum over days 14, 28, and 42 of the experiment. All ELISA results were presented as geometric mean titers with 95% confidence intervals. *: p<0.05, **: p<0.005, ***: p<0.0005, ns: not significant. [Figure 5A]Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5B] Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5C]Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5D] Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5E]Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5F] Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5G]Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5H] Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 5I]Figure 5 shows the gene expression results of various pro-inflammatory cytokines and chemokines in vivo after intranasal immunization against SARS-CoV-2 with NC-CoV-01 vaccine. Figure 5A shows a schematic diagram of the mouse intranasal immunization model. NP-RBD was mixed with either R20 or R266 and administered intranasally to BALB / c mice. BALF was collected 16 hours after administration. RNA was extracted from the cell pellets of these BALF and analyzed by RT-qPCR. Figure 5B-I show the induction of interferon-β (IFN-β, Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I), all of which are presented as fold ± SD. [Figure 6A] We show that the NC-CoV-01 vaccine protects mice against the development of SARS-CoV-2 infection. Figure 6A provides a schematic of the mouse intranasal immunization model. Figures 6B-C show viral infectious titer levels in lung (Figure 6B) and nasal turbinate (Figure 6C) homogenates analyzed by plaque assay. Data are presented as PFU per gram of tissue. Figure 6D shows immunohistology and H&E staining of mouse lungs, with SARS-CoV-2 nucleocapsid positive staining cells indicated by arrows. ND, not detected; H&E, hematoxylin and eosin. [Figure 6B] We show that the NC-CoV-01 vaccine protects mice against the development of SARS-CoV-2 infection. Figure 6A provides a schematic of the mouse intranasal immunization model. Figures 6B-C show viral infectious titer levels in lung (Figure 6B) and nasal turbinate (Figure 6C) homogenates analyzed by plaque assay. Data are presented as PFU per gram of tissue. Figure 6D shows immunohistology and H&E staining of mouse lungs, with SARS-CoV-2 nucleocapsid positive staining cells indicated by arrows. ND, not detected; H&E, hematoxylin and eosin. [Figure 6C]We show that the NC-CoV-01 vaccine protects mice against the development of SARS-CoV-2 infection. Figure 6A provides a schematic of the mouse intranasal immunization model. Figures 6B-C show viral infectious titer levels in lung (Figure 6B) and nasal turbinate (Figure 6C) homogenates analyzed by plaque assay. Data are presented as PFU per gram of tissue. Figure 6D shows immunohistology and H&E staining of mouse lungs, with SARS-CoV-2 nucleocapsid positive staining cells indicated by arrows. ND, not detected; H&E, hematoxylin and eosin. [Figure 6D] We show that the NC-CoV-01 vaccine protects mice against the development of SARS-CoV-2 infection. Figure 6A provides a schematic of the mouse intranasal immunization model. Figures 6B-C show viral infectious titer levels in lung (Figure 6B) and nasal turbinate (Figure 6C) homogenates analyzed by plaque assay. Data are presented as PFU per gram of tissue. Figure 6D shows immunohistology and H&E staining of mouse lungs, with SARS-CoV-2 nucleocapsid positive staining cells indicated by arrows. ND, not detected; H&E, hematoxylin and eosin. [Figure 7] 1 shows a SARS-CoV-2 / FluA bivalent nanocomplex vaccine against SARS-CoV-2 and influenza A virus antigens. In an exemplary bivalent nanocomplex vaccine format provided herein, a SARS-CoV-2 adapter is fused to an influenza A virus (IAV) antigen and then complexed to a SARS-CoV-2 mini-vRNA scaffold R266 to generate a bivalent nanocomplex (BiNC) vaccine (BiNC-01 and BiNC-02). Alternatively, an IAV adapter is fused to a SARS-CoV-2 antigen and then complexed to a mini-vRNA scaffold (e.g., IAV mini-vRNA, R326, or SARS-CoV-2 mini-vRNA, R266) to generate a BiNC vaccine (BiNC-03, BiNC-04). [Figure 8A]Figure 8 shows mouse antibody responses specific to H1N1 following intranasal vaccination with an exemplary BiNC-01 vaccine. Figure 8A shows serum IgG responses. Figure 8B shows BALF IgG responses. Figure 8C shows BALF IgA responses. [Figure 8B] Figure 8 shows mouse antibody responses specific to H1N1 following intranasal vaccination with an exemplary BiNC-01 vaccine. Figure 8A shows serum IgG responses. Figure 8B shows BALF IgG responses. Figure 8C shows BALF IgA responses. [Figure 8C] Figure 8 shows mouse antibody responses specific to H1N1 following intranasal vaccination with an exemplary BiNC-01 vaccine. Figure 8A shows serum IgG responses. Figure 8B shows BALF IgG responses. Figure 8C shows BALF IgA responses. [Figure 9A] Figure 9 shows mouse antibody responses specific to H5N1 following intranasal vaccination with an exemplary BiNC-02 vaccine. Figure 9A shows serum IgG responses. Figure 9B shows BALF IgG responses. Figure 9C shows BALF IgA responses. [Figure 9B] Figure 9 shows mouse antibody responses specific to H5N1 following intranasal vaccination with an exemplary BiNC-02 vaccine. Figure 9A shows serum IgG responses. Figure 9B shows BALF IgG responses. Figure 9C shows BALF IgA responses. [Figure 9C] Figure 9 shows mouse antibody responses specific to H5N1 following intranasal vaccination with an exemplary BiNC-02 vaccine. Figure 9A shows serum IgG responses. Figure 9B shows BALF IgG responses. Figure 9C shows BALF IgA responses. [Figure 10] Two exemplary influenza A-specific nanocomplex vaccines constructed using the adapter-antigen method are shown below: (1) an H1N1-specific (NC-IAV-01) vaccine, and (2) an H5N1-specific (NC-IAV-02) vaccine. [Figure 11A]We provide an outline of the viral complex (FIG. 11A) and in vivo vaccination experimental design (FIG. 11B). FIG. 11A provides a ribbon diagram showing the protein structure of the NC-IAV-01 nanocomplex vaccine. FIG. 11B provides a schematic showing immunization of animals with two doses of NC-IAV-01 administered intranasally. R326, an exemplary mini-vRNA scaffold derived from the IAV genome. [Figure 11B] We provide an outline of the viral complex (FIG. 11A) and in vivo vaccination experimental design (FIG. 11B). FIG. 11A provides a ribbon diagram showing the protein structure of the NC-IAV-01 nanocomplex vaccine. FIG. 11B provides a schematic showing immunization of animals with two doses of NC-IAV-01 administered intranasally. R326, an exemplary mini-vRNA scaffold derived from the IAV genome. [Figure 12A] Figure 12 shows mouse antibody responses specific to H1N1 following intranasal vaccination with an exemplary NC-IAV-01 nanocomplex vaccine. Figure 12A shows serum IgG responses. Figure 12B shows BALF IgG responses. Figure 12C shows BALF IgA responses. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 12B] Figure 12 shows mouse antibody responses specific to H1N1 following intranasal vaccination with an exemplary NC-IAV-01 nanocomplex vaccine. Figure 12A shows serum IgG responses. Figure 12B shows BALF IgG responses. Figure 12C shows BALF IgA responses. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 12C] Figure 12 shows mouse antibody responses specific to H1N1 following intranasal vaccination with an exemplary NC-IAV-01 nanocomplex vaccine. Figure 12A shows serum IgG responses. Figure 12B shows BALF IgG responses. Figure 12C shows BALF IgA responses. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 13A]Figure 13 shows neutralization of H1N1 by the mouse immune system after intranasal vaccination of BALB / c mice with an exemplary NC-IAV-01 nanocomposite vaccine. Figure 13A shows the in vivo serum hemagglutination inhibition response. Figure 13B shows the in vivo serum FRNT50 neutralization response. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 13B] Figure 13 shows neutralization of H1N1 by the mouse immune system after intranasal vaccination of BALB / c mice with an exemplary NC-IAV-01 nanocomposite vaccine. Figure 13A shows the in vivo serum hemagglutination inhibition response. Figure 13B shows the in vivo serum FRNT50 neutralization response. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 14A] Figure 14 shows the experimental design and associated results of live H1N1 virus challenge in mice intranasally vaccinated with two doses of an exemplary NC-IAV-01 nanocomplex vaccine. Figure 14A provides an outline of the experimental design, in which BALB / c mice were intranasally vaccinated with two doses of NC-IAV-01 and then challenged with live H1N1 virus. Figure 14B shows the results of monitoring the weight of mice over a 14-day period post-infection. Figure 14C shows the survival curve of infected mice up to 14 days post-infection. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 14B] Figure 14 shows the experimental design and associated results of live H1N1 virus challenge in mice intranasally vaccinated with two doses of an exemplary NC-IAV-01 nanocomplex vaccine. Figure 14A provides an outline of the experimental design, in which BALB / c mice were intranasally vaccinated with two doses of NC-IAV-01 and then challenged with live H1N1 virus. Figure 14B shows the results of monitoring the weight of mice over a 14-day period post-infection. Figure 14C shows the survival curve of infected mice up to 14 days post-infection. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 14C]Figure 14 shows the experimental design and associated results of live H1N1 virus challenge in mice intranasally vaccinated with two doses of an exemplary NC-IAV-01 nanocomplex vaccine. Figure 14A provides an outline of the experimental design, in which BALB / c mice were intranasally vaccinated with two doses of NC-IAV-01 and then challenged with live H1N1 virus. Figure 14B shows the results of monitoring the weight of mice over a 14-day period post-infection. Figure 14C shows the survival curve of infected mice up to 14 days post-infection. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 15A] A schematic of the NC-IAV-02 viral complex (FIG. 15A) and in vivo vaccination experimental design (FIG. 15B) are provided. FIG. 11A provides a ribbon diagram showing the protein structure of the NC-IAV-02 nanocomplex vaccine. FIG. 11B provides a schematic showing immunization of animals with two doses of NC-IAV-02 administered intranasally. R326, an exemplary mini-vRNA scaffold derived from the IAV genome. [Figure 15B] A schematic of the NC-IAV-02 viral complex (FIG. 15A) and in vivo vaccination experimental design (FIG. 15B) are provided. FIG. 11A provides a ribbon diagram showing the protein structure of the NC-IAV-02 nanocomplex vaccine. FIG. 11B provides a schematic showing immunization of animals with two doses of NC-IAV-02 administered intranasally. R326, an exemplary mini-vRNA scaffold derived from the IAV genome. [Figure 16A] Figure 16 shows mouse antibody responses specific to H5N1 following intranasal vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 16A shows serum IgG responses. Figure 16B shows BALF IgG responses. Figure 16C shows BALF IgA responses. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 16B]Figure 16 shows mouse antibody responses specific to H5N1 following intranasal vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 16A shows serum IgG responses. Figure 16B shows BALF IgG responses. Figure 16C shows BALF IgA responses. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 16C] Figure 16 shows mouse antibody responses specific to H5N1 following intranasal vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 16A shows serum IgG responses. Figure 16B shows BALF IgG responses. Figure 16C shows BALF IgA responses. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 17A] Figure 17 shows the experimental design and associated results of live H5N1 virus challenge in mice intranasally vaccinated with two doses of an exemplary NC-IAV-02 nanocomplex vaccine. Figure 17A provides an outline of the experimental design, in which BALB / c mice were intranasally vaccinated with two doses of NC-IAV-02 and then challenged with live H5N1 virus. Figure 17B shows the results of monitoring the weight of mice over a 14-day period post-infection. Figure 17C shows the survival curve of infected mice up to 14 days post-infection. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 17B] Figure 17 shows the experimental design and associated results of live H5N1 virus challenge in mice intranasally vaccinated with two doses of an exemplary NC-IAV-02 nanocomplex vaccine. Figure 17A provides an outline of the experimental design, in which BALB / c mice were intranasally vaccinated with two doses of NC-IAV-02 and then challenged with live H5N1 virus. Figure 17B shows the results of monitoring the weight of mice over a 14-day period post-infection. Figure 17C shows the survival curve of infected mice up to 14 days post-infection. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 17C]Figure 17 shows the experimental design and associated results of live H5N1 virus challenge in mice intranasally vaccinated with two doses of an exemplary NC-IAV-02 nanocomplex vaccine. Figure 17A provides an outline of the experimental design, in which BALB / c mice were intranasally vaccinated with two doses of NC-IAV-02 and then challenged with live H5N1 virus. Figure 17B shows the results of monitoring the weight of mice over a 14-day period post-infection. Figure 17C shows the survival curve of infected mice up to 14 days post-infection. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 18-1] Figure 18A shows the cross-reactivity of IAV adapter proteins against different IAV subtypes. Figure 18A provides an outline of the experimental design, where mice were intranasally immunized with either the exemplary NC-IAV-01 or the exemplary NC-IAV-02 nanocomplex vaccine. BALF cells and spleen cells were harvested 7 days after administration of the second dose and assayed by ELISpot using the original immunogen or NPs from different subtypes. Figures 18B-18C show the results of ELISpot assays using cells stimulated with the same immunogen as the vaccine (Figure 18B: NC-IAV-01, and Figure 18C: NC-IAV-02). Figure 18D shows the results of ELISpot assays using cells stimulated with viral nucleocapsids of different influenza A subtypes, i.e., H1N1, H5N1, H3N2, or H7N9, where the vaccine was NC-IAV-02. NP, nucleocapsid; R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 18-2]Figure 18A shows the cross-reactivity of IAV adapter proteins against different IAV subtypes. Figure 18A provides an outline of the experimental design, where mice were intranasally immunized with either the exemplary NC-IAV-01 or the exemplary NC-IAV-02 nanocomplex vaccine. BALF cells and spleen cells were harvested 7 days after administration of the second dose and assayed by ELISpot using the original immunogen or NPs from different subtypes. Figures 18B-18C show the results of ELISpot assays using cells stimulated with the same immunogen as the vaccine (Figure 18B: NC-IAV-01, and Figure 18C: NC-IAV-02). Figure 18D shows the results of ELISpot assays using cells stimulated with viral nucleocapsids of different influenza A subtypes, i.e., H1N1, H5N1, H3N2, or H7N9, where the vaccine was NC-IAV-02. NP, nucleocapsid; R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 19A] Figure 19 shows cross-protection against different IAV subtypes resulting from vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 19A provides an outline of the experimental design, where mice were intranasally immunized with two doses of NC-IAV-02 and then challenged with two different live IAV subtypes (H1N1 / PR8 and H7N9 / AH1). Figures 19B-19C show the weight change over 14 days (Figure 19B) and survival curves up to 14 days (Figure 19C) of mice challenged with live H1N1 / PR8 virus. Figures 19D-19E show the weight change over 14 days (Figure 19D) and survival curves up to 14 days (Figure 19E) of mice challenged with live H7N9 / AH1 virus. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 19B]Figure 19 shows cross-protection against different IAV subtypes resulting from vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 19A provides an outline of the experimental design, where mice were intranasally immunized with two doses of NC-IAV-02 and then challenged with two different live IAV subtypes (H1N1 / PR8 and H7N9 / AH1). Figures 19B-19C show the weight change over 14 days (Figure 19B) and survival curves up to 14 days (Figure 19C) of mice challenged with live H1N1 / PR8 virus. Figures 19D-19E show the weight change over 14 days (Figure 19D) and survival curves up to 14 days (Figure 19E) of mice challenged with live H7N9 / AH1 virus. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 19C] Figure 19 shows cross-protection against different IAV subtypes resulting from vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 19A provides an outline of the experimental design, where mice were intranasally immunized with two doses of NC-IAV-02 and then challenged with two different live IAV subtypes (H1N1 / PR8 and H7N9 / AH1). Figures 19B-19C show the weight change over 14 days (Figure 19B) and survival curves up to 14 days (Figure 19C) of mice challenged with live H1N1 / PR8 virus. Figures 19D-19E show the weight change over 14 days (Figure 19D) and survival curves up to 14 days (Figure 19E) of mice challenged with live H7N9 / AH1 virus. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 19D]Figure 19 shows cross-protection against different IAV subtypes resulting from vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 19A provides an outline of the experimental design, where mice were intranasally immunized with two doses of NC-IAV-02 and then challenged with two different live IAV subtypes (H1N1 / PR8 and H7N9 / AH1). Figures 19B-19C show the weight change over 14 days (Figure 19B) and survival curves up to 14 days (Figure 19C) of mice challenged with live H1N1 / PR8 virus. Figures 19D-19E show the weight change over 14 days (Figure 19D) and survival curves up to 14 days (Figure 19E) of mice challenged with live H7N9 / AH1 virus. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. [Figure 19E] Figure 19 shows cross-protection against different IAV subtypes resulting from vaccination with an exemplary NC-IAV-02 nanocomplex vaccine. Figure 19A provides an outline of the experimental design, where mice were intranasally immunized with two doses of NC-IAV-02 and then challenged with two different live IAV subtypes (H1N1 / PR8 and H7N9 / AH1). Figures 19B-19C show the weight change over 14 days (Figure 19B) and survival curves up to 14 days (Figure 19C) of mice challenged with live H1N1 / PR8 virus. Figures 19D-19E show the weight change over 14 days (Figure 19D) and survival curves up to 14 days (Figure 19E) of mice challenged with live H7N9 / AH1 virus. R326, an exemplary mini-vRNA scaffold derived from an IAV genome. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] The present application provides novel vaccine compositions and methods for vaccinating or treating individuals (e.g., humans) against a target disease, disorder, or infection, such as a viral infection. Specifically, the inventors have designed and tested a novel vaccine nanocomplex platform that includes two parts: (i) a nucleoprotein, also known as an adaptor-antigen polypeptide, fused with a target antigen (e.g., a viral antigen), and (ii) a nucleic acid scaffold that includes a viral RNA, e.g., a miniviral RNA (mini-vRNA). Since the nucleoprotein has a high affinity for the nucleic acid scaffold (e.g., viral RNA), the nucleic acid scaffold (e.g., viral RNA) scaffold is capable of binding multiple adaptor-antigen polypeptides. This vaccine nanocomplex platform demonstrates high vaccination efficacy that is significantly improved by both the formation of the adaptor-antigen / RNA nanocomplex, which increases the size of the immunogenic complex compared to conventional vaccines, and the presence of the nucleic acid scaffold (e.g., viral RNA) as an adjuvant to activate host innate immunity. Without being bound by theory, the use of this nanocomposite vaccine platform has many advantages: 1) the efficacy of vaccination by mucosal administration is safe and highly effective. 2) nanocomposite vaccines show an improved safety profile with no or low side effects compared to conventional vaccines (e.g., mild or indistinguishable symptoms, or nearly none, lower than conventional vaccines). 3) nasal spray of protein vaccines is relatively less invasive than intramuscular injections, potentially improving the induction of mucosal immunity to fight infections in the mucosa. 4) nasal spray of recombinant protein vaccines does not involve handling of infectious materials, and therefore does not involve safety concerns associated with infectious materials. 5) A mix-and-match approach to the construction of adaptor-antigenic polypeptides can provide effective bivalent vaccination from a single vaccine molecule. 6) Nanocomposite vaccines are capable of providing heterosubtypic protection against multiple virus subtypes (e.g., but not limited to, a nanocomposite vaccine targeting influenza A virus subtype H5N1 and also protecting against IAV subtypes H1N1, N3N2, and / or H7N9).
[0031] Thus, in one aspect, the present application provides a vaccine composition comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a nucleic acid (e.g., viral RNA); and ii) an adaptor-antigen polypeptide comprising a target antigen (e.g., viral antigen) fused to a viral nucleoprotein capable of binding to the nucleic acid (e.g., viral RNA).
[0032] In another aspect, methods are provided for preventing or treating a disease, disorder, or infection (e.g., a viral infection) in an individual (e.g., a human), comprising administering to the individual an effective amount of a vaccine composition. In some embodiments, the vaccine composition is administered by intranasal or intradermal administration.
[0033] All publications, including patent documents, scientific articles, and databases, referenced in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. To the extent that the definitions set forth herein conflict or are inconsistent with definitions set forth in the patents, applications, published applications, and other publications incorporated herein by reference, the definitions set forth herein take precedence over the definitions incorporated herein by reference.
[0034] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0035] I. Definition It will be understood by those skilled in the art that both uracil and thymine can be represented by "t" instead of "u" for uracil and "t" for thymine, and it will be understood that in the context of ribonucleic acids, unless otherwise indicated, "t" is used to represent uracil.
[0036] The term "genomic RNA" as used herein refers to the hereditary genetic information of an RNA virus. However, in the context of the present invention, the term "genome" also typically refers to the genome of an RNA virus, and thus to an RNA genome having a ribonucleic acid sequence. Those skilled in the art will understand that the genome of an RNA virus can also be provided as a DNA sequence in a vector such as a plasmid. The RNA genome is then generated in a host cell via transcription after transfection of the host cell. Thus, when referring to the nucleic acid sequence of a positive-sense RNA virus, it will be understood that the sequence in the "Sequence Listing" section can refer to an RNA sequence (with "U" replaced with "T") or a DNA sequence.
[0037] The term "gene" as used herein refers to a DNA or RNA locus of an inherited genomic sequence that affects the traits of an organism (e.g., an RNA virus) by being expressed as a functional product or by regulating gene expression. Genes and polynucleotides may include introns and exons, as in a genomic sequence, or only coding sequences, as in a cDNA, such as an open reading frame (ORF) that includes a start codon (methionine codon) and a translation stop codon. Genes and polynucleotides may also include regions that regulate their expression, such as transcription initiation, translation, and transcription termination. Thus, regulatory elements, such as promoters, are also included.
[0038] As used herein, the terms "nucleic acid," "nucleotide," and "polynucleotide" are used interchangeably and refer to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end, and include double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), single-stranded RNA (ssRNA, negative and positive sense), double-stranded RNA (dsRNA), genomic DNA, cDNA, cRNA, recombinant DNA, or recombinant RNA, and derivatives thereof, such as those containing modified backbones.
[0039] As used herein, the term "ribonucleic acid," "RNA," or "RNA oligonucleotide" describes a molecule consisting of a sequence of nucleotides constructed from nucleic acid bases, ribose sugars, and phosphate groups. RNA is usually a single-stranded molecule and can perform a variety of functions.
[0040] The terms "upstream" and "downstream" refer to relative positions in DNA or RNA. Each strand of DNA or RNA has a 5' end and a 3' end that are related to the terminal carbon positions of the deoxyribose or ribose units. Conventionally, "upstream" means toward the 5' end of a polynucleotide, while "downstream" means toward the 3' end of a polynucleotide. In the case of double-stranded DNA, e.g., genomic DNA, the term "upstream" means toward the 5' end of the coding strand, while "downstream" means toward the 3' end of the coding strand.
[0041] The term "coding strand" or "positive-sense strand" refers to the RNA strand that encodes the protein.
[0042] The terms "non-coding strand," "antisense strand," or "negative sense strand" or "negative strand" refer to the RNA strand that must be transcribed into positive strand RNA by RNA-dependent RNA polymerase before translation.
[0043] The terms "encode" and "code for" broadly refer to any process in which information in a polymeric macromolecule is used to direct the production of a second molecule that is different from the first molecule. The second molecule may have a different chemical structure than the chemical nature of the first molecule. For example, the term "encode" describes the process of semi-conservative DNA replication in which one strand of a double-stranded DNA molecule is used as a template to code for a newly synthesized complementary sister strand by a DNA-dependent DNA polymerase. Furthermore, a DNA molecule can code for an RNA molecule (e.g., by using a DNA-dependent RNA polymerase) or an RNA molecule (negative strand) can code for an RNA molecule (positive strand) (e.g., by using an RNA-dependent RNA polymerase). An RNA molecule (positive strand) can also code for a polypeptide, as in the process of translation. When used to describe the translation process, the term "encode" also extends to triplet codons that code for amino acids. An RNA molecule can also code for a DNA molecule, for example, by the process of reverse transcription using an RNA-dependent DNA polymerase. When referring to a DNA molecule encoding a polypeptide, reference is made to the processes of transcription and translation.
[0044] The term "expression" as used herein refers to the transcription and / or translation of a heterologous nucleic acid sequence in a host cell. The expression level of a gene product of interest in a host cell can be determined based on either the amount of corresponding mRNA (or positive strand RNA) present in the cell or the amount of a polypeptide encoded by a selected sequence. For example, RNA transcribed from a selected sequence can be quantified by Northern blot hybridization, ribonuclease RNA protection, in situ hybridization to cellular RNA, or PCR such as qPCR. The protein encoded by a selected sequence can be quantified by various methods, for example, by ELISA, by Western blotting, by radioimmunoassay, by immunoprecipitation, by assaying for protein biological activity, by immunostaining of the protein followed by FACS analysis, or by homogeneous time-resolved fluorescence (HTRF) assay. The expression level of a non-coding RNA, such as miRNA or shRNA, can be quantified by PCR, such as qPCR.
[0045] A "reference sequence" of a virus is a sequence that does not contain any human mutations (i.e., the wild-type virus sequence) and is the virus sequence against which all other versions are compared. For example, the reference SARS-CoV-2 virus is the strain that was originally isolated and is described as the hCoV-19 reference sequence by the Global Initiative on Sharing Avian Influenza Data (GISAID) under NIH GenBank Locus NC_045512.
[0046] As used herein, "treatment" or "treating" is an approach to obtain beneficial or desired results, including clinical results. For purposes of this application, beneficial or desired clinical results include, but are not limited to, one or more of the following: preventing the onset of a disease, enhancing immunity to a disease, reducing one or more symptoms resulting from a disease, attenuating the extent of a disease, stabilizing a disease (e.g., preventing or delaying the worsening of a disease), preventing or delaying the spread or transmission of a disease, preventing or delaying the onset or recurrence of a disease (i.e., infection or reinfection), delaying or slowing the progression of a disease, improving a disease state, reducing the dose of one or more other pharmaceutical agents required to treat a disease, delaying the progression of a disease, improving quality of life, and / or extending survival. Also encompassed by "treatment" is the reduction of pathological consequences of a disease. The methods of this application contemplate any one or more of these aspects of treatment.
[0047] As used herein, "preventing" includes providing prophylaxis against the occurrence or recurrence of a disease in a subject who may be susceptible to or at risk for a disease, but who has not yet suffered from or been diagnosed as having the disease.
[0048] The term "vaccine" is used in the broadest sense and specifically covers any biological preparation that provides active adaptive immunity against a particular infectious disease.
[0049] As used herein, the term "vaccination" refers to a clinical intervention designed to administer a therapeutically effective amount of a vaccine to an individual who has been exposed or may be exposed to a pathogen such as a virus in order to prevent infection, prophylactically immunize, prevent transmission, reduce the severity, induce an immune response, or treat infection in an individual in need thereof. For example, an effectively vaccinated individual may not suffer from disease caused by infection or may suffer only from mild disease, compared to an unvaccinated individual.
[0050] As used herein, "heterosubtypic immunity" refers to the ability to induce immunity in subjects across multiple virus species, subtypes, or subspecies. In this regard, a vaccine designed to target one virus subtype (e.g., influenza A virus subtype H5N1) will simultaneously provide cross-protection against other virus subtypes (e.g., IAV H1N1, H3N2, and / or H7N9) that were not specifically targeted by the vaccine, for example, due to genetic similarity. Heterosubtypic immunity can further extend to several viruses of different species of the same genus that are closely related genetically.
[0051] As used herein, the term "multivalent" when used in conjunction with a vaccine composition refers to a vaccine composition capable of inducing immunity against two, three, or more different virus species using one vaccine molecule, including virus species from the same virus genus or family and / or from different virus families or genera. For example, the two or more viruses may be genetically distinct such that they are unlikely to generate heterosubtypic immunity.
[0052] As used herein, "effective amount" refers to an amount of an agent or drug effective to vaccinate or treat a viral infection in a subject. A "therapeutically effective amount" may vary depending on the compound or cells, the disease and its severity, and the age, weight, etc., of the subject being treated.
[0053] The terms "individual," "subject," and "patient" are used interchangeably herein to describe a mammal, including a human. In some embodiments, the individual is a human. In some embodiments, the individual is a non-human. In some embodiments, the individual is suffering from a respiratory infection. In some embodiments, the individual is in need of treatment.
[0054] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, including, but not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition. The term also includes post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for purposes of this application, "polypeptide" refers to a protein containing modifications such as deletions, additions, and substitutions (generally conservative in nature) to the native sequence, so long as the protein maintains a desired activity. These modifications may be deliberate, through site-directed mutagenesis, or may be accidental, such as through errors due to mutations of the host producing the protein or PCR amplification.
[0055] As used herein, the terms "substantially similar" or "substantially the same" refer to a sufficiently high degree of identity between two or more numerical values that one of skill in the art would consider the difference between the two or more values to have little or no biological and / or statistical significance within the context of the biological characteristic measured by the values. In some embodiments, two or more substantially similar values differ by no more than any one of about 5%, 10%, 15%, 20%, 25%, or 50%.
[0056] A polypeptide "variant" refers to a biologically active polypeptide having at least about 80% amino acid sequence identity and up to 100% identity with a native sequence polypeptide after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Such variants include, for example, polypeptides in which one or more amino acid residues are added or deleted at the N-terminus or C-terminus of the polypeptide. In some embodiments, a variant has at least about 80% amino acid sequence identity. In some embodiments, a variant has at least about 90% amino acid sequence identity. In some embodiments, a variant has at least about 95% amino acid sequence identity with a native sequence polypeptide.
[0057] As used herein, "percent (%) amino acid sequence identity" with respect to a peptide, polypeptide, or antibody sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a particular peptide or polypeptide sequence, without considering any conservative substitutions as part of the sequence identity, after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in various ways within the skill of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring alignment, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.
[0058] As used herein, "percent (%) nucleic acid sequence identity" and "homology" with respect to a nucleic acid, DNA, or RNA sequence are defined as the percentage of nucleic acid nucleotides in a candidate sequence that are identical to the nucleic acid nucleotides in a particular DNA or RNA sequence, without considering any conservative substitutions as part of the sequence identity, after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms necessary to achieve maximum alignment over the entire length of the sequences being compared.
[0059] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that encode the same amino acid sequence, degenerate versions of each other. The phrase nucleotide sequence encoding a protein or RNA may also include introns to the extent that a nucleotide sequence encoding a protein may contain an intron(s) in some versions.
[0060] The term "operably linked" refers to a functional link between a regulatory sequence and a heterologous nucleic acid sequence, resulting in the expression of the heterologous nucleic acid sequence. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked if the promoter affects the transcription or expression of a coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, are in the same reading frame.
[0061] The term "vector" is used to describe a polynucleotide that can be engineered to contain a cloned polynucleotide(s) that can be propagated in a host cell. A vector can contain one or more of the following elements: an origin of replication, one or more regulatory sequences (such as, for example, a promoter and / or enhancer) that regulate the expression of a polypeptide of interest, and / or one or more selectable marker genes (such as, for example, antibiotic resistance genes and genes that can be used in colorimetric assays, such as, for example, β-galactosidase). The term "expression vector" refers to a vector used to express a polypeptide of interest in a host cell.
[0062] The term "cell" includes the primary subject cell and its progeny. "Host cell" refers to a cell that can be or is the recipient of a vector or isolated polynucleotide. A host cell may be a prokaryotic or eukaryotic cell. Exemplary eukaryotic cells include mammalian cells, such as primate or non-primate animal cells; fungal cells, such as yeast; plant cells; and insect cells. Non-limiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6® cells (Crucell), and 293 and CHO cells, and their derivatives, such as 293-6E cells and DG44 cells, respectively.
[0063] As used herein, "pharmacologically acceptable" or "pharmacologically compatible" means a material that is not biologically or undesirable, e.g., the material can be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. A pharma-ceutically acceptable carrier or excipient preferably meets the required standards of toxicological and manufacturing testing and / or is included in the Inactive Ingredients Guide prepared by the U.S. Food and Drug Administration.
[0064] It is understood that embodiments of the invention described herein include "consisting of" and / or "consisting essentially of" embodiments.
[0065] Reference herein to "about" a value or parameter includes (and accounts for) the variation relative to that value or parameter itself. For example, a statement referring to "about X" includes the statement of "X."
[0066] As used herein, the term "about X to Y" has the same meaning as "about X to about Y."
[0067] As used herein, a reference to "not" a value or parameter generally means and describes "other" than the value or parameter. For example, not using the method to treat cancer type X means using the method to treat types of cancer other than type X.
[0068] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0069] II. Nanocomposite Vaccine Compositions Provided herein is a vaccine composition comprising one or more nanocomplexes, the vaccine composition comprising: i) a scaffold molecule comprising a nucleic acid; and ii) an adaptor-antigen polypeptide comprising a target antigen fused to a viral nucleoprotein capable of binding to the nucleic acid. The scaffold molecule may comprise an RNA molecule or a DNA molecule. In some embodiments, the scaffold molecule comprises viral RNA. In some embodiments, the target antigen is a viral antigen. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are from different viruses. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigen are from the same virus. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus and the viral antigen are from different viruses. In some embodiments, the viral RNA and viral antigen are from the same virus and the viral nucleoprotein are from different viruses.
[0070] In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule (e.g., viral RNA) is at least about 5:1. In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is about 6:1 to about 12:1, such as about 6:1 to about 10:1, about 8:1 to about 12:1, or about 6:1 to about 8:1. For example, in some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is about any of 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, or 12:1, or a range between any of these ratios.
[0071] In some embodiments, a vaccine composition is provided that includes a nanocomplex, the nanocomplex including: i) a scaffold molecule that includes a viral RNA; and ii) an adaptor-antigen polypeptide that includes a viral antigen fused to a viral nucleoprotein that can bind to the viral RNA. In some embodiments, the viral antigen is, for example, a SARS-CoV-2 protein or a fragment or variant thereof, such as a SARS-CoV-2 spike protein or a fragment or variant thereof that includes an RBD peptide. In some embodiments, the SARS-CoV-2 viral antigen includes an amino acid sequence of SEQ ID NO: 14 or 15, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 14 or 15. In some embodiments, the viral antigen is an influenza virus protein or a fragment or variant thereof, such as an influenza HA protein or a fragment or variant thereof. In some embodiments, the influenza virus antigen comprises an influenza A virus (IAV) comprising, for example, an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31. In some embodiments, the influenza virus antigen comprises an influenza B virus (IBV) antigen, for example, an IBV virus antigen comprising, for example, an amino acid sequence of SEQ ID NO: 19 or 20, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 19 or 20. In some embodiments, the viral antigen is a RSV protein or a fragment or variant thereof, for example, a RSV F protein or a fragment or variant thereof.In some embodiments, the RSV viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 21 or 22. In some embodiments, the viral antigen is an HCV protein or a fragment or variant thereof, such as an HCV E2 protein or a fragment or variant thereof. In some embodiments, the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 23 or 24. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genera, species, or subtypes. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigens are derived from the same virus. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigens are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral antigens are derived from the same virus and the viral nucleoprotein is derived from different viruses. In some embodiments, the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplexes in the vaccine composition have a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1).In some embodiments, the viral RNA is about 10 to about 500 (eg, about 200 to about 500) nucleotides in length. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein.
[0072] In some embodiments, a vaccine composition is provided that includes a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from SARS-CoV-2. In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 12, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 12. In some embodiments, the viral nucleoprotein and viral antigen are derived from the same virus. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genus, species, or subtypes. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigen are derived from the same virus. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are derived from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are from different viruses. In some embodiments, the viral RNA and the viral nucleoprotein are from the same virus and the viral antigen are from different viruses. In some embodiments, the viral RNA and the viral antigen are from the same virus and the viral nucleoprotein is from different viruses. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of the adaptor-antigen polypeptide to the scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500) nucleotides in length.In some embodiments, the viral RNA is derived from SARS-CoV-2, for example, including nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome set forth in SEQ ID NO: 25. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker).
[0073] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from an IAV (e.g., H1N1, H3N2, H5N1, or H7N9). In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 13, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 13. In some embodiments, the viral nucleoprotein and viral antigen are derived from the same virus. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genus, species, or subtypes. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigen are derived from the same virus. In some embodiments, the viral RNA and the viral nucleoprotein are from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are from different viruses. In some embodiments, the viral RNA and the viral nucleoprotein are from the same virus and the viral antigen are from different viruses. In some embodiments, the viral RNA and the viral antigen are from the same virus and the viral nucleoprotein are from different viruses. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of the adaptor-antigen polypeptide to the scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500) nucleotides in length.In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker).
[0074] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral RNA comprises a non-translated region of a viral genome (e.g., a 5' or 3' non-translated region of a viral gene of the viral genome). In some embodiments, the viral RNA comprises a non-translated region (e.g., a 5' or 3' non-translated region) of a viral gene of the genome of SARS-CoV-2. In some embodiments, the viral RNA comprises nucleotides 1-266 of a viral gene of the genome of SARS-CoV-2 (e.g., as set forth in SEQ ID NO: 25). In some embodiments, the viral RNA and the viral nucleoprotein are derived from the same virus. In some embodiments, the viral nucleoprotein is derived from SARS-CoV-2. In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising i) a scaffold molecule comprising a viral RNA, and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral RNA comprises nucleotides 1-266 of a viral gene of the SARS-CoV-2 genome set forth in SEQ ID NO:25. In some embodiments, the viral nucleoprotein is derived from an IAV. In some embodiments, the viral RNA comprises an untranslated region (e.g., the 5' untranslated region or the 3' untranslated region) of the genome of the IAV. In some embodiments, the viral RNA comprises nucleotides 1-326 of a viral gene of the genome of the IAV (e.g., as set forth in SEQ ID NO:30). Thus, in some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising i) a scaffold molecule comprising a viral RNA, and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral RNA comprises nucleotides 1-326 of a viral gene of the IAV genome set forth in SEQ ID NO:30.In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigens are derived from different viruses, e.g., different viral families, genus, species, or subtypes. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigens are derived from the same virus. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigens are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral antigens are derived from the same virus and the viral nucleoprotein is derived from a different virus. In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500, or about 200 to about 300) nucleotides in length. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker).
[0075] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral nucleoprotein is derived from SARS-CoV-2, and the viral RNA comprises a 5' or 3' untranslated region of a viral gene of the viral genome (such as the 5' or 3' UTR of a SARS-CoV-2 gene or an IAV gene). In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from SARS-CoV-2, and the viral RNA comprising (a) a 5' untranslated region (e.g., nucleotides 1-266) of a viral gene in the genome of SARS-CoV-2 (SARS-CoV-2 Reference Sequence: SEQ ID NO:25) or (b) a 5' untranslated region (e.g., nucleotides 1-326) of a viral gene in the genome of IAV (IAV H7N9 Reference Sequence: SEQ ID NO:30). In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO:12, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO:12. In some embodiments, the viral antigen is, for example, a SARS-Cov-2 protein or a fragment or variant thereof, such as, for example, a SARS-CoV-2 spike protein or a fragment or variant thereof, including an RBD peptide. In some embodiments, the viral antigen is an influenza virus protein or a fragment or variant thereof, such as, for example, an influenza HA protein or a fragment or variant thereof. In some embodiments, the viral antigen is an RSV protein or a fragment or variant thereof, such as, for example, an RSV F protein or a fragment or variant thereof.In some embodiments, the viral antigen is an HCV protein or a fragment or variant thereof, such as an HCV E2 protein or a fragment or variant thereof. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are from different viruses, e.g., different viral families, genus, species, or subtypes. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigen are from the same virus. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus and the viral antigen are from different viruses. In some embodiments, the viral RNA and viral antigen are from the same virus and the viral nucleoprotein is from a different virus. In some embodiments, the viral RNA and viral antigen are from the same virus and the viral nucleoprotein is from a different virus. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 300) nucleotides in length. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker).
[0076] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adapter-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral nucleoprotein is derived from an IAV (e.g., H1N1, H3N2, H5N1, or H7N9), and the viral RNA comprises a 5' or 3' untranslated region of a viral gene of the viral genome (such as the 5' or 3' UTR of a SARS-CoV-2 gene or an IAV gene). In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from an IAV, and the viral RNA comprising: a) a 5' untranslated region (e.g., nucleotides 1-266) of a viral gene in the genome of SARS-CoV-2 (SARS-CoV-2 Reference Sequence: SEQ ID NO:25) or (b) a 5' untranslated region (e.g., nucleotides 1-326) of a viral gene in the genome of an IAV (IAV H7N9 Reference Sequence: SEQ ID NO:30). In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO:13, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO:13. In some embodiments, the viral antigen is, for example, a SARS-Cov-2 protein or a fragment or variant thereof, such as, for example, a SARS-CoV-2 spike protein or a fragment or variant thereof, including an RBD peptide. In some embodiments, the viral antigen is an influenza virus protein or a fragment or variant thereof, such as, for example, an influenza HA protein or a fragment or variant thereof. In some embodiments, the viral antigen is an RSV protein or a fragment or variant thereof, such as, for example, an RSV F protein or a fragment or variant thereof.In some embodiments, the viral antigen is an HCV protein or a fragment or variant thereof, such as an HCV E2 protein or a fragment or variant thereof. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are from different viruses, e.g., different viral families, genus, species, or subtypes. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigen are from the same virus. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus and the viral antigen are from different viruses. In some embodiments, the viral RNA and viral antigen are from the same virus and the viral nucleoprotein is from a different virus. In some embodiments, the viral RNA and viral antigen are from the same virus and the viral nucleoprotein is from a different virus. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500) nucleotides in length. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker).
[0077] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral nucleoprotein is derived from SARS-CoV-2 (e.g., comprising SEQ ID NO: 12), the viral RNA comprises a 5' untranslated region of a gene of the SARS-CoV-2 genome (e.g., nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome sequence of SEQ ID NO: 25), and the viral antigen is a SARS-CoV-2 protein or a fragment or variant thereof (e.g., SARS-CoV-2 spike protein or a fragment or variant thereof comprising the RBD peptide). In some embodiments, the SARS-CoV-2 viral antigen comprises the amino acid sequence of SEQ ID NO: 14 or 15, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 14 or 15. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigens are from different viral strains, e.g., different viral subspecies, variants, subvariants, or subtypes (e.g., SARS-CoV-2 variants, e.g., B.1.1.7, B.1.351, B.1.526, B1.526.1, B1.617, B.1.617.1, B.1.617.2, B1.617.3, P.2, P.1, or B.1.1.28.1, A.23.1, CAL.20C, B.1.427, B.1.429, B.1.525, BA.2, BA.5, BA.2.75.2, BQ.1, BQ.1.1, XBB, and / or P.1.351). In some embodiments, the viral RNA, viral nucleoprotein, and viral antigens are from the same viral strain. In some embodiments, the viral RNA and the viral nucleoprotein are from the same viral strain.In some embodiments, the viral nucleoprotein and viral antigens are from the same viral strain. In some embodiments, the viral nucleoprotein and viral antigens are from different viral strains. In some embodiments, the viral RNA and viral nucleoprotein are from the same viral strain and the viral antigens are from different viral strains. In some embodiments, the viral RNA and viral antigens are from the same viral strain and the viral nucleoprotein is from different viral strains. In some embodiments, the adapter-antigen polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or 2. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 300 (e.g., about 200 to about 300) nucleotides in length.
[0078] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from SARS-CoV-2 (e.g., comprising SEQ ID NO: 12), the viral RNA comprising a 5' untranslated region of a gene of the SARS-CoV-2 genome (e.g., nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome sequence of SEQ ID NO: 25), and the viral antigen being an influenza virus protein or a fragment or variant thereof (e.g., an influenza HA protein or a fragment or variant thereof). In some embodiments, the influenza virus protein or a fragment or variant thereof is derived from an IAV or IBV. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral antigen is an IAV antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31. In some embodiments, the adapter-antigen polypeptide comprises the amino acid sequence of SEQ ID NO: 26 or 27. In some embodiments, the viral antigen is an IBV antigen comprising an amino acid sequence of SEQ ID NO: 19 or 20, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 19 or 20. In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigens are derived from different viruses, e.g., different viral families, genera, species, and / or subtypes.In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigen is derived from a different virus. In some embodiments, the viral RNA and viral nucleoprotein are derived from different viral strains (e.g., viral subtypes or subspecies). In some embodiments, the viral RNA and viral nucleoprotein are derived from the same viral strain. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 300 (e.g., about 200 to about 300) nucleotides in length.
[0079] In some embodiments, a vaccine composition is provided that includes a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from SARS-CoV-2 (e.g., comprising SEQ ID NO: 12), the viral RNA comprising a 5' untranslated region of a gene of the SARS-CoV-2 genome (e.g., nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome sequence of SEQ ID NO: 25), and the viral antigen is a RSV viral protein or a fragment or variant thereof (e.g., a RSV F protein or a fragment or variant thereof). In some embodiments, the RSV viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 21 or 22. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genus, species, and / or subtypes. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are derived from different viral strains (e.g., viral subtypes or subspecies). In some embodiments, the viral RNA and viral nucleoprotein are derived from the same viral strain. In some embodiments, the adapter-antigen polypeptide comprises the amino acid sequence of SEQ ID NO: 8 or 9. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV.In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 300) nucleotides in length.
[0080] In some embodiments, a vaccine composition is provided that includes a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from SARS-CoV-2 (e.g., comprising SEQ ID NO: 12), the viral RNA comprising a 5' untranslated region of a gene of the SARS-CoV-2 genome (e.g., nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome sequence of SEQ ID NO: 25), and the viral antigen is an HCV viral protein or a fragment or variant thereof (e.g., an HCV E2 protein or a fragment or variant thereof). In some embodiments, the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 23 or 24. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genera, species, and / or subtypes. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are derived from different viral strains (e.g., viral subtypes or subspecies). In some embodiments, the viral RNA and viral nucleoprotein are derived from the same viral strain. In some embodiments, the adapter-antigen polypeptide comprises the amino acid sequence of SEQ ID NO: 10 or 11. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV.In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 300) nucleotides in length.
[0081] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral nucleoprotein is derived from an IAV (e.g., comprising SEQ ID NO: 13), the viral RNA comprises a 5' untranslated region of a gene of the IAV genome (e.g., nucleotides 1-326 of the viral gene of the IAV genome sequence of SEQ ID NO: 30), the viral antigen is an influenza virus protein or fragment or variant thereof (e.g., an influenza HA protein or fragment or variant thereof), and the viral antigen is a SARS-Cov-2 protein or fragment or variant thereof (e.g., a SARS-CoV-2 spike protein or fragment or variant thereof comprising an RBD peptide). In some embodiments, the SARS-CoV-2 viral antigen comprises the amino acid sequence of SEQ ID NO: 14 or 15, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 14 or 15. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genera, species, and / or subtypes. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are derived from different viral strains (e.g., viral subtypes or subspecies). In some embodiments, the viral RNA and viral nucleoprotein are derived from the same viral strain. In some embodiments, the adaptor-antigen polypeptide comprises the amino acid sequence of SEQ ID NO:28 or 29.In some embodiments, the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplexes in the vaccine composition have a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500) nucleotides in length.
[0082] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, the viral nucleoprotein being derived from an IAV (e.g., comprising SEQ ID NO: 13), the viral RNA comprising a 5' untranslated region of a gene of an IAV genome (e.g., nucleotides 1-326 of the viral gene of the IAV genome sequence of SEQ ID NO: 30), and the viral antigen being an influenza viral protein or a fragment or variant thereof (e.g., an influenza HA protein or a fragment or variant thereof). In some embodiments, the influenza viral protein or a fragment or variant thereof is derived from an IAV or IBV. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral antigen comprises an IAV antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31. In some embodiments, the adapter-antigen polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5. In some embodiments, the viral antigen comprises an IBV antigen comprising an amino acid sequence of SEQ ID NO: 19 or 20, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 19 or 20. In some embodiments, the adapter-antigen polypeptide comprises the amino acid sequence of SEQ ID NO: 6 or 7. In some embodiments, the viral RNA, viral nucleoprotein, and viral antigens are derived from the same viral strain (e.g., viral subspecies or viral subtype).In some embodiments, the viral RNA and the viral nucleoprotein are from the same viral strain. In some embodiments, the viral nucleoprotein and the viral antigen are from the same viral strain. In some embodiments, the viral nucleoprotein and the viral antigen are from different viral strains. In some embodiments, the viral RNA and the viral nucleoprotein are from the same viral strain and the viral antigen are from different viral strains. In some embodiments, the viral RNA and the viral antigen are from the same viral strain and the viral nucleoprotein is from different viral strains. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of the adaptor-antigen polypeptide to the scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500) nucleotides in length.
[0083] In some embodiments, a vaccine composition is provided comprising a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral nucleoprotein is derived from an IAV (e.g., comprising SEQ ID NO: 13), the viral RNA comprises a 5' untranslated region of a gene of an IAV genome (e.g., nucleotides 1-326 of the viral gene of the IAV genome sequence of SEQ ID NO: 30), the viral antigen is an influenza viral protein or fragment or variant thereof (e.g., an influenza HA protein or fragment or variant thereof), and the viral antigen is a RSV viral protein or fragment or variant thereof (e.g., a RSV F protein or fragment or variant thereof). In some embodiments, the RSV viral antigen comprises an amino acid sequence of SEQ ID NO: 21 or 22, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 21 or 22. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are from different viruses, e.g., different viral families, genera, species, and / or subtypes. In some embodiments, the viral RNA and viral nucleoprotein are from the same virus and the viral antigen are from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are from different viral strains (e.g., viral subtypes or subspecies). In some embodiments, the viral RNA and viral nucleoprotein are from the same viral strain. In some embodiments, the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm, In some embodiments, the nanocomplexes in the vaccine composition have a zeta potential of about -10 mV to about -20 mV.In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 200 to about 500) nucleotides in length.
[0084] In some embodiments, a vaccine composition is provided that includes a nanocomplex, the nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA, wherein the viral nucleoprotein is derived from an IAV (e.g., comprising SEQ ID NO: 13), the viral RNA comprises a 5' untranslated region of a gene of the IAV genome (e.g., nucleotides 1-326 of the viral gene of the IAV genome sequence of SEQ ID NO: 30), and the viral antigen is an HCV viral protein or a fragment or variant thereof (e.g., an HCV E2 protein or a fragment or variant thereof). In some embodiments, the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 23 or 24. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral RNA, viral nucleoprotein, and / or viral antigen are derived from different viruses, e.g., different viral families, genera, species, and / or subtypes. In some embodiments, the viral RNA and viral nucleoprotein are derived from the same virus and the viral antigens are derived from different viruses. In some embodiments, the viral RNA and viral nucleoprotein are derived from different viral strains (e.g., viral subtypes or subspecies). In some embodiments, the viral RNA and viral nucleoprotein are derived from the same viral strain. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. In some embodiments, the molar ratio of adapter-antigen polypeptide to scaffold molecule is at least about 5:1 (e.g., about 6:1 to about 12:1).In some embodiments, the viral RNA is about 10 to about 500 (eg, about 200 to about 500) nucleotides in length.
[0085] Adapter-antigen polypeptides In some embodiments, the adapter-antigen polypeptide comprises a target antigen fused to a nucleoprotein (e.g., a viral nucleoprotein) capable of binding to a nucleic acid (e.g., RNA or DNA). In some embodiments, the target antigen is a viral antigen. In some embodiments, the RNA is a viral RNA, e.g., a miniviral RNA. In some embodiments, the RNA is a non-viral RNA. In some embodiments, the RNA is a host RNA. In some embodiments, the target antigen is fused to the N-terminus of the nucleoprotein (e.g., a viral nucleoprotein). In some embodiments, the target antigen is fused to the C-terminus of the nucleoprotein (e.g., a viral nucleoprotein). In some embodiments, there is a linker (e.g., a peptide linker) connecting the target antigen and the nucleoprotein. Any linker capable of imparting the desired spacing between the adapter-antigen polypeptide components and / or flexibility of the adapter-antigen polypeptide may be used herein. In some embodiments, the linker comprises an amino acid sequence of GS.
[0086] Nuclear proteins In some embodiments, the nucleoprotein (e.g., a viral nucleoprotein) comprises a domain and / or subdomain capable of binding to a nucleic acid, e.g., single- or double-stranded DNA or RNA. In some embodiments, the nucleoprotein comprises an RNA binding domain. In some embodiments, the viral nucleoprotein is capable of binding to RNA, e.g., viral RNA (e.g., miniviral RNA), non-viral RNA (e.g., host RNA). In some embodiments, the nucleic acid (e.g., viral RNA) acts as a scaffold molecule.
[0087] In some embodiments, a nucleoprotein, e.g., a viral nucleoprotein, is naturally associated with a viral RNA. In some embodiments, multiple copies of an adaptor-antigen polypeptide (e.g., 2, 3, 4, 5, 6, 7, 9, 10, 20, 30, 50, 60, 70, 80, 90, 100, or more copies of an adaptor-antigen polypeptide) are bound to a single viral RNA scaffold.
[0088] In some embodiments, the RNA scaffold (e.g., viral RNA) also acts as an adjuvant, such that the attached adapter-antigen polypeptide encases the viral RNA, thereby masking the adjuvant to prevent irritant responses, such as inflammation, caused by conventional exogenous adjuvants upon mucosal administration of conventional vaccines. In some embodiments, the attached adapter-antigen polypeptide prevents the induction of an innate immune response (e.g., an excessive innate immune response), including the production (e.g., excessive production) of inflammatory cytokines upon mucosal administration of the vaccine composition to an individual (e.g., a human individual). Thus, in some embodiments, the vaccine compositions provided herein induce fewer (or no) side effects upon mucosal administration to an individual (e.g., a human individual) than vaccines that include conventional adjuvants as currently known in the art.
[0089] In some embodiments, the vaccine composition is directly phagocytosed by antigen-presenting cells (APCs). In some embodiments, the RNA scaffold (e.g., viral RNA) activates APCs upon phagocytosis of the vaccine composition. In some embodiments, the attached adaptor-antigen polypeptide prevents the induction of an innate immune response prior to APC phagocytosis.
[0090] In some embodiments, the nucleoprotein is derived from a virus, such as any virus known or to be discovered, including any of the exemplary viruses described herein. In some embodiments, the nucleoprotein (e.g., viral nucleoprotein) is derived from SARS-CoV-2. In some embodiments, the nucleoprotein comprises (or consists essentially of, or consists of) a portion of a viral protein, e.g., SARS-CoV-2 RBD. In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 12. In some embodiments, the nucleoprotein (e.g., viral nucleoprotein) is derived from an IAV (e.g., IAV H7N9, e.g., IAV H7N9 / ZJ). In some embodiments, the nucleoprotein comprises (or consists essentially of, or consists of) a portion of an IAV viral protein. In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 13. In some embodiments, the viral nucleoprotein is fused to a target antigen peptide, e.g., a viral antigen peptide, such as any of the target antigen peptides described below. In some embodiments, the nucleoprotein and the target antigen are derived from the same source, e.g., the same virus. In some embodiments, the nucleoprotein and the target antigen are derived from different sources, e.g., different viruses, e.g., different subtypes of a virus, different species of a virus, or different viral families. In some embodiments, the nucleoprotein and the scaffolding molecule (e.g., nucleic acid, e.g., viral RNA) are derived from the same source, e.g., the same virus. In some embodiments, the nucleoprotein and the scaffolding molecule (e.g., nucleic acid, e.g., viral RNA) are derived from different sources, e.g., different viruses, e.g., different subtypes of a virus, different species of a virus, or different viral families.
[0091] target antigen In some embodiments, the target antigen is a viral antigen. In some embodiments, the viral antigen is an antigenic polypeptide (e.g., an immunogenic polypeptide). The viral antigen of the present disclosure can include any viral antigen known or to be discovered in the art. The viral antigen can be a wild-type protein, or a mutant or variant form (e.g., with increased or decreased immunogenic activity).
[0092] In some embodiments, the viral antigen is a peptide encoded by the viral genome. The viral antigen peptide may have a length of about 10 to about 500 amino acids (aa), such as about 100 to about 300 aa, about 200 to about 500 aa, about 10 to about 300 aa, about 100 to about 200 aa, about 10 to about 100 aa, about 200 to about 450 aa, about 300 to about 500 aa, or about 10 to about 80 aa. For example, the viral antigen peptide may have a length of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 350, 400, 450, or 500 amino acids, or a range between any of these aa lengths. The main viral antigens that induce protective antibody responses are surface glycoproteins of viruses that contain a lipid envelope, or proteins present on the surface of icosahedral viruses. IgA antibodies recognize the same viral proteins as IgG antibodies.For example, polyclonal IgA antibodies, such as polyclonal IgG antibodies, can be used to bind to influenza virus hemagglutinin (see, e.g., Clements et al., J Clin Microbiol. 1986, 24(1):157-160 and Murphy et al., Infect Immun. 1982, 36(3):1108-1108), respiratory syncytial virus gp70 (fusion) and gp90 (attachment glycoproteins) (see, e.g., Murphy et al., J Clin Microbiol. 1986, 23(6):1009-1014), Epstein-Barr virus gp340 (see, e.g., Yao et al., Int J Cancer 1991, 48(1):45-50), poliovirus viral proteins (VP) 1, VP2, and VP3 (see, e.g., Zhaori et al., J Infect Immun. 1992, 36(3):1108-1108), and the like. Dis. 1989, 159(6):1018-1024), as well as rotavirus VP4 or VP7 (see, e.g., Conner et al., J Virol. 1991, 65(5):2562-2571; Richardson and Bishop, J Clin Microbiol. 1990, 28(9):1891-1897; and Shaw et al., J Virol. 1991, 65(6):3052-3059).
[0093] Exemplary target antigens derived from viral proteins described below include virion surface or membrane proteins, such as the SARS-CoV-2 spike (S; containing the receptor binding domain) protein, influenza hemagglutinin (HA) protein, respiratory syncytial virus (RSV) fusion (F) protein, or hepatitis C virus (HCV) envelope glycoprotein E2. For example, target antigens including viral envelope, viral membrane, or associated proteins may be beneficial targets for preventing viral entry into host cells. Target antigens including polymerase or viral nucleic acid may be beneficial for preventing viral replication. The vaccine compositions described herein can be designed to target an antigen of interest, such as any of the viral antigens described herein. Viral antigens derived from exemplary target viruses may include any protein encoded by the exemplary target virus, such that the protein can induce an immunological response in an individual (e.g., a human individual).
[0094] In some embodiments, the viral antigen is a viral protein or a fragment or variant thereof. In some embodiments, the viral antigen is a viral surface glycoprotein or a fragment or variant thereof. The viral antigen peptide may have a length of about 10 to about 500 amino acids (aa), for example, about 100 to about 300 aa, about 200 to about 500 aa, about 10 to about 300 aa, about 100 to about 200 aa, about 10 to about 100 aa, about 200 to about 450 aa, about 300 to about 500 aa, or about 10 to about 80 aa. For example, the viral antigen peptide can have a length of about any of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 350, 400, 450, or 500 amino acids, or a range between any of those aa lengths. In some embodiments, the viral antigen comprises (or consists essentially of, or consists of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31. In some embodiments, the viral nucleoprotein and the viral antigen are derived from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are from different viruses, e.g., different subtypes of viruses, different species of viruses, or different viral families. In some embodiments, the viral antigen and the viral RNA are from the same virus. In some embodiments, the viral antigen and the viral RNA are from different viruses, e.g., different subtypes of viruses, different species of viruses, or different viral families.
[0095] In some embodiments, the viral antigen is a SARS-Cov-2 protein or a fragment or variant thereof. In some embodiments, the viral antigen is a SARS-CoV-2 spike protein or a fragment or variant thereof. In some embodiments, the viral antigen comprises a receptor binding domain (RBD) peptide. In some embodiments, the viral antigen comprises an amino acid sequence of SEQ ID NO: 14 or 15, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 14 or 15.
[0096] In some embodiments, the viral antigen is an influenza virus protein or a fragment or variant thereof, e.g., from an IAV or IBV. In some embodiments, the viral antigen is an influenza (e.g., IAV or IBV) HA protein or a fragment or variant thereof. In some embodiments, the influenza virus protein or a fragment or variant thereof is from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. In some embodiments, the IAV viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31. In some embodiments, the influenza virus protein or a fragment or variant thereof is from a Yamagata or Victoria IBV subtype. In some embodiments, the IBV viral antigen comprises the amino acid sequence of SEQ ID NO: 19 or 20, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 19 or 20.
[0097] In some embodiments, the viral antigen is a respiratory syncytial virus (RSV) protein or a fragment or variant thereof, such as from a RSV A subtype or a RSV B subtype. In some embodiments, the viral antigen is a RSV (e.g., subtype A or subtype B) F protein or a fragment or variant thereof. In some embodiments, the viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 21 or 22.
[0098] In some embodiments, the viral antigen is a Hepatitis C virus (HCV) protein or a fragment or variant thereof, such as from HCV genotype 1a or HCV genotype 2a. In some embodiments, the viral antigen is an HCV (e.g., genotype 1a or 2a) E2 protein or a fragment or variant thereof. In some embodiments, the viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 23 or 24.
[0099] Exemplary Viruses Vaccine compositions comprising the nanocomplexes can be designed to target (e.g., induce an immune response or build immunity to) any virus, for example, any sequenced virus. The targeted virus can be a DNA virus or an RNA virus. For example, the vaccine compositions described herein can be used to treat influenza A viruses (e.g., H1N1, H5N1, H3N2, H7N9), influenza B viruses, influenza C viruses, influenza D viruses, Ebola viruses, Marburg viruses, yellow fever viruses, West Nile viruses, dengue viruses, Zika viruses, hepaciviruses B, hepaciviruses C, pegiviruses A, pegiviruses B, pegiviruses C, pestiviruses A, pestiviruses C, alphacoronavirus 229E (HCoV-229E), New Haven coronavirus NL63 (HCoV-NL63), betacoronavirus OC43 (HCoV-OC43), coronavirus HKU1 (HCoV-HKU1), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV ... The vaccine may be designed to target a virus selected from any one of the Orthomyxoviridae, Filoviridae, Flaviviridae, Coronaviridae, or Poxviridae families, including identified or unidentified genera, species, subtypes, strains, and reassortants thereof, such as acute respiratory syndrome coronavirus 2 (SARS-CoV-2), variola virus (smallpox virus), vaccinia virus, cowpox virus, monkeypox virus, orf virus, pseudocowpox, bovine papular stomatitis virus, tanapox virus, Yaba monkey tumor virus, molluscum contagiosum virus (MCV), chikungunya, norovirus, enterovirus, respiratory syncytial virus (RSV), Junin virus, Lassa fever virus, Nipah virus, or Hendra virus.As examples, four viruses, including viral strains, variants, subspecies, or related species, are described herein: sarbecovirus (e.g., SARS-CoV-2 virus), influenza virus, respiratory syncytial virus, and hepatitis C virus. In some embodiments, the nanocomplexes described herein target any of the viruses described herein. In some embodiments, the viral nucleoproteins, viral antigens, and / or viral RNA or DNA are derived from any of the viruses described herein.
[0100] i. Sarbecovirus Sarbecoviruses are a subgenus of the genus Betacoronavirus within the Coronaviridae family of viruses. Examples of sarbecoviruses include SARS-CoV / SARS-CoV-1, SARS-CoV-2, SC2r-CoV, SC2r-CoV GX-P5L, Bat CoV BtKY72, Bat CoV BM48-31, 16BO133, JTMC15, Bat SARS CoV Rf1, BtCoV HKU3, LYRa11, Bat SARS-CoV / Rp3, Bat SL-CoV YNLF_31C, Bat SL-CoV YNLF_34C, SHC014-CoV, WIV1, WIV16, Civet SARS-CoV, (Bat)Rc-o319, Bat SL-ZXC21, Bat SL-ZC45, Pangolin SARSr-CoV-GX, Pangolin SARSr-CoV-GD, Rs7327, Rs4231, Rs4084, Rf4092, JL2012, 273-2005, HeB2013, HuB2013, Rs4247, L ongquan-140, HKU3-1, GX2013, Shaanxi2011, 279-2005, As6526, Yunnan2011, Rs4237, Rs4081, Bat RshSTT182, Bat Examples of variants of concern include, but are not limited to, RshSTT200, (Bat)RacCS203, (Bat)RmYN02, (Bat)RpYN06, YN2013, (Bat)RaTG13, (Bat)BANAL-52, and variants of concern (VOCs) in combination with SARS-CoV-2 (see, e.g., Nature (2022) 603:913-918, incorporated herein by reference in its entirety). A SARS-CoV-2 variant is defined as a "variant of concern" (VOC) upon demonstration of: (i) increased transmissibility or other deleterious changes in epidemiology, (ii) increased virulence or changes in clinical disease manifestations, (iii) escape from immunity derived from natural infection, and / or (iv) reduced effectiveness of public health or clinical countermeasures such as vaccination, treatment in current clinical use, testing if the impact is not easily mitigated by standards, and laboratory quality and regulatory measures.Sarbecoviruses are generally understood to be enveloped, positive-sense, single-stranded RNA viruses that enter host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. For example, SARS-CoV-2 binds to both ACE2 and TMPRSS2, which are expressed by epithelial cells that can be found in various tissues, such as the prostate, testis, ovary, uterus, breast, lung, oral cavity, heart, nasal cavity, ileum, intestine, colon, stomach, thyroid, liver, gallbladder, pancreas, kidney, bladder, cornea, nerve, and placenta. Receptor expression levels are increased in various inflammatory disease states, including, but not limited to, hypertension, COPD, asthma, cardiovascular disease, diabetes, Crohn's disease (CD), inflammatory bowel disease (IBD), and the like. As a result, individuals with any of these or similar diseases, or immunodeficiency diseases, are at increased risk for sarbecovirus infection and its complications.
[0101] In some embodiments, the sarbecovirus is selected from the group consisting of SARS-CoV, SARS-CoV-2, SC2r-CoV, RaTG13, SC2r-CoV GX-P5L, and VOC in combination with SARS-CoV. In some embodiments, the sarbecovirus is SARS-CoV-2.
[0102] Variants may be further referred to as variants of interest, variants of concern, or variants of significant consequence. In some embodiments, the sarbecovirus is a SARS-CoV-2 variant selected from the group consisting of a B.1.1.7 variant, a B.1.351 variant, a B.1.526 variant, a B1.526.1 variant, a B.1.1.529 variant, a B1.617 variant, a B.1.617.1 variant, a B.1.617.2 variant, a B1.617.3 variant, a P.2 variant, a P.1 (also known as B.1.1.28.1) variant, an A.23.1 variant, a CAL.20C variant, a B.1.427 variant, a B.1.429 variant, a B.1.525 variant, a BA.2, a BA.5 variant, a BA.2.75.2 variant, a BQ.1 variant, a BQ.1.1 variant, an XBB variant, and a P.1.351 variant. In some embodiments, the SARS-CoV-2 virus comprises a variant spike gene, including, but not limited to, any one of BA.2, BA.5, BA.2.75.2, BQ.1, BQ.1.1, or XBB. Other variants of SARS-CoV-2 are known in the art. See, for example, Gomez et al., Vaccines 9(3): 243, 2021 and Tang et al., Journal of Infection 82:e27-e28, 2021, which are incorporated herein by reference in their entireties.
[0103] "SARS-CoV-2 genome" refers to the 29,903 nucleotide long sequence described by NIH GenBank Locus NC_045512, or the hCoV-19 reference sequence (SEQ ID NO: 25) described by the Global Initiative on Sharing Avian Influenza Data (GISAID). The DNA sequence of the SARS-CoV-2 genome with coding regions is available on the NCBI website under accession number NC_045512.2. The viral genome contains subunits known as open reading frames (ORFs) that can code for viral proteins. These subunits in the SARS-CoV-2 genome can include ORF1ab, RNA-dependent RNA polymerase, helicase, gene S, nsp3, nsp4B, nsp9, ORF3a, gene E, gene M / ORF5, ORF6, ORF7a, ORF7b, ORF8, gene N / ORF9, and ORF10.
[0104] ORF1ab encodes a large polyprotein that encompasses multiple proteins encoded by other ORFs described herein, as shown in Table 1 below. nsp3, with NCBI accession number YP_009725299.1, encodes a protein containing transmembrane domain 1 (TM1). The nsp3 protein has additional conserved domains, including an N-terminal acidic (Ac), a predicted phosphoesterase, papain-like protease, Y domain, transmembrane domain 1 (TM1), and adenosine diphosphate ribose 1" phosphatase (ADRP). nsp4b, with NCBI accession number YP_009725300, encodes a protein containing transmembrane domain 2 (TM2). nsp9, with NCBI accession number YP_009725305.1, encodes a ssRNA binding protein. Genes E, M, S, and N encode the envelope, membrane, spike, and nucleocapsid proteins, respectively. The viral envelope protein is a membrane protein involved in viral assembly, budding, and envelope formation. The viral membrane protein attaches the virus to the host cell and promotes fusion between the viral membrane and the host cell membrane for viral entry. The viral spike protein binds to specific receptors on the host cell to engage in viral entry into the host cell and initiation of host cell infection. The viral nucleocapsid protein binds to and encapsulates viral RNA. Together, these four proteins constitute the essential structural proteins found in sarbecoviruses, e.g., SARS-CoV-2. [Table 1]
[0105] In some embodiments, the viral antigen is a SARS-CoV-2 protein or a fragment or variant thereof. In some embodiments, the viral antigen is a SARS-CoV-2 spike protein or a fragment or variant thereof. In some embodiments, the viral antigen comprises an RBD peptide. In some embodiments, the viral nucleoprotein and the viral antigen are from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are from different viruses, e.g., different viral variants, or different viral families, genus, species, or subspecies. In some embodiments, the viral nucleoprotein is from SARS-CoV-2, e.g., including an RNA binding domain from SARS-CoV-2. In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 12, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 12. In some embodiments, the viral RNA is from SARS-CoV-2. In some embodiments, the viral RNA is about 10 to about 500 (eg, about 10 to about 300) nucleotides in length. For example, in some embodiments, the viral RNA is about any of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length, or a range between any of those nucleotide lengths.In some embodiments, the viral RNA is about 10-50, about 30-60, about 40-70, about 50-80, about 60-90, about 70-100, about 10-100, about 80-110, about 90-120, about 100-130, about 110-140, about 120-150, about 130-160, about 140-170, about 150-180, about 160-190, about 170-200, about 180-210, about 190-220, about 200-230, about 210-240, about 220-250, about 230-260, about 240-270, about 250-280, about 260-290, about 300-310, about 310-320, about 320-330, about 330-340, about 340-350, about 350-360, about 360-370, about 370-380, about 380-390, about 400-410, about 410-420, about 420-430, about 440-450, about 450-460, about 470-480, about 480-490, about 490-500, about 500-510, about 510-520, about 520-530, about 530-540, about 540-550, about 550-560, about 560-570, about 570-580, about 580-5 0, about 250-280, about 260-290, about 270-300, about 280-310, about 290-320, about 300-330, about 310-340, about 320-350, about 330-360, about 340-370, about 350-380, about 360-390, about 370-400, about 380-410, about 390-420, about 400-430, about 410-440, about 420-450, about 430-460, about 440-470, about 450-480, about 460-490, or about 470-500 nucleotides in length. In some embodiments, the viral RNA is about 200 to about 500 (e.g., about 200 to about 300) nucleotides in length. For example, the viral RNA is at least about any of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length. In some embodiments, the viral RNA comprises nucleotides 1 to 266 of the viral gene of the SARS-CoV-2 genome (e.g., SEQ ID NO: 25) or a modified genome thereof.
[0106] ii. Influenza Influenza, more commonly referred to as the flu, is a contagious viral infection that can cause mild to severe symptoms and life-threatening complications, including death, even in healthy children and adults. Influenza viruses are members of the Orthomyxoviridae family of viruses. Examples of influenza viruses include the genus Alphainfluenzavirus (influenza A virus, or IAV), Betainfluenzavirus (influenza B virus, or IBV), Gammainfluenzavirus (influenza C virus, or ICV), and Deltainfluenzavirus (influenza D virus, or IDV). Each of the four species is the only member of its own genus. IAV and IBV circulate in humans and cause seasonal epidemics, while ICV causes mild infections, primarily in children. IDV can infect humans but is not known to cause disease.
[0107] Influenza A viruses are the only influenza viruses known to cause flu pandemics. IAVs are divided into subtypes based on two proteins on the surface of the virus: hemagglutinin (H) and neuraminidase (N). There are 18 different hemagglutinin subtypes and 11 different neuraminidase subtypes (H1-H18 and N1-N11, respectively). Over 130 IAV subtype combinations have been identified in nature, mainly from wild birds, but many more IAV subtype combinations potentially exist given the propensity for virus reassortment, whereby influenza viruses exchange gene segments, for example, when two influenza viruses infect a host simultaneously and exchange genetic information. For example, very recently, H17N10 and H18N11 IAVs have been identified in fruit bats in Central and South America, demonstrating that previously unidentified strains are very likely already circulating in a yet to be determined reservoir animal. Current subtypes of IAV that routinely circulate in humans include H1N1 and H3N2, and additional examples that are under surveillance or cause for concern in humans include, but are not limited to, H1N1, H1N2, H2N2, H2N3, H3N2, H5N1, H7N7, and H7N9. IAV subtypes can be further broken down into different genetic clades and subclades (e.g., H1N1: clade 6B.1, subclade 6B1.A; or H3N2: clade 3C.2a or 3C.3a, subclade 3C.2a1, 3C.2a2, 3C.2a3, or 3C.2a4). In some embodiments, the IAV is selected from the group consisting of H1N1 / pdm09, H5N1 / 1194, H3N2 / 4801, H7N9 / AH1, and H7N9 / ZJ.
[0108] Influenza B viruses can be separated into two distinct lineages: Yamagata and Victoria. IBV is the most prominent circulating strain of influenza every 4-5 years. Furthermore, IBV infections pose a higher risk of hospitalization compared to IAV, for example, in HIV patients, and IBV has demonstrated a significantly higher mortality rate compared to IAV strains. IBV has shown limited antigenic drift compared to IAV, as well as a lack of reservoirs (see, for example, Sharma et al., Eur Respir J. 2019, 54(2):1901325). IBV subtypes can be further decomposed into different genetic clades and subclades, for example, B / Yamagata (e.g., clades Y1, Y2, Y3), B / Victoria (e.g., subclades V1A.1, V1A.2, V1A.3). Influenza C virus infections generally cause mild illness and are not thought to cause human epidemics. Influenza type D viruses (i.e., Thogotoviruses) first affect cattle and then spread to other animals, but are not known to cause human infection or disease. See, for example, the CDC website entitled Types of Influenza Viruses (www.cdc.gov / flu / about / viruses / types).
[0109] Influenza viruses have a negative-sense, single-stranded, segmented RNA genome. IAV and IBV have eight genome segments that code for ten major proteins: PB1 polymerase, PB2 polymerase, PA polymerase, hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), matrix 1 (M1), matrix 2 (M2), nonstructural 1 (NS1), and nonstructural 2 (NS2) proteins. ICV and IDV have seven genome segments that code for nine major proteins, and instead of HA and NA proteins, ICV and IDV genomes code for a hemagglutinin-esterase fusion (HEF) protein that integrates the functions of HA and NA. The three segments code for three subunits of the RNA-dependent RNA polymerase (RdRp) complex: PB1, PB2, a transcriptase that recognizes the 5' cap, and PA, an endonuclease (P3 in ICV and IDV). The matrix protein (M1) and membrane protein (M2) share a segment, as do the nonstructural protein (NS1) and nuclear export protein (NEP). In IAV and IBV, the hemagglutinin (HA) and neuraminidase (NA) are each encoded on one segment, while ICV and IDV encode the hemagglutinin-esterase fusion (HEF) protein on one segment. The last genome segment encodes the viral nucleoprotein (NP). Influenza viruses also encode several accessory proteins, such as PB1-F2 and PA-X, which can be expressed through alternative open reading frames and are important in host defense suppression, virulence, and pathogenesis.
[0110] Virions consist of the genome bound to nucleoproteins in separate ribonucleoprotein (RNP) complexes for each segment, which are surrounded by a lipid bilayer membrane (i.e., the viral envelope). A copy of RdRp with all subunits assembled is bound to each RNP. The envelope is structurally reinforced by internal matrix proteins, M1 and M2, that surround the RNP and contain HA and NA (or HEF in the case of ICV or IDV) proteins that extend outward from the outer surface of the envelope. The M2 protein forms a proton ion channel through the viral envelope that is required for viral entry and exit, including acidification of the virion interior during viral shedding and control of the pH in the Golgi apparatus of the cell during HA synthesis. See, e.g., Webster et al., Microbiol Rev. 1992, 56(1):152-179 and Wille and Holmes, Cold Spring Harb Perspect Med. 2020, 10(7):a038489.
[0111] In some embodiments, the viral antigen is an influenza protein or a fragment or variant thereof, for example, from an IAV or IBV. In some embodiments, the influenza virus protein or a fragment or variant thereof is from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. In some embodiments, the influenza virus protein or a fragment or variant thereof is from an IBV subtype of Yamagata or Victoria. In some embodiments, the viral antigen is an influenza HA protein or a fragment or variant thereof. In some embodiments, the viral antigen is an IAV or IBV HA protein or a fragment or variant thereof. In some embodiments, the viral antigen is selected from the group consisting of an IAV H1N1 pdm09 HA head peptide, an IAV H5N1 1194 HA head peptide, an IAV H3N2 4801 HA head peptide, an IAV H7N9 / AH1 HA head peptide, an IAV H7N9 / ZJ HA head peptide, an IBV Yamagata HA head, and an IBV Victoria HA head peptide. In some embodiments, the IAV viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31. In some embodiments, the IBV viral antigen comprises an amino acid sequence of SEQ ID NO: 19 or 20. In some embodiments, the adapter-antigen polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-7, 26, and 27, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-7, 26, and 27. In some embodiments, the viral nucleoprotein and the viral antigen are derived from the same virus. In some embodiments, the viral nucleoprotein is derived from an IAV (e.g., IAV H5N1).In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 13, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 13. In some embodiments, the viral nucleoprotein and viral antigens are derived from different viruses, e.g., different viral variants, or different viral families, genus, species, or subspecies. In some embodiments, the viral RNA is derived from influenza (e.g., IAV, e.g., IAV H7N9, e.g., H7N9 / ZJ). In some embodiments, the viral RNA is about 10 to about 500 (e.g., about 10 to about 400) nucleotides in length. For example, in some embodiments, the viral RNA is any of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, or 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length, or a range between any of those nucleotide lengths.In some embodiments, the viral RNA is about 10-50, about 30-60, about 40-70, about 50-80, about 60-90, about 70-100, about 10-100, about 80-110, about 90-120, about 100-130, about 110-140, about 120-150, about 130-160, about 140-170, about 150-180, about 160-190, about 170-200, about 180-210, about 190-220, about 200-230, about 210-240, about 220-250, about 230-260, about 240-270, about 250-280, about 260-290, about 300-310, about 310-320, about 320-330, about 330-340, about 340-350, about 350-360, about 360-370, about 370-380, about 380-390, about 400-410, about 410-420, about 420-430, about 440-450, about 450-460, about 470-480, about 480-490, about 490-500, about 500-510, about 510-520, about 520-530, about 530-540, about 540-550, about 550-560, about 560-570, about 570-580, about 580-5 0, about 250-280, about 260-290, about 270-300, about 280-310, about 290-320, about 300-330, about 310-340, about 320-350, about 330-360, about 340-370, about 350-380, about 360-390, about 370-400, about 380-410, about 390-420, about 400-430, about 410-440, about 420-450, about 430-460, about 440-470, about 450-480, about 460-490, or about 470-500 nucleotides in length. In some embodiments, the viral RNA is about 200 to about 500 nucleotides in length. For example, the viral RNA is at least about any of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length. In some embodiments, the viral RNA comprises nucleotides 1-326 of a viral gene (e.g., the PB2 gene) of an influenza A genome (e.g., H7N9, e.g., H7N9 / ZJ, e.g., as set forth in SEQ ID NO: 30) or a modified genome thereof.
[0112] iii. Respiratory syncytial virus Respiratory syncytial virus (RSV) belongs to the genus Orthopneumovirus within the family Pneumoviridae and the order Mononegavirales. Members of this genus include human RSV, bovine RSV, and pneumonia virus of mice. There are two major antigenic subtypes of human RSV (A and B), determined largely by antigenic drift and duplication in the RSV-G sequence, but with sequence divergence across the genome, including within the RSV-F sequence.
[0113] In addition to its pathological burden on the pediatric population (e.g., children under 5 years of age and especially infants under 6 months of age), RSV is increasingly recognized as an important pathogen in the elderly. RSV infection leads to increased hospitalization rates in those over 65 years of age and to increased mortality in this population that approaches rates seen with influenza.
[0114] Respiratory syncytial viruses are enveloped viruses with a negative-sense, single-stranded, nonsegmented RNA genome of approximately 15,000 nucleotides that contains 10 genes encoding 11 proteins, in that order: nonstructural 1 (Ns1), nonstructural 2 (Ns2), nucleoprotein (N), phosphoprotein (P), matrix (M), small hydrophobic protein (SH), glycoprotein (G), fusion (F), M2-1 cofactor, M2-2 cofactor, and RNA-dependent RNA polymerase (L). The attachment glycoprotein (G) and fusion glycoprotein (F), embedded in the virion envelope, mediate viral attachment and entry, respectively.
[0115] RSV G enhances virulence in vivo and facilitates attachment to host cells, but is not absolutely required for infection. The RSV G protein is produced in two forms: a full-length membrane-bound form (no insertion) containing approximately 298 amino acids, and a secreted form (sG) that is translated through an internal initiation at a second AUG codon (Met48). The full-length G protein is a type II membrane protein and contains an N-terminal cytoplasmic domain (amino acids (aa) 1-36), a transmembrane domain (aa 37-67), and an ectodomain (aa 68-298). The ectodomain consists of two hypervariable mucin-like domains adjacent to a conserved central domain (CCD) and a heparin-binding domain (HBD). The two mucin-like domains contain 30-40 O-linked glycans and 3-5 N-linked glycans and are associated with the antigenicity of RSV. The CCD contains three amino acids that constitute the CX3C motif, which is a protective target of RSV neutralizing antibodies and interacts with the human chemokine receptor CX3CR1, a key step in RSV infection. The HBD, which contains heparan sulfate and other glycosaminoglycans (GAGs), promotes binding of RSV to potential attachment receptors. See Zhao et al., Front Microbiol. 2022,13:966235.
[0116] RSV F is a class I fusion protein that mediates the fusion of viral and host cell membranes, a process that imposes an insurmountable energy barrier to viral entry. Initially, the F protein exists in a metastable prefusion conformation that is anchored to the viral membrane by the transmembrane domain. In this structure, the hydrophobic fusion peptide is buried within the central cavity of the protein. An unknown event causes prefusion F to undergo a dramatic conformational change in which five distinct structural elements flanking the fusion peptide refold into a single alpha helix, resulting in the insertion of the fusion peptide into the host cell membrane. In this state, called the prehairpin intermediate, two heptad repeats (HRA and HRB) are located at opposite ends of the F molecule. The collapse of these heptad repeats into a stable six-helix bundle is an energetically favorable conformational change that is linked to the fusion of two lipid bilayers. Antibodies that bind to F can interrupt the fusion process, thereby preventing viral entry and reducing the severity of RSV-associated disease. Recently, it has been established that antibodies that specifically recognize the pre-fusion conformation of F are generally more potently neutralizing than antibodies that also bind post-fusion F. See Gilman et al., Nat Commun. 2019, 10(1):2105.
[0117] In some embodiments, the viral antigen is a respiratory syncytial (RSV) protein or a fragment or variant thereof. In some embodiments, the viral antigen is a RSV F protein or a fragment or variant thereof. In some embodiments, the RSV F protein or a fragment or variant thereof is derived from a RSV A subtype or a RSV B subtype. In some embodiments, the RSV viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22. In some embodiments, the viral nucleoprotein and viral antigen are derived from the same virus. In some embodiments, the viral nucleoprotein and viral antigen are derived from different viruses, e.g., different viral variants, or different viral families, genus, species, or subspecies. In some embodiments, the viral nucleoprotein is derived from RSV. In some embodiments, the viral RNA is derived from RSV. In some embodiments, the viral RNA is about 10 to about 500 nucleotides in length. For example, in some embodiments, the viral RNA is about any of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length, or a range between any of those nucleotide lengths.In some embodiments, the viral RNA is about 10-50, about 30-60, about 40-70, about 50-80, about 60-90, about 70-100, about 80-110, about 90-120, about 10-100, about 100-130, about 110-140, about 120-150, about 130-160, about 140-170, about 150-180, about 160-190, about 170-200, about 180-210, about 190-220, about 200-230, about 210-240, about 220-250, about 230-260, about 240-260, about 270-280, about 280-290, about 300-310, about 310-320, about 320-330, about 330-340, about 340-350, about 350-360, about 360-370, about 370-380, about 380-390, about 400-410, about 420-440, about 450-460, about 470-480, about 480-490, about 490-500, about 500-510, about 510-520, about 520-530, about 530-540, about 540-550, about 550-560, about 560-570, about 570-580, about 580-590, about 600-600, about 600-6 In some embodiments, the viral RNA is at least about 70, about 250-280, about 260-290, about 270-300, about 280-310, about 290-320, about 300-330, about 310-340, about 320-350, about 330-360, about 340-370, about 350-380, about 360-390, about 370-400, about 380-410, about 390-420, about 400-430, about 410-440, about 420-450, about 430-460, about 440-470, about 450-480, about 460-490, or about 470-500 nucleotides in length. In some embodiments, the viral RNA is at least about 200 nucleotides in length. For example, the viral RNA is at least any of about 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length.
[0118] iv. Hepatitis: Hepatitis C virus Hepatitis C virus (HCV, hepacivirus) belongs to the genus Hepacivirus within the family Flaviviridae. HCV includes at least seven genotypes (i.e., gt1-7) and numerous subtypes. Hepatitis C virus (HCV) is a small, enveloped, positive single-stranded RNA virus approximately 9600 nucleotides long. HCV encodes a single polyprotein, which is processed by cellular and viral proteases to generate 10 polypeptides. The HCV genome also contains an overlapping +1 reading frame, which may result in the synthesis of additional proteins (i.e., F protein from an alternative reading frame). The 10 polypeptides cleaved from the single polyprotein include three structural proteins, including the core protein and two envelope proteins (core, E1, E2), as well as seven nonstructural (NS) proteins NS1, NS3, NS4A, NS4B, NS5A, and NS5B, which are involved in cleavage, assembly, transcription, and additional functions. The structural and nonstructural proteins of HCV are multifunctional.
[0119] The core protein forms the nucleocapsid. The mature form of the core protein is a dimeric alpha-helical protein that behaves as a membrane protein and an RNA-binding protein. The viral spikes on the virion membrane are formed by heterodimers of E1 and E2 glycoproteins. These E1 and E2 proteins are essential for the HCV virus to enter the host cell and participate in the assembly of infectious viral particles. See Dubuisson, World J Gastroenterol. 2007, 13(17):2406-2415. [Table 2]
[0120] In some embodiments, the viral antigen is a Hepatitis C (HCV) protein or a fragment or variant thereof. In some embodiments, the viral antigen is an HCV E2 protein or a fragment or variant thereof. In some embodiments, the HCV E2 protein or a fragment or variant thereof is derived from HCV genotype 1a or HCV genotype 2a. In some embodiments, the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24. In some embodiments, the viral nucleoprotein and the viral antigen are derived from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are derived from different viruses, e.g., different viral variants, or different viral families, genus, species, or subspecies. In some embodiments, the viral nucleoprotein is derived from HCV. In some embodiments, the viral RNA is derived from HCV. In some embodiments, the viral RNA is about 10 to about 500 nucleotides in length. For example, in some embodiments, the viral RNA is about any of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length, or a range between any of those nucleotide lengths.In some embodiments, the viral RNA is about 10-50, about 30-60, about 40-70, about 50-80, about 60-90, about 70-100, about 10-100, about 80-110, about 90-120, about 100-130, about 110-140, about 120-150, about 130-160, about 140-170, about 150-180, about 160-190, about 170-200, about 180-210, about 190-220, about 200-230, about 210-240, about 220-250, about 230-260, about 240-270, about 250-280, about 260-290, about 300-310, about 310-320, about 320-330, about 330-340, about 340-350, about 350-360, about 360-370, about 370-380, about 380-390, about 400-410, about 410-420, about 420-430, about 440-450, about 450-460, about 470-480, about 480-490, about 490-500, about 500-510, about 510-520, about 520-530, about 530-540, about 540-550, about 550-560, about 560-570, about 570-580, about 580-5 0, about 250-280, about 260-290, about 270-300, about 280-310, about 290-320, about 300-330, about 310-340, about 320-350, about 330-360, about 340-370, about 350-380, about 360-390, about 370-400, about 380-410, about 390-420, about 400-430, about 410-440, about 420-450, about 430-460, about 440-470, about 450-480, about 460-490, or about 470-500 nucleotides in length. In some embodiments, the viral RNA is about 200 to about 300 nucleotides in length. For example, the viral RNA is at least about any of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 or more nucleotides in length.
[0121] Nucleoprotein-antigen fusion peptide In some embodiments, the viral nucleoprotein described herein and the target antigen peptide described herein are attached, e.g., fused, via an optional linker (e.g., a GS linker). In some embodiments, the viral nucleoprotein and the viral antigen peptide are fused to create an adapter-antigen polypeptide. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein. In some embodiments, the viral antigen is fused to the N-terminus of the viral nucleoprotein. In some embodiments, the nucleoprotein and the target antigen are from the same source, e.g., the same virus. In some embodiments, the nucleoprotein and the target antigen are from different sources, e.g., different viruses, e.g., different subtypes of a virus, different species or genera of a virus, or different virus families.
[0122] In some embodiments, the nucleoprotein, e.g., viral nucleoprotein, is fused to a target antigen peptide, e.g., a viral target antigen, and naturally associates with viral RNA, thereby forming a large immunogenic complex. In some embodiments, multiple copies of adapter-antigen are attached to the viral RNA scaffold. In some embodiments, the viral RNA also acts as an adjuvant, so that the attached adapter-antigen peptide envelops the viral RNA, thereby masking the adjuvant to prevent natural immune responses, including the production of inflammatory cytokines, upon mucosal administration of the vaccine composition to an individual (e.g., a human individual).
[0123] In some embodiments, the adapter-antigen polypeptide comprises a viral antigen fused to a viral nucleoprotein capable of binding to viral RNA (e.g., comprises an RNA binding domain). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from SARS-CoV-2. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from influenza (e.g., IAV, IBV, ICV, or IDV, e.g., H1N1, H3N2, H5N1, H7N9, Yamagata, or Victoria). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from Hepatitis C Virus (HCV). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from Respiratory Syncytial Virus (RSV). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV fused with an antigen from influenza (e.g., an IAV, IBV, ICV, or IDV, e.g., H1N1, H3N2, H5N1, H7N9, Yamagata, or Victoria). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV H5N1 fused with an antigen from an IAV selected from the group consisting of H1N1, H3N2, H5N1, and H7N9. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV fused with an antigen from an IBV, Yamagata, or Victoria. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from HCV fused with an antigen from HCV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from RSV fused with an antigen from RSV. In some embodiments, the viral antigen is a viral protein or a fragment or variant thereof. In some embodiments, the viral antigen is a viral surface glycoprotein or a fragment or variant thereof.In some embodiments, the viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31. In some embodiments, the viral nucleoprotein is derived from SARS-CoV-2. In some embodiments, the viral nucleoprotein is derived from an IAV (e.g., IAV H5N1). In some embodiments, the viral antigen comprises an amino acid sequence of SEQ ID NO: 12 or 13, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 12 or 13. In some embodiments, the viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11 and 26-29, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11 and 26-29.
[0124] In some embodiments, the adapter-antigen polypeptide comprises (or consists essentially of, or consists of) a viral antigen from a first virus fused to a viral nucleoprotein from a second virus capable of binding to viral RNA or DNA. In some embodiments, the viral antigen is a viral protein or a fragment or variant thereof from the first virus, e.g., SARS-CoV-2, IAV, IBV, RSV, or HCV. In some embodiments, the viral antigen is a viral surface glycoprotein or a fragment or variant thereof from the first virus. In some embodiments, the viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31. In some embodiments, the viral nucleoprotein (or a scaffold molecule, e.g., a fragment or variant capable of binding to viral RNA or DNA) is derived from a second virus, e.g., SARS-CoV-2, IAV, IBV, RSV, or HCV. The first virus and the second virus may be the same or different. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from an influenza A virus (IAV). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from an influenza B virus (IBV). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from a hepatitis C virus (HCV). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from SARS-CoV-2 fused with an antigen from a respiratory syncytial virus (RSV). In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV fused with an antigen from SARS-CoV-2.In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV fused with an antigen from an IBV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV fused with an antigen from an HCV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IAV fused with an antigen from an RSV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IBV fused with an antigen from a SARS-CoV-2. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IBV fused with an antigen from an IAV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IBV fused with an antigen from an HCV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an IBV fused with an antigen from an RSV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an HCV fused with an antigen from an SARS-CoV-2. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an HCV fused with an antigen from an IAV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from an HCV fused with an antigen from an IBV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from HCV fused to an antigen from RSV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from RSV fused to an antigen from SARS-CoV-2. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from RSV fused to an antigen from IAV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from RSV fused to an antigen from IBV. In some embodiments, the adapter-antigen polypeptide comprises a nucleoprotein from RSV fused to an antigen from HCV.In some embodiments, the viral antigen comprises the amino acid sequence of SEQ ID NO: 12 or 13, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to SEQ ID NO: 12 or 13. In some embodiments, the adapter-antigen polypeptide comprises a viral nucleoprotein comprising the amino acid sequence of SEQ ID NO: 12 or 13, and a viral antigen comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31, wherein the viral nucleoprotein and the viral antigen are not derived from the same virus. In some embodiments, the viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-11 and 26-29, or a variant thereof having at least about 80% (e.g., at least about any of 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-11 and 26-29.
[0125] Scaffolding molecules In some embodiments, the scaffold molecule comprises a nucleic acid. In some embodiments, the scaffold molecule comprises a DNA or RNA molecule. In some embodiments, the scaffold molecule comprises (or consists of, or consists essentially of) a DNA molecule. In some embodiments, the DNA is a single-stranded DNA (ssDNA) molecule. In some embodiments, the DNA is a double-stranded DNA (dsDNA) molecule. In some embodiments, the scaffold molecule comprises (or consists of, or consists essentially of) an RNA molecule, such as ssRNA. In some embodiments, the scaffold molecule comprises a viral RNA molecule. In some embodiments, the scaffold molecule comprises a miniviral RNA molecule. In some embodiments, the scaffold molecule comprises a non-viral RNA molecule (e.g., host RNA). When the scaffold molecule comprises viral RNA or DNA, it can be either wild-type or mutant (e.g., containing insertion(s), deletion(s), and / or substitution(s)).
[0126] Scaffold RNA (e.g., viral RNA) can be small RNA derived from transcription, long complex RNA derived from large viral genome, or long genomic RNA derived during replication. In some embodiments, viral RNA also functions as an internal adjuvant. In some embodiments, viral RNA activates innate immunity when administered intra-individual, i.e., to an individual (e.g., a human individual) as an adjuvant. In some embodiments, the adjuvant activity of activating innate immunity in an individual (e.g., a human individual) is mediated by Toll-like receptors and / or RIG-I-like receptors.
[0127] In some embodiments, the viral RNA naturally associates with the viral nucleoprotein, e.g., the fused adaptor-antigen protein, thereby forming a large immunogenic complex, or nanocomplex. In some embodiments, the RNA scaffold (e.g., viral RNA) acts as a scaffold to allow the binding of multiple copies of the adaptor-antigen. Within this nanocomplex, the antigen peptide can include any of the antigen peptides described in this disclosure, including any viral antigen known in the art. In some embodiments, the vaccine composition comprising the nanocomplex is multivalent.
[0128] In some embodiments, the scaffold molecule comprises (or consists of, or consists essentially of) an RNA molecule. In some embodiments, the scaffold molecule comprises a miniviral RNA molecule. In some embodiments, the viral RNA also functions as an internal adjuvant. In some embodiments, the viral RNA comprises a non-translated region of a viral gene of the viral genome. In some embodiments, the viral RNA comprises a 5' non-translated region or a 3' non-translated region of a viral gene of the viral genome. In some embodiments, the viral RNA comprises a 5' non-translated region of a viral gene of the viral genome. In some embodiments, the 5' non-translated region folds into a highly structured scaffold for genome replication. In some embodiments, the viral RNA comprises a 3' non-translated region of a viral gene of the viral genome.
[0129] In some embodiments, the scaffold molecule is about 10 to about 2000 nucleotides (nt) long, e.g., about 10 to about 300 nt, about 200 to about 300 nt, about 10 to about 200 nt, about 200 to about 500 nt, about 500 to about 1000 nt, about 10 to about 500 nt, about 100 to about 1000 nt, about 1000 to about 2000 nt, or about 100 to about 500 nt long. In some embodiments, the scaffold molecule is at least about 200 nucleotides long, e.g., about 200 to about 500 nucleotides long, or about 200 to about 300 nucleotides long. In some embodiments, the scaffold molecule comprises DNA or RNA, such as any DNA or RNA molecule that can function as a scaffold for binding to an adaptor-antigen polypeptide. The scaffold molecule may be derived from any organism, including, but not limited to, mammals, birds, insects, bacteria, viruses, yeast, or plants. In some embodiments, the scaffold molecule comprises viral RNA. In some embodiments, the scaffold molecule comprises a non-viral RNA, such as a host RNA (e.g., a mammalian RNA, such as human RNA). In some embodiments, the scaffold molecule encodes a protein, or a fragment or variant thereof. In some embodiments, the scaffold molecule does not encode a protein, or a fragment or variant thereof. In some embodiments, the scaffold molecule functions as an adjuvant to enhance the host's immune response to a target antigen. In some embodiments, the scaffold molecule is about 10 to about 500 nt, or about 200 to about 500 nt in length. For example, in some embodiments, the scaffold molecule (e.g., viral RNA) is any of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length, or a range between any of those nucleotide lengths.In some embodiments, the scaffold molecule (e.g., viral RNA) is about 10-50, about 30-60, about 40-70, about 50-80, about 60-90, about 70-100, about 80-110, about 90-120, about 10-100, about 100-130, about 110-140, about 120-150, about 130-160, about 140-170, about 150-180, about 160-190, about 170-200, about 180-210, about 190-220, about 200-230, about 210-240, about 220-250, about 230-260, about 270-280, about 290-300, about 300-310, about 310-320, about 320-330, about 330-340, about 340-350, about 350-360, about 360-370, about 370-380, about 380-390, about 400-410, about 420-440, about 450-460, about 470-480, about 490-500, about 500-510, about 520-530, about 540-550, about 550-560, about 560-570, about 570-580, about 580-590, about 600-600, about 600-610, about 610-620, about 620-630, about 630- 40-270, about 250-280, about 260-290, about 270-300, about 280-310, about 290-320, about 300-330, about 310-340, about 320-350, about 330-360, about 340-370, about 350-380, about 360-390, about 370-400, about 380-410, about 390-420, about 400-430, about 410-440, about 420-450, about 430-460, about 440-470, about 450-480, about 460-490, or about 470-500 nucleotides in length. In some embodiments, the scaffold molecule (e.g., viral RNA) is at least about 200 nucleotides in length. In some embodiments, the scaffold molecule (e.g., viral RNA) is about 200 to about 500 nucleotides in length. For example, the scaffold molecule (e.g., viral RNA) is at least about any of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length.
[0130] In some embodiments, the scaffold molecule (e.g., viral RNA) comprises a non-translated region of a viral genome. In some embodiments, the viral RNA comprises a 5' non-translated region or a 3' non-translated region of a viral gene of the viral genome. In some embodiments, the viral RNA comprises a 5' non-translated region of a viral gene of the viral genome. In some embodiments, the viral RNA is derived from SARS-CoV-2. In some embodiments, the viral RNA comprises nucleotides 1-266 of a viral gene of the SARS-CoV-2 genome (e.g., SEQ ID NO:25). In some embodiments, the viral RNA is derived from an IAV. In some embodiments, the viral RNA comprises nucleotides 1-326 of a viral gene of an IAV genome (e.g., SEQ ID NO:30).
[0131] In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 50 nm to about 200 nm. For example, in some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, or 150 nm. In some embodiments, the nanocomplex in the vaccine composition has an average particle size of about 50 nm to 80 nm, about 60 nm to 90 nm, about 70 nm to 100 nm, about 80 nm to 110 nm, about 90 nm to 120 nm, about 100 nm to 130 nm, about 110 nm to 140 nm, about 120 nm to 150 nm, about 130 nm to 160 nm, about 140 nm to 170 nm, about 150 nm to 180 nm, about 160 nm to 190 nm, or about 170 nm to 200 nm. In some embodiments, the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm. In some embodiments, the particle size (e.g., average particle size) of the nanocomplexes in the vaccine composition can be measured by any of SDS-PAGE, native-PAGE, high performance size exclusion chromatography (HP-SEC), sedimentation velocity analytical ultracentrifugation (SV-AUC), dynamic light scattering (DLS), flow field separation, nanoparticle tracking analysis (NTA), resonance mass spectrometry (RMM), light obscuration, flow imaging microscopy, visual inspection, and the like. In some embodiments, HP-SEC or flow field separation can be combined with a continuous online detector, such as UV / VIS absorbance, static light scattering, fluorescence, or refractive index.
[0132] In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about 0 mV to about -50 mV. For example, in some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about 0 mV, about -10 mV, about -20 mV, about -30 mV, about -40 mV, or about -50 mV. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about 0 mV to about -10 mV, about -5 mV to about -15 mV, about -10 mV to about -20 mV, about -15 mV to about -25 mV, about -20 mV to about -30 mV, about -25 mV to about -35 mV, about -30 mV to about -40 mV, about -35 mV to about -45 mV, or about -40 mV to about -50 mV. In some embodiments, the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV.
[0133] Thus, in some embodiments, there is provided a vaccine composition comprising a nanocomplex comprising: i) a scaffold molecule comprising a viral RNA; and ii) an adaptor-antigen polypeptide comprising a viral antigen comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-24 and 31 fused to a viral nucleoprotein capable of binding to the viral RNA. In some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule is at least about 5:1, e.g., about 6:1 to about 12:1, about 6:1 to about 10:1, about 8:1 to about 12:1, or about 6:1 to about 8:1. For example, in some embodiments, the molar ratio of adaptor-antigen polypeptide to scaffold molecule (e.g., viral RNA) is any of about 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, or 12:1, or a range between any of these ratios. In some embodiments, the viral antigen is fused to the C-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral antigen is a viral protein or a fragment or variant thereof. In some embodiments, the viral antigen is fused to the N-terminus of the viral nucleoprotein via an optional linker (e.g., a GS linker). In some embodiments, the viral nucleoprotein and the viral antigen are from the same virus. In some embodiments, the viral nucleoprotein and the viral antigen are from different viruses, e.g., different viral variants, or different viral families, genus, species, or subspecies. In some embodiments, the viral nucleoprotein is from SARS-CoV-2 or IAV. In some embodiments, the viral nucleoprotein comprises the amino acid sequence of SEQ ID NO: 12 or 13. In some embodiments, the adapter-antigen polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11 and 26-29. In some embodiments, the viral RNA comprises an untranslated region of the viral genome. In some embodiments, the viral RNA comprises a 5' untranslated region or a 3' untranslated region of a viral gene of the viral genome (e.g., a 5' or 3' UTR of a viral gene).In some embodiments, the viral RNA comprises a 5' untranslated region of a viral gene of the viral genome (e.g., a 5' UTR of a viral gene). In some embodiments, the viral RNA is about 10 to about 500 nucleotides in length. For example, in some embodiments, the viral RNA is any of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length. In some embodiments, the viral RNA is about 20 to 50, about 30 to 60, about 40 to 70, about 50 to 80, about 60 to 90, about 70 to 100, about 80 to 110, about 90 to 120, about 100 to 130, about 110 to 140, about 120 to 150, about 130 to 160, about 140 to 170, about 150 to 180, about 160 to 190, about 170 to 200, about 180 to 210, about 190 to 220, about 200 to 230, about 210 to 240, about 220 to 250, about 230 to 260, about 240 to 270, about 250 to 280, about 260 to 280, about 290 to 300, about 300 to 310, about 310 to 320, about 320 to 330, about 330 to 340, about 340 to 350, about 350 to 360, about 360 to 370, about 370 to 380, about 380 to 390, about 400 to 410, about 420 to 430, about 440 to 450, about 450 to 460, about 470 to 480, about 490 to 500, about 500 to 510, about 520 to 530, about 540 to 550, about 550 to 560, about 570 to 580, about 590 to 600 50-280, about 260-290, about 270-300, about 280-310, about 290-320, about 300-330, about 310-340, about 320-350, about 330-360, about 340-370, about 350-380, about 360-390, about 370-400, about 380-410, about 390-420, about 400-430, about 410-440, about 420-450, about 430-460, about 440-470, about 450-480, about 460-490, or about 470-500 nucleotides in length. In some embodiments, the viral RNA is about 200 to about 500 nucleotides in length. For example, the viral RNA is at least any of about 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides in length.In some embodiments, the viral RNA is derived from SARS-CoV-2. In some embodiments, the viral RNA comprises nucleotides 1-266 of the viral gene of the SARS-CoV-2 genome set forth in SEQ ID NO:25. In some embodiments, the viral RNA is derived from an IAV. In some embodiments, the viral RNA is derived from an IAV H7N9. In some embodiments, the viral RNA comprises nucleotides 1-326 of the viral gene of the IAV H7N9 genome (e.g., as set forth in SEQ ID NO:30) or a modified genome thereof. In some embodiments, the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm. In some embodiments, the nanocomplexes in the vaccine composition have a uniform size. In some embodiments, the nanocomplexes in the vaccine composition have a zeta potential of about -10 mV to about -20 mV.
[0134] III. Host Cells for the Production of Nanocomposite Vaccines Also provided herein are host cells for producing the adapter-antigen polypeptide and / or nucleic acid scaffold (e.g., viral RNA) components of the vaccine compositions described herein.
[0135] Suitable host cells can include, but are not limited to, higher eukaryotic cells, such as mammalian cells, including, but not limited to, invertebrate and insect cells, and vertebrate cells.
[0136] Host cells can be transfected as part of standard methods of genome editing using any suitable method known in the art, including, but not limited to, DEAE-dextran mediated delivery, calcium phosphate precipitation, cationic lipid mediated delivery, liposome mediated transfection, electroporation, lentiviral transduction, microprojectile gun, receptor mediated gene delivery, polylysine, histone, chitosan, and peptide mediated delivery. Standard methods for transfection and transformation of cells for expression of vectors of interest are well known in the art.
[0137] Any suitable host cell may be used herein. Host cells can include, but are not limited to, BHK21 cells, VeroE6 cells, L929 cells, CHO cells, BHK cells, MDCK cells, C3H 10T1 / 2 cells, FLY cells, Psi-2 cells, BOSC23 cells, PA317 cells, WEHI cells, COS cells, BSC1 cells, BSC40 cells, BMT10 cells, VERO cells, W138 cells, MRC5 cells, A549 cells, HT1080 cells, 293 cells, 293T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos-2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, NS0 cells, PerC6 cells, Sp2 / 0 cells, BHK cells, C127 cells, 211A cells, and any host cell derived from any of these cells. In some embodiments, suitable host cells are genetically engineered to express components of the vaccine compositions described herein (e.g., any one or more of SEQ ID NOs: 1-11, and 26-29 and / or an RNA scaffold molecule, e.g., any of SEQ ID NOs: 25 or 30).
[0138] III. Method of Preparation The vaccine compositions described herein can be prepared by any of the nucleic acid expression, protein production, and in situ synthesis methods known in the art. The adapter-antigen polypeptide can be expressed and produced in a host cell, including any of the host cells described above. The adapter-antigen polypeptide can then be harvested from the host cell or culture medium (e.g., when the adapter-antigen polypeptide is secreted from the host cell). The nucleic acid scaffold molecule (e.g., viral RNA) can be expressed in the host cell, transcribed in vitro, or completely synthesized in vitro. For example, the RNA scaffold molecule (e.g., viral RNA) can be transcribed in vitro using SP6 or T7 polymerase, chemically synthesized, or produced in the host cell (e.g., transcribed from a DNA template such as a vector).
[0139] In some embodiments, the nucleic acid(s) encoding the viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) components are inserted into a vector, such as an expression vector, a viral vector, or a cloning vector. Thus, vectors encoding any of the viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) components described herein are also provided. For expression of the viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) components, the vector can be introduced into a host cell to allow expression of the nucleic acid encoding the viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) components in the host cell. The expression vector can contain various elements for controlling expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selectable markers, and signal sequences. These elements can be appropriately selected by those skilled in the art. For example, the promoter sequence can be selected to promote transcription of the nucleic acid in the vector. Suitable promoter sequences include, but are not limited to, T7 promoter, T3 promoter, SP6 promoter, beta actin promoter. EF1a promoter, CMV promoter, and SV40 promoter. Enhancer sequences may be selected to enhance transcription of the nucleic acid. Selectable markers may allow for the selection of host cells into which the vector has been inserted from those that have not, for example, the selectable marker may be a gene that confers antibiotic resistance. Signal sequences may be selected to allow the expressed viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) components to be transported outside the host cell.
[0140] Suitable vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that include one or more free ends and no free ends (e.g., circular); nucleic acid molecules that include DNA, RNA, or both; and a variety of other polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication, and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and are thereby replicated along with the host genome. Additionally, certain vectors are capable of directing the transcription or expression of coding nucleotide sequences to which they are operatively linked. Such vectors are referred to herein as "expression vectors."
[0141] In some embodiments, the expression vectors encoding viral nucleoproteins, viral antigens, and / or nucleic acid scaffold (e.g., viral RNA) components are selected from the group consisting of viral vectors, bacterial vectors, and mammalian cell vectors. Viral vector technology is well known in the art and described, for example, in Sambrook et al. (2012), and Ausubel et al. (1999), and other virology and molecular biology manuals. Viruses that are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses (AAV), herpes viruses, and lentiviruses. In some embodiments, a murine stem cell virus (MSCV) vector is used to express the desired nucleic acid. MSCV vectors have been demonstrated to efficiently express the desired nucleic acid in cells. Other examples of viral vectors are based on Moloney murine leukemia virus (MoMuLV) and human immunodeficiency virus (HIV). In some embodiments, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers. (See, e.g., WO01 / 96584, WO01 / 29058, and U.S. Pat. No. 6,326,193.) In some embodiments, the vector is a recombinant adeno-associated virus (rAAV) vector. In some embodiments, the rAAV vector is a vector derived from an AAV serotype, including but not limited to, the AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, caprine AAV, bovine AAV, or murine AAV capsid serotypes. In some embodiments, the vector is encapsulated in a rAAV particle. In some embodiments, the vector is a lentiviral vector.
[0142] In some embodiments, the method of making a vaccine composition described herein further comprises transfecting a host cell with a nucleic acid or vector encoding a viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) component. In some embodiments, the nucleic acid(s) or vector(s) encoding the viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) component are transfected simultaneously into the host cell. In some embodiments, the nucleic acid(s) or vector(s) encoding the viral nucleoprotein, viral antigen, and / or nucleic acid scaffold (e.g., viral RNA) component are transfected sequentially into the host cell. The nucleic acids, or vectors (e.g., viral vectors) described herein can be delivered directly to a host cell or an individual (e.g., a human) for gene therapy purposes. Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycations or lipids:nucleic acid complexes, electroporation, nanoparticles, exosomes, microvesicles, or gene guns, naked DNA, and artificial virions. The use of RNA or DNA virus-based systems for the delivery of nucleic acids has high efficiency in targeting viruses to specific cells and transporting viral payloads to the cell nucleus.
[0143] The adaptor-antigen polypeptide (or nucleic acid encoding same) or nucleic acid scaffold (e.g., viral RNA) components of the vaccine compositions described herein can be introduced into host cells using any suitable method known in the art, including, but not limited to, DEAE-dextran mediated delivery, calcium phosphate precipitation, cationic lipid mediated delivery, liposome mediated transfection, electroporation, lentiviral transduction, microprojectile gun, receptor mediated gene delivery, polylysine, histone, chitosan, and peptide mediated delivery. Standard methods for transfection and transformation of cells are well known in the art.
[0144] In some embodiments, the present application provides a method of making an adaptor-antigen polypeptide (or a single component of an adaptor or antigen) and / or a nucleic acid scaffold (e.g., viral RNA) component of a vaccine composition described herein, comprising culturing an isolated host cell comprising the adaptor-antigen polypeptide (or a single component of an adaptor or antigen) and / or a nucleic acid scaffold (e.g., viral RNA) component under conditions suitable for expression of the component, and obtaining the expressed component from the host cell (e.g., from a cell culture). Suitable conditions for expression can include, but are not limited to, a suitable medium, a suitable density of host cells in the culture medium, the presence of necessary nutrients, the presence of cofactors, suitable temperature and humidity, and the absence of microbial contaminants. Those skilled in the art can select suitable conditions for expression as appropriate.
[0145] After the adaptor-antigen polypeptide (or a single component of the adaptor or antigen) is harvested from the host cell and the nucleic acid scaffold (e.g., viral RNA) is synthesized (e.g., in vitro transcribed) or harvested from the host cell, these molecules can then be combined to form the nanocomplexes described herein. The adaptor-antigen polypeptide naturally binds to the nucleic acid scaffold molecule (e.g., viral RNA) described herein, and multiple adaptor-antigen polypeptides can bind to the same nucleic acid scaffold molecule described herein. The synthesized nanocomplex is then isolated and prepared by standard methods (e.g., purification) as described herein, and administered to an individual (e.g., a human).
[0146] In some embodiments, the methods of making vaccine compositions described herein further include purifying and / or enriching the adaptor, antigen, and / or nucleic acid scaffold molecule (e.g., viral RNA) components. For example, viral RNA can be purified by the phenol-chloroform-isopropanol method. Any protein purification method known in the art (e.g., ion exchange, filtration, affinity purification, mixed mode purification) can be used herein for protein component purification. In some embodiments, the purity of the adaptor, antigen, and / or nucleic acid scaffold molecule is at least about 90%, such as at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
[0147] In some embodiments, purified adaptor, antigen, and nucleic acid scaffold molecule (e.g., viral RNA) components are mixed in a buffer and incubated under suitable conditions (e.g., a temperature suitable for protein / nucleic acid binding) for a period of time (e.g., at least about 5 minutes) to form a nanocomplex described herein. In some embodiments, purified adaptor and antigen are mixed in a buffer and incubated under suitable conditions (e.g., a temperature suitable for protein / protein binding) for a period of time (e.g., at least about 5 minutes) to form an adaptor-antigen polypeptide described herein, and then the adaptor-antigen polypeptide and nucleic acid scaffold molecule (e.g., viral RNA) components are mixed in a buffer and incubated under suitable conditions (e.g., a temperature suitable for protein / nucleic acid binding) for a period of time (e.g., at least about 5 minutes) to form a nanocomplex described herein.
[0148] IV. PHARMACEUTICAL COMPOSITIONS, UNIT DOSE DOSE, ARTICLE ARTICLE, AND KITS Further provided by the present application is a pharmaceutical composition comprising any one of the vaccine compositions comprising the nanocomplex described herein, and optionally a pharma- ceutically acceptable carrier.
[0149] The pharmaceutical composition may be suitable for a variety of administration methods described herein, including, for example, systemic or local administration. Exemplary routes of administration of any of the vaccine compositions (or pharmaceutical compositions thereof) described herein include, but are not limited to, oral, intravenous, intracavitary, intratumoral, intraarterial, intramuscular, subcutaneous, parenteral, transmucosal, transdermal, ocular, topical, intraperitoneal, intracranial, intrapleural, and epithelial routes, or delivered to lymphatic glands, body spaces, organs, or tissues known to harbor virus-infected cells. In some embodiments, the pharmaceutical composition is formulated for mucosal administration. In some embodiments, the pharmaceutical composition is formulated for administration by nasal spray. In some embodiments, the pharmaceutical composition is formulated for administration by nasal drops. In some embodiments, the pharmaceutical composition is administered parenterally, such as by intramuscular or intradermal administration. In some embodiments, the pharmaceutical composition is administered as a single dose. In some embodiments, the pharmaceutical composition is administered as multiple doses. In some embodiments, the individual (such as a human) is of any age. In some embodiments, the individual (such as a human) is 65 years of age or older, e.g., 65, 70, 75, 80, 85, 86, 87, 88, 89, 90 years of age or older. In some embodiments, the individual (such as a human) is 18 years of age or younger, e.g., 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 years of age or younger. In some embodiments, the individual (such as a human) is a child aged 1 year or younger (e.g., 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 month or younger). In some embodiments, the individual (such as a human) is healthy. In some embodiments, the individual (such as a human) has a medical condition, pre-existing condition, or condition that reduces the function of the heart, lungs, brain, or immune system. In some embodiments, the individual (such as a human) is immunocompromised.
[0150] Delivery systems based on micro- and nano-carriers as nasal vaccines induce humoral, cellular, and mucosal immunity. The nasal route of vaccination can also provide immunity at some remote mucosal sites (e.g., oral cavity, rectum, vagina, and lung). Nasal vaccine delivery blocks pathogen entry at mucosal sites by inducing local immunity, shows increased bioavailability over other routes of administration, demonstrates rapid uptake into the blood circulation via mucosal absorption, and encourages better patient compliance than other routes of administration, such as parenteral routes (see, for example, Ramvikas et al. (2016) Micro and Nanotechnology in Vaccine Development 2017:279-301, which is incorporated herein by reference in its entirety). Nasal vaccine delivery formulations can include, but are not limited to, microparticle, nanoparticle, and liposomal forms.
[0151] In some cases, the subject methods involve administering to an individual in need thereof an effective amount of a vaccine composition (or a pharmaceutical composition thereof) comprising the nanocomplex. In some embodiments, an "effective amount" of a subject vaccine is an amount that, when administered to an individual in one or more doses, in monotherapy, or in combination therapy, is effective to prevent viral infection or transmission or reduce symptoms of a viral infection in an individual by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100%, compared to the individual in the absence of administration with the vaccine.
[0152] As used herein, "carrier" includes pharma- ceutically acceptable carriers, excipients, or stabilizers that are non-toxic to cells or individuals exposed at the dosages and concentrations used. In many cases, physiologically acceptable carriers are pH-buffered aqueous solutions. Acceptable carriers, excipients, or stabilizers are compatible with nucleic acid constructs (i.e., RNA and / or DNA), and the solutions containing the carriers, excipients, or stabilizers may further include one or more inhibitors of RNase and / or DNase activity. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include, for example, buffers, such as phosphates, citrates, and other organic acids, antioxidants including ascorbic acid and methionine, preservatives (such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens, such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol), low molecular weight (less than about 10 residues) polypeptides, proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).
[0153] In some embodiments, the pharmaceutical composition is formulated to have a pH in the range of about 4.5 to about 9.0, including any one of the pH ranges of about 5.0 to about 8.0, about 6.5 to about 7.5, or about 6.5 to about 7.0. In some embodiments, the pharmaceutical composition is formulated to have a pH in the range of about 4.5 to about 6.5. In some embodiments, the pharmaceutical composition can also be made isotonic with blood by the addition of a suitable isotonicity modifying agent.
[0154] Pharmaceutical compositions used for in vivo administration are generally formulated in a sterile, substantially isotonic state and in full compliance with all Good Manufacturing Practice (GMP) regulations of the United States Food and Drug Administration. Sterility is easily achieved by filtration through a sterile filtration membrane. In some embodiments, the composition is pathogen-free. For parenteral administration, the pharmaceutical composition may be in the form of a liquid solution, for example, in the form of a physiologically compatible buffer, for example, Hank's solution or Ringer's solution. In addition, the pharmaceutical composition may be in solid form and may be redissolved or suspended, for example, in water, immediately before use. Lyophilized compositions are also included.
[0155] Aerosol formulations suitable for administration via inhalation can also be made. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
[0156] In some embodiments, the pharmaceutical composition is formulated according to normal procedures as a pharmaceutical composition suitable for intravenous, intraperitoneal, subcutaneous, intramuscular or intravitreal injection.In some embodiments, the subject delivery system comprises a device for nasal or pulmonary delivery.For example, the compositions described herein can be formulated for delivery by nebulizer, inhaler device, etc.
[0157] In some embodiments, the pharmaceutical composition is formulated according to the usual procedures as a pharmaceutical composition suitable for mucosal administration, such as intranasal administration. Intranasal administration can be achieved via nasal powder, nasal drops, nasal aerosol, nasal gel, and the like. In some embodiments, the pharmaceutical composition is formulated according to the usual procedures as a pharmaceutical composition suitable for intravenous, intraperitoneal, subcutaneous, intramuscular, or intravitreal injection. Typically, the composition for injection is a solution in a sterile isotonic aqueous buffer. If necessary, the composition may also include a solubilizing agent and a local anesthetic, such as lignocaine, to ease pain at the injection site. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a sealed, sealed container, such as an ampoule or sachet indicating the quantity of active agent. When the composition is to be administered, it can be reconstituted as necessary.
[0158] In some embodiments, the pharmaceutical composition is suitable for administration to humans. In some embodiments, the pharmaceutical composition is suitable for administration to rodents (e.g., mice, rats), non-human primates (e.g., cynomolgus monkeys), monkeys, cats, dogs, horses, cows, pigs, sheep, goats, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets. In some embodiments, the pharmaceutical composition is contained in a single-use vial, such as a single-use sealed vial. In some embodiments, the pharmaceutical composition is contained in a multi-use vial. In some embodiments, the pharmaceutical composition is contained in bulk in a container. In some embodiments, the pharmaceutical composition is stored frozen.
[0159] The term "unit dosage form" refers to physically discrete units suitable as single administration to an individual, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient. These unit dosage forms may be stored in suitable packaging in single or multiple unit dosage amounts, and may further be sterilized and sealed.
[0160] The present application further provides an article of manufacture comprising the compositions (such as pharmaceutical compositions) described herein in suitable packaging. Suitable packaging for the compositions (such as pharmaceutical compositions) described herein is known in the art and includes, for example, vials (e.g., sealed vials), nasal spray or nasal drop bottles, containers, ampoules, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. These articles may be further sterilized and / or sealed.
[0161] The application also provides kits that include the compositions (such as pharmaceutical compositions) described herein, and may further include instruction(s) regarding how to use the compositions, such as the uses described herein. The kits described herein may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, spray bottles, nebulizers, inhaler devices, needles, syringes, and package inserts containing instructions for practicing any of the methods described herein.
[0162] V. Methods of Vaccination One aspect of the application provides a method of preventing (e.g., vaccinating) or treating a viral infection (e.g., SARS-CoV-2 infection, influenza virus, hepatitis virus, respiratory syncytial virus) in an individual (such as a human), comprising administering to the individual an effective amount of any of the vaccine compositions or pharmaceutical compositions thereof described herein. In some embodiments, the vaccine composition is administered by intranasal or intradermal administration. In some embodiments, the vaccine composition is administered in an initial dose, followed by one or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) booster doses. In some embodiments, the method for preventing (e.g., vaccinating) or treating a viral infection (e.g., infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus) further prevents or treats infection in the individual from one or more additional viral species from different viral families (e.g., providing multivalent immunity) and / or one or more viral strains or subtypes of a virus (e.g., providing heterosubtypic immunity). In some embodiments, the method induces multivalent immunity against two or more viral species (e.g., two or more of SARS-CoV-2, IAV, IBV, RSV, and HCV). In some embodiments, the method induces heterosubtypic immunity against two or more viral subtypes (e.g., two or more IAV subtypes selected from H1N1, H5N1, H3N2, and H7N9; IBV subtypes Yamagata and Victoria; two or more SARS-CoV-2 strains; two or more HCV genotypes or subtypes; or two or more RSV strains). In some embodiments, the method for preventing (e.g., vaccinating) or treating a viral infection (e.g., an infection from a SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus) further comprises enhancing the individual's immunity against the viral infection.In some embodiments, the method for preventing (e.g., vaccinating) or treating a viral infection (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus) further includes reducing the risk of contracting an infection with a variant of the viral infection (e.g., a variant strain of SARS-CoV2, a subtype or variant of IAV, a subtype or variant of IBV, a subtype or variant of RSV, and / or a subtype or variant of HCV).
[0163] In some embodiments, the method of vaccinating an individual includes a method of prophylactically immunizing an individual against a viral infection (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating an individual includes a method of preventing an individual from contracting a viral infection (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating an individual includes a method of preventing viral transmission from a vaccinated individual to an unvaccinated individual. In some embodiments, the method of vaccinating or treating an individual includes a method of reducing the severity of a viral infection in an individual (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating an individual includes a method of enhancing immunity in an individual against a viral infection (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating an individual includes a method of reducing the risk of the individual contracting a viral infection (e.g., an infection from a SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating or treating an individual further includes a method of treating an individual with a viral infection (e.g., an infection from a SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating or treating an individual includes a method of eliciting an immune response in an individual against a viral infection (e.g., an infection from a SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus).In some embodiments, the method of vaccinating or treating an individual includes a method of enhancing the individual's T cell response against a viral infection (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of eliciting an immune response in an individual, e.g., enhancing a T cell response, further includes a method of activating CD4+ T cells against a viral infection (e.g., an infection from SARS-CoV-2 virus, influenza virus, hepatitis virus, or respiratory syncytial virus). In some embodiments, the method of vaccinating or treating an individual includes administering a vaccine composition comprising a nanocomplex as described herein, wherein the vaccine provides multivalent protection against different viral species within the same family, or against different families. In some embodiments, the method of vaccinating or treating an individual includes administering a vaccine composition comprising a nanocomplex as described herein, wherein the vaccine further provides heterosubtypic protection against different viral species within the same family, or against different viral strains, subtypes, or subspecies. In some embodiments, the individual is a mammal, such as a human, a cow, a horse, a cat, a dog, a rodent, or a primate. In some embodiments, the individual is a human. In some embodiments, the individual is at risk of contracting or has contracted a viral infection. In some embodiments, the individual is at high risk of dying when contracting a viral infection. In some embodiments, the individual (such as a human) is of any age. In some embodiments, the individual (such as a human) is 65 years of age or older, such as any of 65, 70, 75, 80, 85, 86, 87, 88, 89, 90 years of age or older. In some embodiments, the individual (such as a human) is 18 years of age or younger, such as any of 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 years of age or younger. In some embodiments, the individual (such as a human) is 6 months of age or younger, e.g., any of the following: 6, 5, 4, 3, 2, 1 month old, or a newborn. In some embodiments, the individual (such as a human) is healthy.In some embodiments, the individual (such as a human) has a medical condition, pre-existing disease, or condition that reduces heart, lung, brain, or immune system function. In some embodiments, the individual (such as a human) is immunocompromised. In some embodiments, the individual has a compromised adaptive immune system and / or a compromised innate immune system. In some embodiments, the individual has a weakened immune system. In some embodiments, the individual has a weakened adaptive immune system and / or a weakened innate immune system. In some embodiments, the individual is administered one or more courses of an immunosuppressant. In some embodiments, the individual has been administered one or more courses of an immunosuppressant.
[0164] Symptoms of viral infections may present differently based on the virus and the tissue or organ infected in an individual. Often, some symptoms overlap, such as fatigue, malaise, headache, or in more severe cases, sepsis, organ failure, elevated levels of inflammatory cytokines, and sometimes death. Further examples are provided below.
[0165] In some embodiments, symptoms of sarbecovirus infection, e.g., SARS-CoV-2 infection, include any one of fever, cough, sore throat, stuffy nose, fatigue, headache, muscle pain, shortness of breath, mild pneumonia, severe pneumonia, acute pneumonia, sepsis, septic shock, or any combination thereof. Signs of infection include altered mental status, dyspnea or tachypnea, low oxygen saturation, reduced urine output, rapid heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulation disorders, thrombocytopenia, acidosis, hyperlactosis, or hyperbilirubinemia. In some embodiments, sarbecovirus infection, e.g., SARS-CoV-2 infection, significantly increases the levels of inflammatory cytokines in infected individuals. In some embodiments, the increased levels of inflammatory cytokines, i.e., cytokine storm, causes excessive, uncontrolled systemic inflammation. In some cases, in individuals infected with sarbecoviruses, uncontrolled systemic inflammation leads to pneumonia, respiratory failure, shock, organ failure, secondary bacterial pneumonia, and potential death.
[0166] In some embodiments, symptoms of influenza infection, e.g., H3N2, include any one of fever, chills, cough, sore throat, stuffy nose, fatigue, headache, muscle pain, vomiting, diarrhea, shortness of breath, mild pneumonia, severe pneumonia, acute pneumonia, or any combination thereof. Signs of severe influenza infection in individuals infected with influenza virus include pneumonia, myocarditis, encephalitis, myositis, rhabdomyolysis, multiple organ failure, extreme inflammatory response, sepsis, secondary bacterial pneumonia, and potential death.
[0167] In some embodiments, the symptoms of hepatitis virus, for example, hepatitis C virus (HCV), include any one of jaundice, fatigue, depression, abdominal pain, ascites, clay-colored or pale stool, dark urine, fever, itching, loss of appetite, nausea, vomiting, cirrhosis, liver cancer, or any combination thereof.In some cases, the individual with hepatitis virus presents no symptoms or mild symptoms.In some cases, the individual with hepatitis virus presents symptoms after developing hepatitis-induced cirrhosis or liver cancer.
[0168] In some embodiments, symptoms of respiratory syncytial virus (RSV) include any one of the following: stuffy nose, loss of appetite, dehydration, coughing, sneezing, fever, shortness of breath or wheezing, difficulty breathing, irritability, reduced activity, fatigue, tiredness, pain, or any combination thereof. In more severe cases in individuals infected with respiratory syncytial virus, RSV symptoms can further include bronchitis and / or pneumonia, and potentially death. Individuals at highest risk include the elderly (e.g., 65 years or older) and infants under 6 months of age.
[0169] In some embodiments, the severity of a viral infection in an individual is reduced after vaccination or treatment with any one of the vaccine compositions described herein, for example, reduced by at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, compared to the severity of the same viral infection in an individual that has not been vaccinated or treated with any one of the vaccine compositions described herein. In some embodiments, an immune response in the individual is elicited after vaccination or treatment with any one of the vaccine compositions described herein. In some embodiments, the elicited immune response comprises a T cell response, such as T cell activation in the individual. In some embodiments, enhancing the T cell response in the individual further comprises a method of activating CD4+ T cells. In some embodiments, the progression of a viral infection in an individual is delayed by vaccination or treatment with any one of the vaccine compositions described herein. In some embodiments, death caused by a viral infection in an individual is prevented by vaccination or treatment with any one of the vaccine compositions described herein. In some embodiments, individuals who become or are already infected with a virus and who are vaccinated or treated with any one of the vaccine compositions described herein are prevented from transmitting the viral infection to unvaccinated individuals.
[0170] In some embodiments, vaccination or treatment with any one of the vaccine compositions described herein may induce heterosubtypic immunity against more than one viral subvariant or subtype, e.g., against two or more viral subvariants or subtypes. In some embodiments, the virus is IAV and the two or more subvariants or subtypes are selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. In some embodiments, the virus is IBV and the two or more subvariants or subtypes are Yamagata and Victoria. In some embodiments, the virus is SARS-CoV-2 and two or more subvariants or subtypes are selected from the group consisting of a B.1.1.7 variant, a B.1.351 variant, a B.1.526 variant, a B1.526.1 variant, a B1.617 variant, a B.1.617.1 variant, a B.1.617.2 variant, a B1.617.3 variant, a P.2 variant, a P.1 (also known as B.1.1.28.1) variant, an A.23.1 variant, a CAL.20C variant, a B.1.427 variant, a B.1.429 variant, a B.1.525 variant, a BA.2, a BA.5 variant, a BA.2.75.2 variant, a BQ.1 variant, a BQ.1.1 variant, an XBB variant, and a P.1.351 variant. In some embodiments, the virus is HCV and the two or more subvariants or subtypes are from any of HCV genotypes 1-7, including, but not limited to, any one or more of HCV genotypes 1a, 1b, 1c, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 2j, 2k, 3a, 3b, 3c, 3d, 3e, 3f, 3g, 3h, 3i, 3j, 3k, 4a, 4b, 4c, 4d, 5a, 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, and 7a. In some embodiments, the virus is RSV and the two or more subvariants or subtypes are RSV A and RSV B.
[0171] The efficacy of the treatments described herein can be assessed, for example, by measuring viral load (e.g., via detection of viral DNA), individual survival time, quality of life, viral protein expression and / or activity, detection of serological antibodies to coronavirus, assessment of respiratory function, and / or computed tomography (CT) imaging.
[0172] The effectiveness of a vaccine composition can be assessed, for example, by the level of neutralizing antibodies in serum or other bodily fluids (such as, but not limited to, bronchoalveolar lavage fluid) against one or more proteins of the virus (such as SARS-CoV-2, influenza, hepatitis, or respiratory syncytial virus), or by the neutralizing activity of serum or other bodily fluids against one or more strains of the virus (such as SARS-CoV-2, influenza, hepatitis, or respiratory syncytial virus).
[0173] In some embodiments, the method includes administering to an individual an effective amount of any one of the vaccine compositions described herein, wherein the individual exhibits an increase in serum neutralizing antibody levels against a target viral antigen (e.g., against the SARS-CoV-2 spike RBD) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits an increase in serum neutralizing antibody levels against a variant target viral antigen compared to before administration of the vaccine composition. In some embodiments according to any one of the methods described herein, the individual exhibits an increase in neutralizing antibody levels by about any one of 10%, 20%, 50%, 75%, 100%, 2-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 500-fold, or 1000-fold or more compared to before administration of the vaccine composition. In some embodiments, the neutralizing antibody level is determined at any one of about 1, 7, 14, 21, 30, 45, 60, 90, 120, 180, 240, 360, 480, or 720 days after administration of the vaccine composition. In some embodiments, the method includes administering to an individual an effective amount of any one of the vaccine compositions described herein, and the individual exhibits an increase in serum neutralizing antibody levels against two or more target viral antigens (e.g., SARS-CoV-2 spike RBD and IAV proteins), e.g., an increase of at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, compared to before administration of the vaccine composition. In some embodiments, the individual exhibits an increase in serum neutralizing antibody levels against two or more target viral antigens, compared to before administration of the vaccine composition. In some embodiments, administration of the vaccine composition induces heterosubtypic protection in a subject against two or more target viral antigens from two or more viral subtypes of the same virus (e.g., two or more IAV subtypes selected from H1N1, H5N1, H3N2, and H7N9).
[0174] In some embodiments, the method comprises administering to a mucosa of an individual an effective amount of any one of the vaccine compositions described herein, and the individual exhibits an increase in mucosal immunity against the target virus compared to before administration of the vaccine composition. In some embodiments, the individual exhibits an increase in mucosal immunity against two or more target viruses, e.g., at least about any of 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, or more, compared to before administration of the vaccine composition. In some embodiments, the two or more target viruses are part of the same genus, optionally part of the same family. In some embodiments, the two or more target viruses are part of different families. In some embodiments, the individual exhibits increased mucosal immunity against three or more target viruses (e.g., against three or more subtypes of IAV selected from H1N1, H1N5, H2N3, and H7N9) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits induction of lung-resident memory B cells after administration of the vaccine composition. In some embodiments, the individual exhibits induction of follicular helper T cells after administration of the vaccine composition. In some embodiments, the individual exhibits increased neutralizing antibody levels in bronchoalveolar lavage (BAL) fluid against a target virus (e.g., against SARS-CoV-2, RSV, or influenza) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased neutralizing antibody levels in bronchoalveolar lavage (BAL) fluid against two or more target viruses (e.g., against SARS-CoV-2 and IAV) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased levels of neutralizing antibodies in bronchoalveolar lavage (BAL) fluid against three or more target viruses (e.g., against three or more subtypes of IAV selected from H1N1, H1N5, H2N3, and H7N9) compared to before administration of the vaccine composition. In some embodiments, the neutralizing antibodies include IgA.In some embodiments according to any one of the methods described herein, the individual exhibits an increase in neutralizing antibody levels by about any one of 10%, 20%, 50%, 75%, 100%, 2-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 500-fold, or 1000-fold or more compared to before administration of the vaccine composition. In some embodiments, the neutralizing antibody levels are determined about any one of 1, 7, 14, 21, 30, 45, 60, 90, 120, 180, 240, 360, 480, or 720 days after administration of the vaccine composition.
[0175] In some embodiments, the method includes administering to an individual an effective amount of any one of the vaccine compositions described herein, wherein the individual exhibits increased serum neutralizing activity against a target virus (e.g., against SARS-CoV-2, influenza, RSV, or HCV) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased serum neutralizing activity against two or more target viruses (e.g., two or more of SARS-CoV-2, IAV, IBV, RSV, and / or HCV) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased serum neutralizing activity against three or more target viruses (e.g., against three or more subtypes of IAV selected from H1N1, H1N5, H2N3, and H7N9) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased serum neutralizing activity against a variant of the target virus compared to before administration of the vaccine composition. In some embodiments, the neutralizing activity is quantitatively determined by a focus reduction neutralization assay against a virus strain. In some embodiments according to any one of the methods described herein, the individual exhibits an increase in neutralizing activity of about any one of 10%, 20%, 50%, 75%, 100%, 2-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 500-fold, or 1000-fold or more compared to before administration of the vaccine composition. In some embodiments, the neutralizing activity is determined about any one of 1, 7, 14, 21, 30, 45, 60, 90, 120, 180, 240, 360, 480, or 720 days after administration of the vaccine composition.
[0176] In some embodiments, the method comprises administering to a mucosa of an individual an effective amount of any one of the vaccine compositions described herein, wherein the individual exhibits increased mucosal immunity against the target virus compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased neutralizing activity in bronchoalveolar lavage fluid (BAL) against the target virus (e.g., against SARS-CoV-2, RSV, or influenza) compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased neutralizing activity in serum against two or more target viruses compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased mucosal immunity against two or more viral subtypes compared to before administration of the vaccine composition. In some embodiments, the individual exhibits increased neutralizing activity in bronchoalveolar lavage fluid (BAL) against two or more target viruses (e.g., against both SARS-CoV-2 and IAV). In some embodiments, the individual exhibits increased neutralizing activity in bronchoalveolar lavage fluid (BAL) against two or more virus subtypes (e.g., against two or more IAV subtypes selected from H1N1, H5N1, H3N2, and H7N9). In some embodiments, the neutralizing activity is quantitatively determined by a focus reduction neutralization assay against authentic live virus. In some embodiments according to any one of the methods described herein, the individual exhibits an increase in neutralizing activity of about any one of 10%, 20%, 50%, 75%, 100%, 2-fold, 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 500-fold, or 1000-fold or more compared to before administration of the vaccine composition. In some embodiments, neutralizing activity is determined at any one of about 1, 7, 14, 21, 30, 45, 60, 90, 120, 180, 240, 360, 480, or 720 days after administration of the vaccine composition.
[0177] In some embodiments, the vaccine composition (e.g., pharmaceutical composition) is administered once. In some embodiments, the vaccine composition (e.g., pharmaceutical composition) is administered two or more times, for example, at intervals of about 2 weeks to about 1 year. For methods involving multiple doses of the vaccine composition, exemplary dosing frequencies can include, but are not limited to, weekly, weekly without a break, weekly for 2 out of 3 weeks, weekly for 3 out of 4 weeks, biweekly, triweekly, monthly, 6 months, yearly, etc. In some embodiments, the vaccine composition is administered about once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 6 weeks, or once every 8 weeks. In some embodiments, the vaccine composition (such as a pharmaceutical composition) is administered at any of the following intervals: about 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, or yearly. In some embodiments, the vaccine composition (such as a pharmaceutical composition) is administered twice, with the next dose being administered 14 days after the first dose. In some embodiments, the vaccine composition (such as a pharmaceutical composition) is administered three times, with each next dose being administered 14 days after the previous dose.
[0178] In some embodiments, the method is used to vaccinate or treat an individual (such as a human) who has been previously vaccinated. Any of the vaccination or treatment methods provided herein may be used to vaccinate or treat an individual (such as a human) who has not been previously vaccinated. In some embodiments, the method is used to prophylactically immunize an individual (such as a human). In some embodiments, the method is used to prevent viral transmission from a vaccinated individual (such as a human) to an unvaccinated individual. In some embodiments, the method is used to treat a viral infection in an individual (such as a human). In some embodiments, the method further ameliorates or reduces infection and associated symptoms in an infected individual (such as a human). In some embodiments, the method is used to induce an immune response in an individual (such as a human), such as activation of lymphocytes, such as B cells, or T cells, including CD4+ T cells and / or CD8+ T cells; and myeloid cells, including but not limited to monocytes, macrophages, neutrophils, granulocytes, mast cells, dendritic cells, and / or eosinophils. In some embodiments, the method is used as a prophylactic vaccine. In some embodiments, the method is used as a prophylactic and / or therapeutic against two or more different viral species (i.e., against viral species from different families and / or different genera, e.g., against two or more of SARS-CoV-2, IAV, IBV, RSV, and / or HCV). In some embodiments, the method is used as a prophylactic and / or therapeutic against two or more different viral subspecies (i.e., against different strains or subspecies of the same viral species or genus, e.g., against two or more IAV subtypes selected from H1N1, H5N1, H3N2, and H7N9). In some embodiments, the method is used as a prophylactic and / or therapeutic against three or more different viral subspecies (i.e., against different strains or subspecies of the same viral species or genus, e.g., against two or more IAV subtypes selected from H1N1, H5N1, H3N2, and H7N9).In some embodiments, the method is used to enhance T cell responses in an individual (such as a human). In some embodiments, the method is used as a first or second line therapy to ameliorate or reduce viral infection and its associated symptoms. In some embodiments, the individual (such as a human) is of any age. In some embodiments, the individual (such as a human) is 65 years old or older, e.g., 65, 70, 75, 80, 85, 86, 87, 88, 89, 90 years old or older. In some embodiments, the individual (such as a human) is 18 years old or younger, e.g., 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 years old or younger. In some embodiments, the individual (such as a human) is 6 months old or younger, e.g., 6, 5, 4, 3, 2, 1 month old, or a newborn. In some embodiments, the individual (such as a human) is healthy. In some embodiments, the individual (such as a human) has a medical condition, pre-existing condition, or condition that reduces the function of the heart, lungs, brain, or immune system. In some embodiments, the individual (such as a human) is immunocompromised.
[0179] The methods or vaccine compositions described herein are suitable for vaccination against a variety of viruses and / or treatment of diseases associated with a variety of viruses. The route of administration, the dosage administered, and the extent to which viral infection is prevented, ameliorated, reduced, treated, or cured will depend on the target virus and the target antigen. For example, target antigens including viral envelope, viral membrane, or associated proteins may be beneficial targets for preventing viral entry into host cells. Target antigens including polymerase or viral nucleic acid may be beneficial for preventing viral replication. The vaccine compositions described herein may be designed to target an antigen of interest, such as any of the viral antigens described herein, and the method of administering the vaccine compositions described herein may be safely modified as necessary based on the target virus and / or target antigen due to its improved safety profile compared to current conventional vaccines. In some embodiments, the vaccine compositions described herein may be designed to target two or more viral families, genera, or species, e.g., two or more of SARS-CoV-2, IAV, IBV, RSV, and HCV, and methods of administering the vaccine compositions described herein may be safely modified as needed based on the target virus and / or target antigen due to their improved safety profile compared to current conventional vaccines.
[0180] For example, in some embodiments, the vaccine composition vaccinates or treats against a sarbecovirus (e.g., SARS-CoV-2) and the target antigen comprises an antigenic or immunogenic polypeptide derived from any virus in the sarbecovirus family. In some embodiments, the methods described herein apply to SARS-CoV / SARS-CoV-1, SARS-CoV-2, SC2r-CoV, SC2r-CoV GX-P5L, Bat CoV BtKY72, Bat CoV BM48-31, 16BO133, JTMC15, Bat SARS CoV Rf1, BtCoV HKU3, LYRa11, Bat SARS-CoV / Rp3, Bat SL-CoV YNLF_31C, Bat SL-CoV YNLF_34C, SHC014-CoV, WIV1, WIV16, Civet SARS-CoV, (Bat)Rc-o319, Bat SL-ZXC21, Bat SL-ZC45, Pangolin SARSr-CoV-GX, Pangolin SARSr-CoV-GD, Rs7327, Rs4231, Rs4084, Rf4092, JL2012, 273-2005, HeB2013, HuB2013, Rs4247, L ongquan-140, HKU3-1, GX2013, Shaanxi2011, 279-2005, As6526, Yunnan2011, Rs4237, Rs4081, Bat RshSTT182, Bat The vaccine composition is applicable to all sarbecoviruses, including RshSTT200, (Bat)RacCS203, (Bat)RmYN02, (Bat)RpYN06, YN2013, (Bat)RaTG13, (Bat)BANAL-52, and SARS-CoV in combination with variants of concern (VOCs) (see, e.g., Nature (2022) 603:913-918, which is incorporated herein by reference in its entirety). In some embodiments, the vaccine composition induces heterosubtypic protection against multiple viruses of the coronavirus family, including any of the coronaviruses listed above.In some embodiments, the vaccine composition vaccinates or treats against a coronavirus and a virus from another family, genus, or species (e.g., IAV, IBV, RSV, or HCV). In some embodiments, the vaccine composition vaccinates or treats against a sarbecovirus and an influenza virus (e.g., IAV or IBV). In some embodiments, the vaccine composition vaccinates or treats against a sarbecovirus and a hepatitis virus. In some embodiments, the vaccine vaccinates or treats against a sarbecovirus and a respiratory syncytial virus (RSV, e.g., RSV-A or RSV-B).
[0181] In some embodiments, the vaccine composition vaccinates or treats against influenza virus (e.g., IAV or IBV), and the target antigen comprises an antigenic or immunogenic polypeptide derived from any virus of the influenza family. In some embodiments, the methods or vaccine compositions described herein are suitable for vaccination against any influenza virus, e.g., any of influenza A virus, influenza B virus, influenza C virus, or influenza D virus (i.e., Thogotovirus). For example, the methods described herein are applicable to all influenza viruses, including, but not limited to, H1N1, H1N2, H2N2, H2N3, H3N2, H5N1, H7N7, H7N9, B / Yamagata (e.g., clades Y1, Y2, Y3), B / Victoria (e.g., subclades V1A.1, V1A.2, V1A.3), and any of their variants. In some embodiments, the vaccine composition vaccinates or treats against two or more influenza strains, e.g., any two or more of influenza A virus (IAV), influenza B virus (IBV), influenza C virus (ICV), or influenza D virus (IDV). In some embodiments, the vaccine composition vaccinates or treats against two or more substrains of IAV, e.g., any two or more of H1N1, H1N2, H2N2, H2N3, H3N2, H5N1, H7N7, and / or H7N9. In some embodiments, the vaccine composition vaccinates or treats against two or more substrains of IBV, e.g., Yamagata and Victoria, or substrains thereof, e.g., two or more of Yamagata subclades Y1, Y2, and / or Y3, or two or more of Victoria subclades V1A.1, V1A.2, and / or V1A.3.
[0182] In some embodiments, the vaccine composition vaccinates or treats against a hepatitis virus (e.g., HCV), and the target antigen comprises an antigenic or immunogenic polypeptide derived from any hepatitis virus. In some embodiments, the method or vaccine composition described herein is suitable for vaccination against any hepatitis virus, such as hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, or any combination thereof. For example, the method described herein is applicable to all hepatitis C virus, including HCV genotype 1a, HCV genotype 1b, HCV genotype 2a, HCV genotype 2b, HCV genotype 2c, HCV genotype 3a, or HCV genotype 3b. In some embodiments, the vaccine composition is suitable for vaccination against any two or more species of hepatitis virus, such as hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, or any combination thereof. In some embodiments, the vaccine composition provides heterosubtypic protection against any two or more Hepatitis C strains, e.g., HCV genotype 1a, HCV genotype 1b, HCV genotype 2a, HCV genotype 2b, HCV genotype 2c, HCV genotype 3a, and / or HCV genotype 3b.
[0183] In some embodiments, the vaccine composition vaccinates or treats against respiratory syncytial virus (RSV), and the target antigen comprises an antigenic or immunogenic polypeptide from any RSV strain, variant, or subspecies. In some embodiments, the method or vaccine composition described herein is suitable for vaccination against any respiratory syncytial virus, for example, any of the 16 RSV-A or 22 RSV-B subtypes (e.g., GA1, GA2, GA5, GA7, BA, etc.). In some embodiments, the vaccine composition vaccinates against any two or more strains, variants, or subspecies of respiratory syncytial virus, for example, any two or more strains, variants, or subspecies selected from the 16 RSV-A or 22 RSV-B subtypes (e.g., GA1, GA2, GA5, GA7, BA, etc.). In some embodiments, the vaccine composition provides heterosubtypic protection against any two or more strains, variants, or subspecies of respiratory syncytial virus, e.g., any two or more strains, variants, or subspecies selected from the 16 RSV-A or 22 RSV-B subtypes (e.g., GA1, GA2, GA5, GA7, BA, etc.).
[0184] In some embodiments, a vaccine composition is provided for use in vaccination or treatment against a first virus and a second virus, the vaccine composition comprising a target antigenic or immunogenic polypeptide (i.e., viral antigen) from the first virus and a nucleoprotein from the second virus. In some embodiments, the first virus and the second virus are each independently selected from the group consisting of SARS-CoV-2, IAV, IBV, HCV, and RSV, or a strain, variant, or subspecies thereof. In some embodiments, a vaccine composition is provided for use in vaccination against SARS-CoV-2 and IAV, the vaccine composition comprising a viral nucleoprotein from SARS-CoV-2 and a viral antigen from IAV. In some embodiments, a vaccine composition is provided for use in vaccination against SARS-CoV-2 and IBV, the vaccine composition comprising a viral nucleoprotein from SARS-CoV-2 and a viral antigen from IBV. In some embodiments, a vaccine composition is provided for use in vaccination against SARS-CoV-2 and RSV, the vaccine composition comprising a viral nucleoprotein from SARS-CoV-2 and a viral antigen from RSV. In some embodiments, a vaccine composition is provided for use in vaccination against SARS-CoV-2 and HCV, the vaccine composition comprising a viral nucleoprotein from SARS-CoV-2 and a viral antigen from HCV. In some embodiments, a vaccine composition is provided for use in vaccination against IAV and SARS-CoV-2, the vaccine composition comprising a viral nucleoprotein from IAV and a viral antigen from SARS-CoV-2. In some embodiments, a vaccine composition is provided for use in vaccination against IAV and IBV, the vaccine composition comprising a viral nucleoprotein from IAV and a viral antigen from IBV. In some embodiments, a vaccine composition is provided for use in vaccination against IAV and HCV, the vaccine composition comprising a viral nucleoprotein from IAV and a viral antigen from HCV.In some embodiments, a vaccine composition is provided for use in vaccination against IAV and RSV, the vaccine composition comprising a viral nucleoprotein from IAV and a viral antigen from RSV. In some embodiments, a vaccine composition is provided for use in vaccination against IBV and SARS-CoV-2, the vaccine composition comprising a viral nucleoprotein from IBV and a viral antigen from SARS-CoV-2. In some embodiments, a vaccine composition is provided for use in vaccination against IBV and IAV, the vaccine composition comprising a viral nucleoprotein from IBV and a viral antigen from IAV. In some embodiments, a vaccine composition is provided for use in vaccination against IBV and HCV, the vaccine composition comprising a viral nucleoprotein from IBV and a viral antigen from HCV. In some embodiments, a vaccine composition is provided for use in vaccination against IBV and RSV, the vaccine composition comprising a viral nucleoprotein from IBV and a viral antigen from RSV. In some embodiments, a vaccine composition is provided for use in vaccination against HCV and SARS-CoV-2, the vaccine composition comprising a viral nucleoprotein from HCV and a viral antigen from SARS-CoV-2. In some embodiments, a vaccine composition is provided for use in vaccination against HCV and IAV, the vaccine composition comprising a viral nucleoprotein from HCV and a viral antigen from IAV. In some embodiments, a vaccine composition is provided for use in vaccination against HCV and IBV, the vaccine composition comprising a viral nucleoprotein from HCV and a viral antigen from IBV. In some embodiments, a vaccine composition is provided for use in vaccination against HCV and RSV, the vaccine composition comprising a viral nucleoprotein from HCV and a viral antigen from RSV.In some embodiments, a vaccine composition is provided for use in vaccination against RSV and SARS-CoV-2, the vaccine composition comprising a viral nucleoprotein from RSV and a viral antigen from SARS-CoV-2. In some embodiments, a vaccine composition is provided for use in vaccination against RSV and IAV, the vaccine composition comprising a viral nucleoprotein from RSV and a viral antigen from IAV. In some embodiments, a vaccine composition is provided for use in vaccination against RSV and IBV, the vaccine composition comprising a viral nucleoprotein from RSV and a viral antigen from IBV. In some embodiments, a vaccine composition is provided for use in vaccination against RSV and HCV, the vaccine composition comprising a viral nucleoprotein from RSV and a viral antigen from HCV.
[0185] The methods described herein may be used as a treatment to vaccinate, prevent viral transmission, or reduce disease, and the treatment may act as a first therapy, a second therapy, a third therapy, or in an adjuvant or neoadjuvant setting, as a combination therapy with other types of antiviral therapies known in the art, such as therapeutic agents selected from the group consisting of corticosteroids, anti-inflammatory signaling regulators, beta2-adrenergic receptor agonist bronchodilators, anticholinergics, mucolytic agents, antiviral agents, antifibrotic agents, hypertonic saline, antibodies, vaccines, and mixtures thereof, and the like. For example, the antiviral agent can be further selected from the group consisting of remdesivir, lopinavir / ritonavir, IFN-α, lopinavir, ritonavir, penciclovir, galidesivir, disulfiram, darunavir, cobicistat, ASC09F, disulfiram, nafamostat, Griffithsin, alisporivir, chloroquine, nitazoxanide, baloxavir marboxil, oseltamivir, zanamivir, peramivir, amantadine, rimantadine, favipiravir, laninamivir, ribaline, umifenovir, and any combination thereof. In one aspect, a method of vaccinating an individual against a virus is provided, comprising administering to the individual a vaccine composition comprising the nanocomplex.
[0186] The dosing regimen of a vaccine composition (or pharmaceutical composition thereof) administered to an individual (such as a human) can vary depending on the particular vaccine composition, the method of administration, and the particular type and stage of viral infection being treated. In some embodiments, an effective amount of a vaccine is below a level that induces toxic effects (i.e., effects above clinically acceptable levels of toxicity) or at a level where potential side effects can be controlled or tolerated when the composition is administered to an individual. EXAMPLES
[0187] The following examples are included for illustrative purposes only and are not intended to limit the scope of the disclosure.
[0188] Example 1: Generation of nanocomposite vaccines against various targeted viral infections Nanocomplex vaccines are composed of two parts: i) a nucleoprotein fused with a viral antigen, also known as an adapter-antigen, and ii) a miniviral RNA (mini-vRNA). The mini-vRNA acts as a scaffold to allow the attachment of multiple copies of the adapter-antigen. The nucleoprotein has a high affinity for the vRNA and serves as an adapter in nanocomplex vaccines. Vaccine efficacy is significantly improved both by the formation of the complex, which increases the size of the immunogenic complex, and by the presence of an RNA adjuvant, which activates innate immunity. Thus, the nanocomplex technology by fusing the corresponding antigen to the adapter protein can be applied to any vaccine, making it a versatile option for vaccine development.
[0189] A total of eleven exemplary nanocomplex vaccines were designed to vaccinate against infections caused by SARS-CoV-2 coronavirus, influenza virus, respiratory syncytial virus, and hepatitis C virus, as shown in Figures 1A-1D, 2, and 10. Each type of nanocomplex vaccine contained antigens derived from various strains or subtypes of the respective pathogens.
[0190] Additionally, bivalent nanocomplex vaccines can be generated in which the adapter protein and viral antigens are derived from different viruses. Exemplary bivalent nanocomplex vaccines (BiNCs) are provided in FIG. 7 (BiNC-01 to BiNC-04). BiNC-01 and BiNC-02 contain an influenza A virus (IAV) adapter fused to an IAV antigen and then complexed to a SARS-CoV-2 R266 mini-vRNA scaffold (nucleotide positions 1 to 266 in the 5' untranslated region of the viral genes of the SARS-CoV-2 genome). BiNC-03 and BiNC-04 contain an IAV adapter fused to a SARS-CoV-2 antigen and then complexed to either a SARS-CoV-2 R266 mini-vRNA scaffold or an IAV R326 mini-vRNA scaffold (nucleotide positions 1 to 326 in the 5' untranslated region of the viral genes of the IAV genome).
[0191] Example 2: Nanocomposite vaccines protect against targeted viral infections Exemplary SARS-CoV-2 Nanocomplex Vaccines An exemplary nanocomplex vaccine targeting SARS-CoV-2 infection was designated NC-CoV-01. The adapter-antigen component contained the SARS-CoV-2 nucleoprotein (adapter) fused to the SARS-CoV-2 spike RBD (antigen), and the miniviral RNA was derived from the 5' untranslated region of the SARS-CoV-2 genome (nucleotide positions 1-266, i.e., the "R266 minivRNA scaffold").
[0192] Figure 3A shows the predicted structure of the adapter-antigen, whose quality and expression were confirmed by Coomassie blue staining (Figure 3B). As shown in Figure 3C, the secondary and tertiary structures of the mini-vRNA, R266, were predicted (left and right panels, respectively). The 5' untranslated region folded into a highly structured scaffold for genome replication. In vitro transcribed R266 was visualized using urea-PAGE (Figure 3D). In addition, the nanocomplex of NC-CoV-01 was confirmed by gel shift assay and fluorescence polarization assay, both of which demonstrated the complex formation of the adapter-antigen with the mini-vRNA scaffold (Figures 3E and 3F).
[0193] NC-CoV-01 elicited mucosal and systemic immunity as demonstrated by mouse in vivo assays. Due to the irritant responses caused by various exogenous adjuvants, traditional adjuvants such as alum were inappropriate for use in mucosal vaccination in the human airways. However, nanocomplex vaccines, e.g., NC-CoV-1, were designed to prevent this side effect by enveloping the immune-stimulating mini-vRNA (in this case, R266) with multiple copies of the adapter-antigen fusion peptide. Thus, the nanocomplex is expected to be phagocytosed by antigen-presenting cells (APCs), and R266 within the nanocomplex will then directly activate the APCs.
[0194] As shown via a mouse intranasal immunization model (Figure 4A), induction of both IgA and IgG in lung bronchoalveolar fluid (BALF) demonstrated a strong mucosal immune response (Figure 4B and Figure 4C), while the strong induction of spike RBD-specific IgG in serum samples indicated a robust systemic adaptive immune response (Figure 4D). MiniRNA (R20, which was 20 nucleotides long) was included as a negative control to assess the importance of complex formation and size. Mice immunized with a mixture of adapter-antigen and R20 elicited antibody responses, but less when compared to the NC-CoV-01 nanocomplex vaccine containing the R266 minivRNA scaffold.
[0195] Furthermore, activation of innate immune responses occurs primarily through the sensing of viral RNA mediated by Toll-like receptors and / or RIG-I-like receptors. Viral RNA can be small RNA derived from transcription, long and complex RNA derived from large viral genomes, or long genomic RNA induced during replication. As shown using an intranasal immunization mouse model (Figure 5A), vaccination with both NP-RBD+R20 and NP-RBD+R266 activated interferon-β (IFN-β) production (Figure 5B), interferon-stimulated genes (IFITM3, Figure 5C; and RIG-I, Figure 5D), chemokines (CXCL10, Figure 5F; and CCL5, Figure 5G), and pro-inflammatory cytokines (IL-6, Figure 5E; IL-1β, Figure 5H; and TNFα, Figure 5I). NP-RBD without the RNA scaffold served as a control.
[0196] NC-CoV-01 nanocomplex vaccine efficacy was evaluated in a mouse intranasal infection model (Figure 6A). Groups of BALB / c mice were mock immunized or intranasally immunized with three doses of NP-RBD+R266 (NC-CoV-01). Seven days after the third dose was administered, the mice were lethally infected with SARS-CoV-2 beta (B.1.351) virus via intranasal inoculation. Two days after infection, lungs and nasal turbinates were harvested. It was found that the mice were completely protected from suffering from SARS-CoV-2 virus infection, as evidenced by the absence of viral titers in the lungs (Figure 6B) and nasal turbinates (Figure 6C). In addition, the absence of nuclear protein staining indicated the absence of viral replication in the lungs of vaccinated mice (Figure 6D).
[0197] Exemplary Influenza A Virus Nanocomplex Vaccines Two exemplary nanocomposite vaccines targeting influenza A infection were designated NC-IAV-01 (targeting H1N1) and NC-IAV-02 (targeting H5N1). See FIG. 10 for exemplary structures. In NC-IAV-01, the adapter-antigen component comprised an IAV H5N1 / 1194 nucleoprotein (adapter) fused to an IAV H1N1 pdm09 hemagglutinin (HA) protein (antigen), and the miniviral RNA was derived from the 5' untranslated region of the IAV genome (nucleotide positions 1-326, i.e., the "R326 minivRNA scaffold"). In NC-IAV-02, the adapter-antigen component comprised an IAV H5N1 / 1194 nucleoprotein (adapter) fused to an IAV H5N1 / 1194 hemagglutinin (HA) protein (antigen), and the miniviral RNA was the R326 minivRNA scaffold.
[0198] H1N1 targeted nanocomposite vaccine Figure 11A shows the predicted ribbon structure of the IAV adapter-antigen protein that is part of NC-IAV-01. Figure 11B provides a schematic outlining the immunization protocol of BALB / c mice with two doses of (i) IAV adapter-antigen protein alone (NP-H1N1-HA, negative control), or (ii) NC-IAV-01 containing the R326 mini-vRNA scaffold; each administered intranasally twice, 14 days apart (n=3 mice per group).
[0199] NC-IAV-01 induced mucosal and systemic immunity as demonstrated by mouse in vivo assays. As shown via a mouse intranasal immunization model (Figure 11B), the induction of both IgA and IgG in the lung bronchoalveolar fluid (BALF) demonstrated a strong mucosal immune response (Figures 12B and 12C), and the strong induction of H1N1 HA-specific IgG in serum samples indicated a robust systemic adaptive immune response (Figure 12A). Mice immunized with NP-H1N1-HA alone induced an antibody response, but this response was significantly lower than the antibody response elicited by the NC-IAV-01 nanocomplex vaccine containing the R326 mini-vRNA scaffold. Furthermore, the titers of H1N1-HA neutralizing antibodies after vaccination were significantly higher in the sera of mice administered intranasal NC-IAV-01 nanocomplex vaccine containing R326 mini-vRNA scaffold compared to NP-H1N1-HA alone (Figure 13A), indicating increased H1N1 HA inhibition. Immune neutralization of live H1N1 was assessed by a Focus Reduction Neutralization Test, where serum samples collected from vaccinated mice were mixed with live virus. As shown in Figure 13B, the FRNT50 titer represents the reciprocal dilution of serum that neutralizes 50% of the input virus (i.e., H1N1). As shown in FIG. 13B, sera collected from mice administered intranasal NC-IAV-01 nanocomplex vaccine containing the R326 mini-vRNA scaffold showed significantly higher neutralization compared to sera collected from mice administered intranasal NP-H1N1-HA alone, indicating higher levels of functional HA neutralizing antibodies in the serum.
[0200] NC-IAV-01 nanocomplex vaccine efficacy was evaluated in a mouse intranasal infection model (Figure 14A). Groups of BALB / c mice were intranasally immunized with two doses (14 days apart) of (i) PBS, (ii) NP-H1N1-HA alone, or (iii) NP-H1N1-HA + R326 (NC-IAV-01 nanocomplex vaccine with R326 mini-vRNA scaffold). On day 14 after the second dose was administered, the mice were then infected with influenza A virus subtype H1N1 / pdm09 via intranasal inoculation. Body weight was tracked for 14 days post-infection, and mice immunized with NP-H1N1-HA + R326 showed no change in body weight over time, whereas mice administered PBS or NP-H1N1-HA alone gradually lost weight as well (Figure 14B). Furthermore, mice immunized with NP-H1N1-HA+R326 showed a higher survival rate compared to mice administered PBS or NP-H1N1-HA alone (FIG. 14C).
[0201] H5N1 targeted nanocomposite vaccine Figure 15A shows the predicted ribbon structure of the IAV adaptor-antigen protein that is part of NC-IAV-02. Figure 15B provides a schematic outlining the immunization protocol of BALB / c mice with two doses of (i) IAV adaptor-antigen protein alone (NP-H5N1-HA, negative control), or (ii) NC-IAV-02 containing the R326 mini-vRNA scaffold; each administered intranasally twice, 14 days apart (n=3 mice per group).
[0202] NC-IAV-02 elicited mucosal and systemic immunity as demonstrated by mouse in vivo assays. As shown via a mouse intranasal immunization model (Figure 15B), the induction of both IgA and IgG in the lung bronchoalveolar fluid (BALF) demonstrated a strong mucosal immune response (Figures 16B and 16C), while the strong induction of H5N1 HA-specific IgG in serum samples indicated a robust systemic adaptive immune response (Figure 16A). Mice immunized with NP-H5N1-HA alone elicited an antibody response, but this response was significantly lower than that elicited by the NC-IAV-02 nanocomplex vaccine containing the R326 mini-vRNA scaffold.
[0203] Furthermore, NC-IAV-02 nanocomplex vaccine efficacy was evaluated in a mouse intranasal infection model (Figure 17A). Groups of BALB / c mice were intranasally immunized with two doses (14 days apart) of (i) PBS, (ii) NP-H5N1-HA alone, or (iii) NP-H5N1-HA + R326 (NC-IAV-02 nanocomplex vaccine containing the R326 mini-vRNA scaffold). On day 14 after the second dose was administered, the mice were then infected with influenza A virus subtype H5N1 / 1194 via intranasal inoculation. Body weight was tracked for 14 days post-infection, and mice immunized with NP-H5N1-HA + R326 showed no change in body weight over time, whereas mice administered PBS or NP-H5N1-HA alone gradually lost weight as well (Figure 17B). Furthermore, mice immunized with NP-H5N1-HA+R326 showed a higher survival rate compared to mice administered PBS or NP-H5N1-HA alone (FIG. 17C).
[0204] Taken together, these data demonstrate that the nanocomposite vaccine provided herein is not only effective in protecting against infection with a variety of viruses in vivo, but is also safe. Example 3: Influenza Virus A (IAV) Nanocomplex Vaccines Cross-React with Different IAV Subtype Immunogens
[0205] BALB / c mice were intranasally immunized with two doses (14 days apart) of either the exemplary NC-IAV-01 or exemplary NC-IAV-02 nanocomplex vaccine, or PBS as a negative control. BALF and spleen cells were harvested 7 days after administration of the second vaccine dose and assayed by ELISpot using original immunogens or nucleocapsid proteins from different IAV subtypes (i.e., H1N1, H5N1, N3N2, or H7N9) for stimulation. See Figure 18A for the test workflow. When stimulated with the same immunogen (H1N1 or H5N1, respectively), both NC-IAV-01 (Figure 18B) and NC-IAV-02 (Figure 18C) induced strong immune responses in BALF and spleen. Surprisingly, when stimulated with H1N1, H5N1, N3N2, or H7N9 nucleocapsid proteins, the exemplary NC-IAV-02 nanocomplex vaccine was capable of stimulating an immune response against each subtype tested (Figure 18D).
[0206] Next, we tested the ability of NC-IAV-02 to cross-protect against different IAV subtypes after vaccination, as shown in Figure 19A. BALB / c mice were intranasally immunized with two doses (14 days apart) with the exemplary NC-IAV-02 nanocomplex vaccine or PBS as a negative control. On day 14 after the second dose was administered, the mice were then infected with IAV subtype H1N1 / PR8 or IAV subtype H7N9 / AH1 via intranasal inoculation. Body weight was tracked for 14 days after infection, and mice immunized with NP-H5N1-HA+R326 showed significantly less weight loss compared to mice administered PBS (H1N1 / PR8 inoculation: Figure 19B, and H7N9 / AH1 inoculation: Figure 19D). Furthermore, mice immunized with NP-H5N1-HA+R326 showed higher survival rates compared to mice administered PBS (H1N1 / PR8 inoculation: FIG. 19C, and H7N9 / AH1 inoculation: FIG. 19E).
[0207] Thus, these data demonstrate that IAV nanocomplex vaccines, such as NC-IAV-02, can protect mice against IAV viral infection, even against other subtypes of IAV, indicating that the nanocomplex vaccines described herein are capable of effectively protecting against heterosubtypic viruses.
[0208] Example 4: Bivalent nanocomposite vaccine protects against targeted viral infection As described in Example 1 above, bivalent nanocomplex vaccines can be generated in which the adapter protein and viral antigens are derived from different viruses. Exemplary bivalent nanocomplex vaccines (BiNCs) are provided in FIG. 7 (BiNC-01 to BiNC-04). BiNC-01 and BiNC-02 contain an influenza A virus (IAV) adapter fused to an IAV antigen and then complexed to a SARS-CoV-2 R266 mini-vRNA scaffold. BiNC-03 and BiNC-04 contain an IAV adapter fused to a SARS-CoV-2 antigen and then complexed to either a SARS-CoV-2 R266 mini-vRNA scaffold or an IAV R326 mini-vRNA scaffold.
[0209] BiNC-01 induced mucosal and systemic immunity against H1N1 as demonstrated by mouse in vivo assays. Following the mouse intranasal immunization model described above with two doses (14 days apart) of immunization (e.g., for vaccination with NC-CoV-01, NC-IAV-01, or NC-IAV-02), induction of both IgA and IgG in lung bronchoalveolar fluid (BALF) indicated a strong mucosal immune response (Figures 8B and 8C), and strong induction of H1N1 HA-specific IgG in serum samples indicated a robust systemic adaptive immune response (Figure 8A). Mice immunized with CoV-NP / H1N1-HA alone induced an antibody response, but this response was significantly lower than the antibody response elicited by the BiNC-01 nanocomplex vaccine containing the SARS-CoV-2 R266 mini-vRNA scaffold.
[0210] BiNC-02 induced mucosal and systemic immunity against H5N1 as demonstrated by mouse in vivo assays. Following the mouse intranasal immunization model described above with two doses (14 days apart) of immunization (e.g., for vaccination with NC-CoV-01, NC-IAV-01, or NC-IAV-02), induction of both IgA and IgG in lung bronchoalveolar fluid (BALF) indicated a strong mucosal immune response (Figures 9B and 9C), and strong induction of H5N1 HA-specific IgG in serum samples indicated a robust systemic adaptive immune response (Figure 9A). Mice immunized with CoV-NP / H5N1-HA alone induced an antibody response, but this response was significantly lower than the antibody response elicited by the BiNC-02 nanocomplex vaccine containing the SARS-CoV-2 R266 mini-vRNA scaffold.
[0211] Taken together, these data demonstrate that nanocomplex vaccines, e.g., NC-CoV-01, NC-IAV-01, NC-IAV-02, BiNC-01, and BiNC-02, fully protected against viral infections (e.g., SARS-CoV-2 infection, influenza A infection) by promoting robust immune responses, including providing heterosubtypic protection against multiple viral subtypes, as well as providing multivalent protection against multiple viral families (i.e., SARS-CoV-2 and IAV). Furthermore, the nanocomplex vaccines were demonstrated to be safe for in vivo use.
[0212] Sequence Listing SEQ ID NO:1 (NC-CoV-01: Adapter + Antigen: SARS2 NP + SARS2 Spike RBD Ancestral Strain; Reference sequence of ancestral strain spike (EPI_ISL_434571)) [ka] SEQ ID NO:2 (NC-CoV-02: Adapter + Antigen: SARS2 NP-SARS2 spike RBD Omicron BA.5; Reference sequence for Omicron BA.5 spike (EPI_ISL_13777658-hCoV-19 / Hong Kong / HKU-220712-005 / 2022)) [ka] SEQ ID NO:3 (NC-IAV-01: adapter + antigen: IAV NP-IAV H1N1 pdm09 HA head; reference sequence for H1N1 pdm09 HA (GU931802.1-A / Hong Kong / 415742Md / 2009)) [ka] SEQ ID NO:4 (NC-IAV-02: Adapter + antigen: IAV NP-IAV H5N1 1194 HA head; Reference sequence of H5N1 1194 HA (EF541402.1-A / Vietnam / 1194 / 2004)) [ka] SEQ ID NO:5 (NC-IAV-03: Adapter + antigen: IAV NP + IAV H3N2 4801 HA head; reference sequence of H3N2 4801 HA (EPI675797-A / Hong Kong / 4801 / 2014)) [ka] SEQ ID NO:6 (NC-IBV-01: Adapter + antigen: IAV NP-IBV Yamagata HA head; Reference sequence for IBV Yamagata HA (EPI529345-B / PHUKET / 3073 / 2013)) [ka] SEQ ID NO:7 (NC-IBV-02: adapter + antigen: IAV NP-IBV Victoria HA head; reference sequence for IBV Victoria HA (EPI1845793-B / Austria / 1359417 / 2021)) [ka] SEQ ID NO:8 (NC-RSV-01: Adapter + Antigen: SARS2 NP-RSV subtype AF; Reference sequence for RSV subtype AF (EPI_ISL_412866-hRSV / A / England / 397 / 2017)) [ka] SEQ ID NO:9 (NC-RSV-02: Adapter + Antigen: SARS2 NP-RSV subtype BF; Reference sequence for RSV subtype BF (EPI_ISL_1653999-hRSV / B / Australia / VIC-RCH056 / 2019)) [ka] SEQ ID NO: 10 (NC-HCV-01: Adapter + antigen: SARS2 NP-HCV genotype 1a E2; Reference sequence for genotype 1a E2 (NC_038882.1; isolate H77)) [ka] SEQ ID NO: 11 (NC-HCV-02: Adapter + antigen: SARS2 NP-HCV genotype 2a E2; Reference sequence for genotype 2a E2 (NC_009823.1; isolate HC-J6)) [ka] SEQ ID NO: 12 (SARS2 virus nucleoprotein amino acid sequence) SDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARM AGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAF FGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA SEQ ID NO: 13 (IAV virus nucleoprotein amino acid sequence) AAAGTAASYEQMETGGERQNATEIRASVGRMVSGIGRFYIQMCTELKLSDYEGRLIQNSITIERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYRRRDGKWVRELILYDKEEIRRIWRQANN GEDATAGLTHLMIWHSNLNDATYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGTMVMELIRMIKRGINDRNFWRGENGRRTRIAYERMCNILKGKFQTAAQRAMMDQVRESRNPG NAEIEDLIFLARSALILRGSVAHKSCLPACVYGLAVASGYDFEREGYSLVGIDPFRLLQNSQVFSLIRPNENPAHKSQLVWMACHSAAFEDLRVSSFIRGTRVVPRGQLSTRGVQIASNENMEA MDSNTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFERATIMAAFTGNTEGRTSDMRTEIIRMMESARPEDVSFQGRGVFELSDEKATNPIVPSFDMNNEGSYFFGDNAEEYDS SEQ ID NO: 14 (NC-CoV-01 and BiNC-03 antigen amino acid sequence: SARS2 spike RBD ancestral strain; reference sequence of ancestral strain spike (EPI_ISL_434571)) FTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNF SEQ ID NO: 15 (NC-CoV-02 and BiNC-04 antigen amino acid sequence: SARS2 spike RBD omicron BA.5; reference sequence for omicron BA.5 spike (EPI_ISL_13777658-hCoV-19 / Hong Kong / HKU-220712-005 / 2022)) FTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNY KLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF SEQ ID NO: 16 (NC-IAV-01 antigen amino acid sequence: IAV H1N1 pdm09 HA head; reference sequence for H1N1 pdm09 HA (GU931802.1-A / Hong Kong / 415742Md / 2009)) LCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETSSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKENSY PKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRGQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCN SEQ ID NO: 17 (BiNC-01 antigen amino acid sequence: IAV H1N1 pdm09 HA head; reference sequence for H1N1 pdm09 HA (GU931802.1-A / Hong Kong / 415742Md / 2009)) KLCKLRGVAPLHLGKFNIAGWILGNPECESLSTASSWSYIVETSSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGARSFYKNLIWLVKKENSY PKLSKSYINDKGKEVHVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRGQEGRMNYYWTLVEPGDRITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNT SEQ ID NO: 18 (NC-IAV-02 and BiNC-02 antigen amino acid sequence: IAV H5N1 1194 HA head; reference sequence of H5N1 1194 HA (EF541402.1-A / Vietnam / 1194 / 2004)) KLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPVNDLCYPGDFNDYEELKHLLSRINHFEKIQIIPKSSWSSHEASLGVSSACPYQGKSSFFRNVVWLIKKNSTY PTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPRIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNT SEQ ID NO: 19 (NC-IBV-01 antigen amino acid sequence: IBV Yamagata HA head; reference sequence for IBV Yamagata HA (EPI529345-B / PHUKET / 3073 / 2013)) FANLKGTRTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKN ATNPLTVEVPYICTEGEDQITVWGFHSDNKTQMKSLYGDSNPQKFTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCL SEQ ID NO: 20 (NC-IBV-02 antigen amino acid sequence: IBV Victoria HA head; reference sequence for IBV Victoria HA (EPI1845793-B / Austria / 1359417 / 2021)) FANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHVRLSTHNVINTEDAPGGPYEIGTSGSCLNITNGKGFFATMAWAVPKNKTA TNPLTIEVPYICTEEEDQITVWGFHSDDETQMARLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGKSKVIKGSLPLIGEADCL SEQ ID NO: 21 (NC-RSV-01 antigen amino acid sequence: RSV subtype AF; Reference sequence for RSV subtype AF (EPI_ISL_412866-hRSV / A / England / 397 / 2017)) QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPAANSRARQQQQRFLGFLLGVGSAIASGIAVSKVLHLEGEVNKI KSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSSNVQIVRQQSY SIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNIDIFNPKYDCKIMTSKTDVSSS VITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGKSTTN SEQ ID NO: 22 (NC-RSV-02 antigen amino acid sequence: RSV subtype BF; Reference sequence for RSV subtype BF (EPI_ISL_1653999-hRSV / B / Australia / VIC-RCH056 / 2019)) QNITEEFYQSTCSAVSRGYLSALRTGWYTSVITIELSNIKETKCNGTDTKVKLIKQELDKYKNAVTELQLLMQNTPAVNNRARQQQQRFLGFLLGVGSAIASGIAVSKVLHLEGEVNKI KNALQLTNKAVVSLSNGVSVLTSRVLDLKNYINNQLLPMVNRQSCRISNIETVIEFQQKNSRLLEITREFSVNAGVTTPLSTYMLTNSELLSLINDMPITNDQKKLMSSNVQIVRQQSY SIMSIIKEEVLAYVVQLPIYGVIDTPCWKLHTSPLCTTNIKEGSNICLTRTDRGWYCDNAGSVSFFPQADTCKVQSNRVFCDTMNSLTLPSEVSLCNTDIFNSKYDCKIMTSKTDISSS VITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKLEGKNLYVKGEPIINYYDPLVFPSDEFDASISQVNEKINQSLAFIRRSDELLHNVNTGKSTTN SEQ ID NO: 23 (NC-HCV-01 antigen amino acid sequence: HCV genotype 1a E2; reference sequence for genotype 1a E2 (NC_038882.1; isolate H77)) ETHVTGGNAGRTTAGLVGLLTPGAKQNIQLINTNGSWHINSTALNCNESLNTGWLAGLFYQHKFNSSGCPERLASCRRLTDFAQGWGPISYANGSGLDERPYCWHYPPRPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYSWGANDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVC GAPPCVIGGVGNNTLCPTDCFRKHPEATYSRCGSGPWITPRCMVDYPYRLWHYPCTINYTIFKVRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLSTTQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIKWEYVVLLFLLLADARVCSCLWMMLLISQAEA SEQ ID NO: 24 (NC-HCV-02 antigen amino acid sequence: HCV genotype 2a E2; reference sequence for genotype 2a E2 (NC_009823.1; isolate HC-J6)) GTTTVGGAVARSTNVIAGVFSHGPQQNIQLINTNGSWHINRTALNCNDSLNTGFLAALFYTNRFNSSGCPGRLSACRNIEAFRIGWGTLQYEDNVTNPEDMRPYCWHYPPKPCGVVPARSVCGPVYCFTPSPVVVGTTDRRGVPTYTWGENETDVFLLNSTRPPQGSWFGCTWMNSTGFTKTC GAPPCRTRADFNASTDLLCPTDCFRKHPDATYIKCGSGPWLTPKCLVHYPYRLWHYPCTVNFTIFKIRMYVGGVEHRLTAACNFTRGDRCDLEDRDRSQLSPLLHSTTEWAILPCTYSDLPALSTGLLHLHQNIVDVQYMYGLSPAITKYVVRWEWVVLLFLLLADARVCACLWMLILLGQAEA SEQ ID NO: 25 (SARS-CoV-2 DNA sequence, reference sequence) SEQ ID NO:26 (BiNC-01: Adapter + antigen: SARS2 NP + IAV H1N1 pdm09 HA head; Reference sequence of H1N1 pdm09 HA (GU931802.1-A / Hong Kong / 415742Md / 2009)) [ka] SEQ ID NO:27 (BiNC-02: Adapter + antigen: SARS2 NP + IAV H5N1 1194 HA head; reference sequence of H5N1 1194 HA (EF541402.1-A / Vietnam / 1194 / 2004)) [ka] SEQ ID NO:28 (BiNC-03: Adapter + Antigen: IAV NP + SARS2 spike RBD ancestral strain; Reference sequence of ancestral strain spike (EPI_ISL_434571)) [ka] SEQ ID NO: 29 (BiNC-04: Adapter + Antigen: IAV NP + SARS2 spike RBD Omicron BA.5; Reference sequence for Omicron BA.5 spike (EPI_ISL_13777658-hCoV-19 / Hong Kong / HKU-220712-005 / 2022)) [ka] SEQ ID NO: 30 (H7N9 / ZJ, EPI_ISL_148744) SEQ ID NO: 31 (NC-IAV-03 antigen amino acid sequence: IAV H3N2 4801 HA head; reference sequence for H3N2 4801 HA (EPI675797-A / Hong Kong / 4801 / 2014)) IDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSSACIRRSSSSFFSRLNWLTHLNYKYPALNVTMPNNEQFDKLYIW GVHHPGTDKDQIFLYAQSSGRITVSTKRSQQAVIPNIGSRPRIRDIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCKSECITPNGSIPNDKPF In an embodiment of the present invention, for example, the following items are provided: (Item 1) A vaccine composition comprising a nanocomplex, the nanocomplex comprising a scaffold molecule comprising viral RNA and an adapter-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA. (Item 2) 2. The vaccine composition of claim 1, wherein the molar ratio of the adapter-antigen polypeptide to the scaffold molecule is greater than about 5:1. (Item 3) 3. The vaccine composition according to item 1 or 2, wherein the viral antigen is an antigenic polypeptide. (Item 4) 3. The vaccine composition according to item 1 or 2, wherein the viral antigen is an immunogenic protein. (Item 5) 5. The vaccine composition according to any one of items 1 to 4, wherein the viral antigen is fused to the C-terminus of the viral nucleoprotein. (Item 6) 5. The vaccine composition according to any one of items 1 to 4, wherein the viral antigen is fused to the N-terminus of the viral nucleoprotein. (Item 7) 7. The vaccine composition according to any one of items 1 to 6, wherein the viral RNA comprises a non-translated region of the viral genome. (Item 8) 8. The vaccine composition of item 7, wherein the viral RNA comprises a 5' untranslated region or a 3' untranslated region of a viral gene of the viral genome. (Item 9) 9. The vaccine composition according to any one of items 1 to 8, wherein the viral RNA is about 10 to about 500 nucleotides in length. (Item 10) 10. The vaccine composition according to item 9, wherein the viral RNA is about 200 to about 500 nucleotides in length. (Item 11) 11. The vaccine composition according to any one of items 1 to 10, wherein the viral RNA is derived from SARS-CoV-2. (Item 12) Item 12. The vaccine composition according to item 11, wherein the viral RNA comprises nucleotides 1 to 266 of the viral gene of the SARS-CoV-2 genome set forth in SEQ ID NO: 25. (Item 13) 11. The vaccine composition according to any one of items 1 to 10, wherein the viral RNA is derived from an influenza A virus (IAV). (Item 14) 14. The vaccine composition according to item 13, wherein the viral RNA comprises nucleotides 1 to 326 of the viral gene of the IAV genome set forth in SEQ ID NO: 30. (Item 15) 15. The vaccine composition according to any one of items 1 to 14, wherein the viral nucleoprotein is derived from SARS-CoV-2. (Item 16) 16. The vaccine composition of claim 15, wherein the viral nucleoprotein derived from SARS-CoV-2 comprises the amino acid sequence of SEQ ID NO: 12. (Item 17) 15. The vaccine composition according to any one of items 1 to 14, wherein the viral nucleoprotein is derived from an IAV. (Item 18) 18. The vaccine composition of item 17, wherein the viral nucleoprotein is derived from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. (Item 19) 19. The vaccine composition according to item 17 or 18, wherein the viral nucleoprotein derived from IAV H5N1 comprises the amino acid sequence of SEQ ID NO: 13. (Item 20) 20. The vaccine composition according to any one of items 1 to 19, wherein the viral nucleoprotein and the viral antigen are derived from the same virus. (Item 21) 20. The vaccine composition according to any one of items 1 to 19, wherein the viral nucleoprotein and the viral antigen are derived from different viruses. (Item 22) 22. The vaccine composition according to any one of items 1 to 21, wherein the viral antigen is a SARS-Cov-2 protein or a fragment or variant thereof. (Item 23) 23. The vaccine composition of claim 22, wherein the viral antigen is a SARS-CoV-2 spike protein or a fragment or variant thereof. (Item 24) 24. The vaccine composition of claim 23, wherein the viral antigen comprises a receptor binding domain (RBD). (Item 25) 25. The vaccine composition of item 23 or 24, wherein the SARS-CoV-2 viral antigen comprises the amino acid sequence of SEQ ID NO: 14 or 15. (Item 26) 22. The vaccine composition according to any one of items 1 to 21, wherein the viral antigen is an influenza virus protein or a fragment or variant thereof. (Item 27) 27. The vaccine composition of claim 26, wherein the viral antigen is an influenza HA protein or a fragment or variant thereof. (Item 28) 28. The vaccine composition according to item 26 or 27, wherein the influenza virus protein or fragment or variant thereof is derived from an IAV or influenza B virus (IBV). (Item 29) 29. The vaccine composition of item 28, wherein the influenza virus protein or fragment or variant thereof is derived from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9. (Item 30) 30. The vaccine composition according to item 29, wherein the IAV viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 to 18 and 31. (Item 31) 29. The vaccine composition of item 28, wherein the influenza virus protein or fragment or variant thereof is derived from the Yamagata or Victoria IBV subtype. (Item 32) 32. The vaccine composition of claim 31, wherein the IBV viral antigen comprises the amino acid sequence of SEQ ID NO: 19 or 20. (Item 33) 22. The vaccine composition of any one of items 1 to 21, wherein the viral antigen is a respiratory syncytial virus ("RSV") protein or a fragment or variant thereof. (Item 34) 34. The vaccine composition of claim 33, wherein the viral antigen is a RSV F protein or a fragment or variant thereof. (Item 35) 35. The vaccine composition of claim 34, wherein the RSV F protein or a fragment or variant thereof is derived from a RSV A subtype or a RSV B subtype. (Item 36) 36. The vaccine composition of claim 34 or 35, wherein the RSV viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22. (Item 37) 22. The vaccine composition of any one of items 1 to 21, wherein the viral antigen is a Hepatitis C Virus ("HCV") protein or a fragment or variant thereof. (Item 38) 38. The vaccine composition of claim 37, wherein the viral antigen is an HCV E2 protein or a fragment or variant thereof. (Item 39) 39. The vaccine composition of item 38, wherein the HCV E2 protein or fragment or variant thereof is derived from HCV genotype 1a or HCV genotype 2a. (Item 40) 40. The vaccine composition according to item 38 or 39, wherein the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24. (Item 41) 41. The vaccine composition according to any one of items 1 to 40, wherein the adapter-antigen polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11 and 26 to 29. (Item 42) 42. The vaccine composition according to any one of items 1 to 41, wherein the nanocomplex in the vaccine composition has an average particle size of about 100 nm to about 130 nm. (Item 43) 43. The vaccine composition according to any one of items 1 to 42, wherein the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV. (Item 44) 44. A method for preventing a viral infection in an individual, comprising administering to said individual an effective amount of a vaccine composition according to any one of items 1 to 43. (Item 45) 45. The method of claim 44, wherein the vaccine composition is administered by intranasal or intradermal administration. (Item 46) 46. The method according to item 44 or 45, wherein the vaccine composition is administered in a priming dose followed by one or two booster doses. (Item 47) 47. The method of claim 46, wherein the initial dose and the one or two booster doses are administered about 7 days to about 21 days apart. (Item 48) 48. The method of claim 47, wherein the initial dose and the one or two booster doses are administered about 14 days apart. (Item 49) 49. The method of any one of items 46 to 48, wherein the initial dose and first booster dose, and the first booster dose and second booster dose are administered at intervals of about 7 to about 21 days, optionally at intervals of about 14 days. (Item 50) 50. The method according to any one of items 44 to 49, wherein the vaccine composition provides heterosubtypic protection against two or more viral subtypes that are part of the same viral species. (Item 51) 51. The method according to any one of items 44 to 50, wherein the method prevents viral infection with two or more viruses from different viral genera. (Item 52) (i) the two or more viral species are from the same viral family; or (ii) The method of claim 51, wherein the two or more viral species are from different viral families. (Item 53) The method prevents viral infection by three or more viral species; (i) the three or more viral species are from the same viral family; (ii) the three or more viral species are from different viral families; or (iii) The method of any one of items 51 to 52, wherein the three or more viral species comprise (a) two or more viral subtypes or subspecies that are from the same viral species, and (b) one or more viral species that are from a different viral family than the virus in (a).
Claims
1. A vaccine composition comprising a nanocomplex, the nanocomplex comprising a scaffold molecule comprising viral RNA and an adapter-antigen polypeptide comprising a viral antigen fused to a viral nucleoprotein capable of binding to the viral RNA.
2. 2. The vaccine composition of claim 1, wherein the molar ratio of said adaptor-antigen polypeptide to said scaffold molecule is greater than about 5:
1.
3. The vaccine composition of claim 1 or 2, wherein the viral antigen is an antigenic polypeptide.
4. The vaccine composition of claim 1 or 2, wherein the viral antigen is an immunogenic protein.
5. The vaccine composition according to any one of claims 1 to 4, wherein the viral antigen is fused to the C-terminus of the viral nucleoprotein.
6. The vaccine composition according to any one of claims 1 to 4, wherein the viral antigen is fused to the N-terminus of the viral nucleoprotein.
7. The vaccine composition according to any one of claims 1 to 6, wherein the viral RNA comprises a non-translated region of the viral genome.
8. The vaccine composition of claim 7, wherein the viral RNA comprises a 5' or 3' untranslated region of a viral gene of the viral genome.
9. The vaccine composition of any one of claims 1 to 8, wherein the viral RNA is from about 10 to about 500 nucleotides in length.
10. 10. The vaccine composition of claim 9, wherein the viral RNA is about 200 to about 500 nucleotides in length.
11. The vaccine composition of any one of claims 1 to 10, wherein the viral RNA is derived from SARS-CoV-2.
12. 12. The vaccine composition of claim 11, wherein the viral RNA comprises nucleotides 1 to 266 of the viral gene of the SARS-CoV-2 genome set forth in SEQ ID NO:
25.
13. The vaccine composition according to any one of claims 1 to 10, wherein the viral RNA is derived from an influenza A virus (IAV).
14. 14. The vaccine composition of claim 13, wherein the viral RNA comprises nucleotides 1 to 326 of the viral gene of the IAV genome set forth in SEQ ID NO:
30.
15. The vaccine composition according to any one of claims 1 to 14, wherein the viral nucleoprotein is derived from SARS-CoV-2.
16. 16. The vaccine composition of claim 15, wherein the viral nucleoprotein derived from SARS-CoV-2 comprises the amino acid sequence of SEQ ID NO:
12.
17. The vaccine composition according to any one of claims 1 to 14, wherein the viral nucleoprotein is derived from IAV.
18. 18. The vaccine composition of claim 17, wherein the viral nucleoprotein is derived from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9.
19. 19. The vaccine composition of claim 17 or 18, wherein the viral nucleoprotein derived from IAV H5N1 comprises the amino acid sequence of SEQ ID NO:
13.
20. The vaccine composition according to any one of claims 1 to 19, wherein the viral nucleoprotein and the viral antigen are derived from the same virus.
21. The vaccine composition according to any one of claims 1 to 19, wherein the viral nucleoprotein and the viral antigen are derived from different viruses.
22. The vaccine composition according to any one of claims 1 to 21, wherein said viral antigen is a SARS-Cov-2 protein or a fragment or variant thereof.
23. 23. The vaccine composition of claim 22, wherein the viral antigen is SARS-CoV-2 spike protein or a fragment or variant thereof.
24. 24. The vaccine composition of claim 23, wherein the viral antigen comprises a receptor binding domain (RBD).
25. 25. The vaccine composition of claim 23 or 24, wherein the SARS-CoV-2 viral antigen comprises the amino acid sequence of SEQ ID NO: 14 or 15.
26. The vaccine composition according to any one of claims 1 to 21, wherein the viral antigen is an influenza virus protein or a fragment or variant thereof.
27. 27. The vaccine composition of claim 26, wherein the viral antigen is an influenza HA protein or a fragment or variant thereof.
28. 28. The vaccine composition of claim 26 or 27, wherein the influenza virus protein or fragment or variant thereof is derived from IAV or influenza B virus (IBV).
29. 29. The vaccine composition of claim 28, wherein the influenza virus protein or fragment or variant thereof is from an IAV subtype selected from the group consisting of H1N1, H5N1, H3N2, and H7N9.
30. 30. The vaccine composition of claim 29, wherein the IAV viral antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-18 and 31.
31. 29. The vaccine composition of claim 28, wherein the influenza virus protein or fragment or variant thereof is derived from a Yamagata or Victoria IBV subtype.
32. 32. The vaccine composition of claim 31 , wherein the IBV viral antigen comprises the amino acid sequence of SEQ ID NO: 19 or 20.
33. 22. The vaccine composition of any one of claims 1 to 21, wherein the viral antigen is a respiratory syncytial virus ("RSV") protein or a fragment or variant thereof.
34. 34. The vaccine composition of claim 33, wherein the viral antigen is an RSV F protein or a fragment or variant thereof.
35. 35. The vaccine composition of claim 34, wherein the RSV F protein or a fragment or variant thereof is derived from an RSV A subtype or an RSV B subtype.
36. 36. The vaccine composition of claim 34 or 35, wherein the RSV viral antigen comprises the amino acid sequence of SEQ ID NO: 21 or 22.
37. 22. The vaccine composition of any one of claims 1 to 21, wherein the viral antigen is a Hepatitis C Virus ("HCV") protein or a fragment or variant thereof.
38. 38. The vaccine composition of claim 37, wherein the viral antigen is an HCV E2 protein or a fragment or variant thereof.
39. 39. The vaccine composition of claim 38, wherein the HCV E2 protein or fragment or variant thereof is derived from HCV genotype 1a or HCV genotype 2a.
40. 40. The vaccine composition of claim 38 or 39, wherein the HCV viral antigen comprises the amino acid sequence of SEQ ID NO: 23 or 24.
41. The vaccine composition of any one of claims 1 to 40, wherein the adapter-antigen polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11 and 26-29.
42. 42. The vaccine composition of any one of claims 1 to 41, wherein the nanocomplexes in the vaccine composition have an average particle size of about 100 nm to about 130 nm.
43. 43. The vaccine composition of any one of claims 1 to 42, wherein the nanocomplex in the vaccine composition has a zeta potential of about -10 mV to about -20 mV.
44. A method for preventing a viral infection in an individual, comprising administering to said individual an effective amount of a vaccine composition according to any one of claims 1 to 43.
45. 45. The method of claim 44, wherein the vaccine composition is administered by intranasal or intradermal administration.
46. 46. The method of claim 44 or 45, wherein the vaccine composition is administered in a priming dose followed by one or two booster doses.
47. 47. The method of claim 46, wherein the initial dose and the one or two booster doses are administered about 7 days to about 21 days apart.
48. 48. The method of claim 47, wherein the initial dose and the one or two booster doses are administered about 14 days apart.
49. 49. The method of any one of claims 46-48, wherein the initial dose and first booster dose, and the first booster dose and second booster dose are administered about 7 to about 21 days apart, optionally about 14 days apart.
50. The method of any one of claims 44 to 49, wherein the vaccine composition provides heterosubtypic protection against two or more viral subtypes that are part of the same viral species.
51. 51. The method of any one of claims 44 to 50, wherein the method prevents viral infection with two or more viruses from different viral genera.
52. (i) the two or more viral species are from the same viral family; or 52. The method of claim 51, wherein (ii) the two or more viral species are from different viral families.
53. The method prevents viral infection by three or more viral species; (i) the three or more viral species are from the same viral family; (ii) the three or more viral species are from different viral families; or 53. The method of claim 51 or 52, wherein (iii) the three or more viral species include (a) two or more viral subtypes or subspecies that are from the same viral species, and (b) one or more viral species that are from a different viral family than the virus in (a).
